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ABSTRACT 
 
One of the predominant concerns with protein therapeutics is their tendency to aggregate 
at various stages of protein production, purification, filling, transportation, and administration.  
This occurrence has biological significance; while there is no definite, general cause and effect 
relationship for all protein drugs, many studies suggest that protein aggregates in certain 
biotherapeutics can decrease efficacy or cause untoward immune responses in human patients. 
Current research suggests that certain types of protein aggregates may be more immunogenic 
than others.   
In this Ph.D. thesis research work, three different IgG monoclonal antibodies (2 IgG1 
mAbs, one in solution and one in lyophilized form and one IgG2 mAb in solution) were stressed 
by a variety of different conditions and the resulting aggregates and particles were characterized 
using a broad array of methods.  Some of the characteristics examined included aggregate/ 
particle size, count, and morphology, as well as the covalent cross-linking and structural integrity 
of the protein within the aggregates. In all cases, accelerated stability studies, similar to those 
performed in the biopharmaceutical industry, were utilized to generate aggregates. In the first 
study, an IgG1 mAb in solution was subjected to freeze-thaw, shaking, stirring, and heat stress in 
the presence and absence of NaCl.  Depending on the solution and stress conditions, very 
different types of aggregates and particles formed.  In the second study, an IgG1 mAb in 
lyophilized form was shaken to mimic worst-case shipping condition, which led to extensive 
cake breakage and upon reconstitution, displayed increased turbidity and subvisible particles 
compared to the unstressed sample. This study highlights potential stability concerns regarding 
lyophilized protein undergoing various shipping processes.    In the third study, the impact of 
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protein particle size on inducing an early and late phase immune response in an in-vitro assay 
using human peripheral blood mononuclear cells (PBMC) was investigated.  Stir-induced IgG2 
mAb aggregates were size-enriched using fluorescence activated cell sorting (FACS) and tested 
for their ability to induce PBMC cytokine responses, at two phases of the immune response.  The 
size-enriched particles were simultaneously characterized to determine traits, other than size, that 
may be responsible for the in-vitro assay responses.  Amorphous subvisible particles 5-10 µm in 
size, containing protein with partially altered secondary structure and elevated surface 
hydrophobicity (compared to controls), and containing elemental fluorine, displayed relatively 
elevated cytokine release profiles compared to other size ranges. 
Studies carried out as part of this Ph.D. thesis highlight the importance of 1) 
comprehensively characterizing protein aggregates and particles to better understand their 
formation, 2) the need for closer evaluation of the effects of shaking stress on lyophilized protein 
formulations during shipping, and 3) studying the potential biological implications of a subset of 
protein particles in an in vitro system, along with developing a better understanding these 
aggregate’s physicochemical properties, should provide improved insights into why some protein 
aggregates elicit higher immune responses than others in vivo.  
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CHAPTER 1: INTRODUCTION 
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1.1 OVERVIEW 
Aggregation of protein biopharmaceuticals can reduce the efficacy of the drug as well as 
increase concerns about its immunogenicity upon administration to patients.  The work presented 
in this thesis will be focused on a specific class of proteins called antibodies, or 
immunoglobulins, which have been gaining a lot of interest in the past two decades as the fastest 
growing category of protein drugs in clinical development.  In this review, monoclonal 
antibodies (mAbs) are of particular interest.  These antibodies, produced by identical B plasma 
immune cells cloned from a single parent cell, are monospecific and usually bind to one epitope 
on one antigen.   
The prevalence of mAbs is also noticeable in the commercial drug markets. As of 2010, 
7% of the global therapeutic market was composed of mAbs (9 blockbusters making more than 
$1 billion in sales).  As of June 2011, there were 28 approved mAbs in the EU or US with 1064 
industry sponsored clinical trials, costing hundreds of millions of dollars.1  Between 2010 to 
2015, it is predicted that all medicines will have a growth rate of 3-6% compound annual growth 
rate.  MAbs alone show a 9.2% compound annual growth rate during this same period.1 So even 
though these biologics make up a small portion of total pharmaceutical sales, they will be 
representing much of the growth during these years.1  This dramatic rise in their production has 
made them very important molecules for study.  
Immunoglobulins are produced by B lymphocytes and function to identify and tag 
foreign antigens for attack by other parts of the immune system or directly neutralize its target by 
recognizing a unique part of the antigen, called the paratope.  The region of the antibody that 
recognizes the paratope is called the epitope. Antibody preparations are often employed as 
research reagents as well as for diagnosis, monitoring, and treatment of various diseases such as 
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cancer, autoimmune, and other inflammatory diseases.  Their high specificity and selectivity also 
allow them to be used in conjunction with radioisotopes, cytotoxic agents, or biologic response 
modifiers that can directly target diseased cells without effecting normal cells, thus causing 
fewer side effects to patients.  
1.1.1 Structure of Antibodies 
Immunoglobulins are glycoproteins that are Y (or an array of Y) shaped structures with two 
identical heavy chains and two identical light chains (see Figure 1) connected by disulfide bonds. 
In the case of IgG molecules, each heavy chain is approximately 50 kDa and each light chain 25 
kDa. There are five types of heavy chains (and five types of immunoglobulins), which define the 
antibody class, or isotype.  They are denoted as α, found in IgA; δ, found in IgD; ε, found in IgE; 
γ, found in IgG; and µ, found in IgM.  The α and γ contain about 450 amino acids while the µ 
and ε contain about 550 amino acids.2 The light chain is either of the λ or κ type, which is about 
211 to 217 amino acids long, respectively.3  Each chain is composed of domains 70-110 amino 
acids long.3  As shown in Figure 1, the light chain is composed of a variable (VL) and constant 
domain (CL).  The heavy chain consists of a variable domain (VH) followed by a constant domain 
(CH1), a hinge region, and two more (CH2, CH3; for isotype γ, α, δ) or three more (CH2, CH3, 
CH4; for µ and ε) constant domains depending on the isotype.  The constant region is the same 
for all antibodies of the same isotype and species, but different in antibodies of different isotypes 
and from different sources. The variable region is different in each B cell producing it, but is the 
same for antibodies produced by a single B cell or a B cell clone. All domains consist of beta 
barrel or immunoglobulin fold structures that are stabilized by disulfide bond and hydrophobic 
interactions.  These individual domains interact with one another and fold into three equal-sized 
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oblong spherical shapes linked by a flexible hinge region.  The hinge region allows flexibility for 
bivalent antigen binding and allows activation of effector functions.   
Antibodies can be divided into Fab (Fragment antigen binding) and Fc (Fragment 
crystallization) regions and have very different functions.  The Fab region, consisting of one 
constant and one variable domain from the heavy and light chain of the antibody, binds to the 
antigen.  At the amino terminal end of the Fab is the antigen-binding site composed of the 
complementary binding regions (CDRs) and the framework (not shown in Figure) region.  CDRs 
are composed of a total of 6 beta loops (3 in the heavy chain and 3 in the light chain), with the 
framework region forming beta sheets in between each CDR. The Fc portion of the antibody 
modulates immune cell activity and comprises two heavy chains, with either two or three 
domains depending on the class of the antibody.  Each domain is composed of between 7 (for the 
constant domains) and 9 (for the variable domains) beta strands. 3 
Our focus for this thesis is on IgG molecules.  IgGs are further divided into the following 
subclasses: IgG1, IgG2, IgG3, and IgG4 consisting of γ1, γ2, γ3, γ4 heavy chains, respectively.  
The differences among these subclasses are mostly due to the length of the hinge region and 
number and location of interchain disulfide bonds. In addition to the interchain disulfide bonds, 
IgGs have intrachain disulfide bonds, residing in each domain of the heavy and light chains 
(indicated by the red –S-S- within each domain).  There is one oligosaccharide chain in IgGs and 
this N-linked sugar chain resides on the CH2 domain at Asn 297.  This oligosaccharide is very 
important for binding of the C1q component of the complement cascade and can effect antibody 
conformation.   
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Figure 1. Representative structure of an IgG antibody.4 (Ref: adapted from 
http://www.novimmune.com/science/antibodies.html with permission) 
1.1.2 Modes of Action of Monoclonal Antibody Therapies 
Antibody therapeutics have many modes of action, which make them very effective 
biological agents.  They can either directly or indirectly inhibit disease progression.  Directly, 
they can block the function of targeting signal molecules, neutralize toxins, inhibit the function 
of growth factor receptors, or hinder the function of adhesion molecules.5,6 Depending on the 
disease, they are capable of changing the rate at which cell surface receptors are internalized or 
cleaved.5,6  Antibodies can also inhibit cell cycle progression or DNA repair, induce regression 
of angiogenesis, and stimulate apoptosis and many targeting functions.5,6  Indirectly, they can 
inhibit disease progression with the help of the immune system by recruiting cells with cytotoxic 
potential, such as monocytes, macrophages, or natural killer cells, in an antibody-dependent cell 
* 
* Carbohydrate 
-s
-s
- -s-s- 
-s
-s
- -s-s- 
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mediated cytotoxicity (ADCC) process.6,7  The Fc region on the antibody binds to Fc receptors 
on the cells while the Fab region of the antibody binds to the cell surface receptors of the target 
cell.  This action can elicit lysis or phagocytosis of the target cell by cytotoxic cells. A 
complement dependent cytotoxicity (CDC) process can also occur when the mAb binds to the 
target cell surface and fixes complement, resulting in activation of a complement cascade and 
generation of a membrane attack complex that leads to cell lysis.5   
1.1.3 Stability of mAbs 
The structural integrity and stability of mAbs, similar to protein molecules in general, is 
governed by covalent bonds as well as by non-covalent electrostatic, weakly polar, and 
hydrophobic interactions. Covalent bonding (present in peptide bonds, disulfide-crosslinking, N 
and O-glycosylation) in combination with various non-covalent interactions maintain the protein 
in the folded state, in its native three dimensional conformation. Electrostatic interactions 
(dipole-dipole, charge-dipole, and charge-charge interactions), present in H-bonding and salt-
bridges, along with stacking interactions of aromatic side chains also contribute to stability of the 
molecule.  The largest contributors to stabilization of the protein in its native, folded 
conformation, however, are hydrophobic interactions (where surface exposure of nonpolar 
regions is minimized) and H bonding.8,9 At the same time, there is only a narrow window of 
stability between the folded and unfolded forms of a protein, and the non-covalent interactions 
governing the folded conformation of the protein can be easily perturbed and cause the protein to 
lose its native conformation. Finally, these different covalent and non-covalent interactions help 
to retain both the physical and chemical stability of mAbs. Chemical stability involves processes 
where covalent bonds within the amino acid residues or the peptide backbone are altered and the 
chemical composition is changed.  Physical stability does not necessarily involve breaking or 
 
 7 
forming of any covalent bonds but alters the physical state of the molecule through disruption of 
non-covalent interactions leading to structural alterations, and under certain conditions, 
irreversible formation of aggregates.10  
1.1.3.a. Chemical and physical stability from a pharmaceutical perspective 
 
There are ample references that discuss chemical stability of protein-based drugs in detail.  
Chemical processes include events such as oxidation11, deamidation12, isomerization13, beta-
elimination14, disulfide scrambling15,16, and peptide fragmentation17, where key amino acid 
residues are involved in each of these processes.2,9  Physical instabilities can manifest themselves 
through denaturation, aggregation, precipitation, and surface adsorption.2,9,18 
1.1.3.b. Colloidal vs. Conformational Stability of mAbs 
 
Both colloidal and conformational stabilities of mAbs can contribute to the overall 
aggregation pathway depending on the specific protein, formulation, and environmental 
stress.19,20 Colloidal stability arises from a balance of attractive and repulsive forces between 
protein molecules as they approach one another.  In general, a solution containing particles is 
colloidally stable if there is repulsion between the particles but is unstable and readily 
agglomerates if there is little or no repulsion between the particles.20  Colloidal stability of 
proteins can be modulated by changing surface charge either by mutating solvent-exposed amino 
acid residues (introducing charged residues to increase repulsive interactions) or by altering the 
solution environment to decrease attractive intermolecular interactions between protein 
molecules. Changing solution pH and/or ionic strength can thus greatly impact the colloidal 
stability of proteins.  
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 Conformational stability arises through modulating the amount of unfolded or partially 
unfolded aggregation-prone protein molecules in solution.  It is maintained by keeping the 
protein in its folded, native state.  Adding nonspecific stabilizing compounds such as sucrose to a 
protein solution, which preferentially excludes from protein surfaces, is one method of increasing 
the conformational stability of a protein.  Mutating amino acid residues within the interior of the 
protein to enhance packing, altering solution conditions to favor the folded state (near-neutral 
pH), or adding specific ligands that bind to a specific binding pocket within the native state of 
the protein molecule can all increase the conformational stability of protein molecules.    
Solution conditions can potentially determine which of these two stability parameters is 
more dominant.  Depending on the situation, either conformational changes or colloidal changes 
can be the rate-limiting step.19-22 Colloidal and conformational stability effects on protein 
aggregation have been studied in detail using a variety of IgG1 mAbs. 21,22  Sahin et al. 
modulated the surface charges of an IgG1 mAb by increasing the pH and observed more 
attractive interactions and concurrently a change from small oligomer formation to high 
molecular weight aggregates and precipitates.21   Brummit et al. hypothesized that in the 
presence of attractive colloidal interactions, amyloid and insoluble aggregates will be observed, 
but under conditions where repulsive interactions are dominant, amorphous aggregates may be 
observed in some cases.22  In terms of effects on conformational stability, the extent of structural 
alterations has also been shown to be strongly correlated with the level of aggregate formed, at 
least in some cases.23 
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1.2. MECHANISMS OF PROTEIN AGGREGATION AND PARTICLE FORMATION 
 
Generally, protein aggregation can proceed by several pathways as described in Figure 2.  
According to Roberts et al, protein aggregation generally involves the following processes: (1) 
protein structural alterations leading to formation of non-native, aggregation prone structures 
(conformational stability effects);24 2) reversible self-association of the protein mediated by 
possible charge-charge interactions among others (colloidal stability effects);24 and 3) 
conformational rearrangement of the oligomers to make the aggregates irreversible.  These 
irreversible aggregates can continue to grow through different methods of aggregation addition 
to form 4) soluble aggregates; 5) soluble, high-molecular weight aggregates; 6) large insoluble 
aggregates.25 
Other mechanisms include homogeneous and heterogeneous nucleation dependent 
aggregation in which impurities induce protein unfolding and aggregation.26  Additionally, it has 
also been proposed that reversible association of the native monomer, surface induced events, or 
chemically-modified products may also play a role in aggregate formation. 27  It is difficult to 
discern which mechanism is dominant because often all of these mechanisms are operating to 
different extents at the same time.  
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Figure 2. Representation of a few important steps in non-native protein aggregation (Ref: 
Obtained with permission from Roberts et al.25 
1.3 IMMUNOGENICITY OF THERAPEUTIC PROTEINS 
 
There have been many instances in which protein aggregates and particles in therapeutic 
drugs were suspected of causing immunogenic responses in patients28-30: (1) patients injected 
with an altered formulation of erythropoetin developed pure red cell aplasia; 31-33 (2) injection of 
aggregated Factor VIII to hemophiliac patients worsened the symptoms of hemophilia; 33 (3)  
patients who were given hGH with 50-70% aggregates developed anti-hGh antibody, but such a 
response was dramatically reduced after they were given a formulation with fewer aggregates; 33 
and (4) and 80-100% patients developed binding and neutralizing antibodies when IL-2 was 
administered subcutaneously over a period of time.  When IVIG (intravenous immunoglobulin) 
was administered, the presence of a large amount of aggregates triggered anaphylaxis due to 
fixation and activation of the complement cascade.  Fortunately, engineered human and 
humanized monoclonal antibodies have shown much lower anti-drug immune responses in 
humans than these earlier-developed biotherapeutics, but the concern to make safer protein 
therapeutics can never be diminished.34  
1.3.1. Factors leading to immunogenicity 
While the presence of protein aggregates and particles can potentially impact the 
immunogenicity of biotherapeutics, other factors related to the drug formulation, process 
development, and patient related factors can also greatly impact the immune responses. Drug 
related factors such as non-human sequences, novel epitopes generated by amino acid 
substitution for enhanced stability, or changes in glycosylation patterns can expose cryptic B cell 
and T cell epitopes in a protein causing it to appear foreign to the immune system. Alterations in 
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structure causing a protein species to show repetitive arrays may lead to efficient crosslinking of 
B cell receptors leading to B cell activation and consequently to breaking of immune tolerance to 
self-protein.35  
Process related factors such as container types, the presence of metal, silicone oil, or 
tungsten derived from various operations can be culprits as well.  Certain excipients used in 
formulating protein drugs have been shown to increase patient immune responses.  One example 
is with Eprex, which is a version of EPO that is formulated with tween 80 instead of human 
serum albumin.  This was thought to be one of the factors responsible for the development of 
antibodies against this protein.36   
Patient related aspects such as genetic factors, age, disease, immune status, and 
concomitant treatment need to be considered as well. The route, frequency, and dose of 
administration can also impact the extent of an immune response. All of these factors can 
complicate our understanding of the immunogenic potential of a therapeutic protein drug.30 
1.3.2 Some proposed biological mechanisms that may result in immunogenicity 
 
The production of binding or neutralizing anti-drug antibodies (ADAs) are thought to be 
the source of the observed immune responses to therapeutic proteins. 37  The effects of these 
ADAs may range from being harmless to their being potentially fatal to patients.  Specifically, 
repeated administration of some drugs can induce the formation of these ADAs, but clinical 
prediction of ADA formation is very difficult.   
ADA formation is thought to arise from 2 pathways: through a classical pathway or by 
breaking of immune tolerance.38-40 The presence of foreign epitopes triggers a classical immune 
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response.  The foreign antigen is internalized, processed, and presented by antigen presenting 
cells (APC) through the major histocompatibility complex II (MHC II) to T cells.  CD4+ T cell 
becomes activated upon recognition of this MHC II-peptide complex.  This primed T cell 
recognizes and activates B cells by secreting certain cytokines causing them to proliferate and 
produce antibodies.40  Foreign antigens generally trigger a classical immune response that is 
dependent on T-cell activation described in detail elsewhere.41  When the antigen contains 
repetitive epitopes, the response can proceed through a T cell independent manner through Toll-
like receptors on the B cell or by antigen cross-linking of the BCR; these processes can also 
stimulate antibody secretion from B cells.42  Many recombinant protein drugs available in the 
market, however, are not foreign but homologous to endogeneous human protein.  So a classical 
immune response is not the expected pathway for immunogenicity; instead breaking of B cell 
tolerance is more likely the source of any immunogenicity.  The body has complex regulating 
mechanisms for suppressing and inactivating self- reactive B and T cells called central and 
peripheral tolerance.  These self-reactive cells can sometimes evade this central tolerance in the 
primary lymphoid organs or peripheral tolerance in the peripheral organs.  When the cells evade 
these control mechanisms and B cell tolerance is broken, antibody production against these 
protein drugs and subsequent immune reactions ensues.38,40 
1.4 MAB PARTICLE FORMATION 
 
Protein aggregation is ubiquitous in pharmaceutical settings and can occur during many 
stages of protein drug production, long-term storage and shipping, and even during 
administration to the patient.43 As discussed above, the formation of aggregates and particles 
may lead to an immune response 44-46, and a decrease in the efficacy of the drug due to cross 
reactivity of antibodies that can neutralize endogeneous proteins, or anaphylactic shock.45,47-50 
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Therefore understanding the parameters causing aggregation and particle formation is essential 
to develop strategies to minimize its occurrence. Recently there has been an increase in interest 
in the 0.1-10 µm sized protein aggregates, often referred to as protein particles, specifically due 
to their potential increased immunogenic responses.51,52 Throughout this chapter, the term 
“aggregation” will be used generally when referring to the formation of all types and sizes of 
aggregates.  However, when aggregates larger than 100 nm are specifically being discussed, they 
will be referred to as “protein particles.”  The focus of this manuscript is on formation of these 
protein particles.  
Temperature53-58, freeze-thaw54,58-61, mechanical stresses55,62-70, and light71,72 all have 
contributed to various instances of mAb particle formation. Each of these environmental stresses 
are typically encountered at various stages of drug development so their impact on particle 
formation is important to understand.  Increased particle formation has even occurred at various 
points during lyophilization, which is performed to increase the storage stability of the protein.73-
77 The potential mechanisms of how these stresses cause particle formation is discussed briefly in 
the next few paragraph.   
Heating a protein solution can either partially unfold or more extensively unfold the 
protein.  This can expose interior hydrophobic regions to varying extents, which may serve as 
hotspots for nucleation and more extensive aggregation. Additionally, elevated temperatures can 
provide sufficient kinetic energy to the protein molecules in the solution to speed up chemical 
reactions such as deamidation or oxidation, both of which can lead to increased aggregation. 2,78 
Cold denaturation is also possible since the strongly temperature-dependent hydrophobic 
interactions, known for keeping the protein in the native conformation, may become weaker at 
lower temperatures. Many studies have shown that IgGs exposed to heating, formed primarily 
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large micron sized particles, consisting of non-native covalent cross-links, with large 
perturbations in secondary structure and high ANS binding. 23,54,58  
Freezing is another stress a protein drug can encounter.  During this process, protein can 
adsorb to ice/liquid interfaces and unfold.  Cryoconcentration of buffer components and protein 
can lead to local concentration differences, or pH changes, since some buffers tend to crystallize.  
These pH or concentration changes in some instances can favor aggregation.  
Mechanical stresses, such as agitation and stirring, introduce shear effects, or may cause a 
protein to adsorb to container-liquid or air-water interface leading to partial unfolding. The 
partially unfolded molecules can be transported throughout the bulk solution, triggering 
increased aggregation events.  Additionally, these agitation stresses, can cause local thermal 
effects or cavitation, creating a favorable environment for the formation of hydroxyl and 
hydrogen radicals capable of oxidation reactions. 79-83,23  
A very common environmental stress that a protein drug may encounter is light. 
Tryptophan, tyrosine, phenylalanine, and cysteine residues can undergo photooxidation 
reactions, which can lead to changes in primary, secondary, and tertiary structures.84   
Lyophilization of a protein solution is one approach commonly employed to stabilize 
proteins that are not sufficiently stable in liquid formulations, but the various stages of the 
lyophilization process such as freezing, primary and secondary drying, and reconstitution may all 
structurally damage proteins.85-89 Freezing causes similar effects to those described above. 85,88,89  
Primary drying removes the frozen bulk water and concentrates the protein and stabilizers, 
permitting the possibility of unfavorable interactions to occur.86,90  During the secondary drying 
step, non-frozen water bound to the protein or excipients is removed, increasing the possibility of 
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protein instability.  The stability of a lyophilized protein may be affected by the reconstitution 
addition rate and diluent composition.76,91  Diluents added too rapidly may not give the dried 
protein enough time to rehydrate and properly assume its native conformation.  If added too 
slowly, however, this may allow an increased amount of time for particles to form. 76,92  Particle 
formation can be affected by choosing diluents with various whetting capabilities (i.e., 
surfactants) or with differing ionic strengths.  Aggregation of mAbs in the lyophilized state upon 
reconstitution has been correlated with non-native intermolecular disulfide bond formation93 and 
an increase in the levels of subvisible particles.94 A freeze-dried cake’s moisture content and 
cake structure are also considerations since they too can affect the extent to which a protein may 
aggregate in the solid state. 73-76,90,95,96 Some lyophilized protein preparations with high moisture 
content have shown increased chemical degradation due to the increased ability of water to 
participate in physical and chemical degradation processes.97  However, this is not a general rule 
and there are exceptions that have been reported.95,98 It has also been shown that cake collapse 
can be an important factor in determining protein stability in the solid state.73-75  
Formulation composition parameters such as concentration, pH, and ionic strength can 
also influence the aggregation of protein pharmaceuticals.  Often high protein concentrations are 
required for best efficacy or for improved patient friendly dosage forms (e,g., self-administration 
by subcutaneous injection). High protein concentrations can make self-association interactions 
more favorable79,99,100,101 but at the same time, can make conformational unfolding less 
favorable.79,102 Such formulations cannot be directly analyzed by many analytical techniques 
without dilution, which can cause weak reversible interactions to dissociate resulting in changes 
in the aggregate population distribution.79,103,104 The pH of the formulation can not only affect 
protein surface electrostatic interactions, but acidic pH can cause hydrolysis reactions in the 
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protein while basic conditions can promote deamidation and oxidation reactions.20,79  Increasing 
the ionic strength of a solution may increase or decrease protein colloidal stability depending on 
the protein, the type and amount of salt and the formulation pH.105,80  The addition of a small 
amount of salt (<0.15 M) can neutralize protein surface charge and decrease electrostatic 
interactions due to increased charge screening.20,106  Generally, these electrostatic interactions are 
usually essential for maintaining a native, folded protein conformation, and its absence can 
destabilize protein solutions and induce aggregation.  If these interactions favor non-native state 
of a protein, reducing them by the addition of salt can hinder aggregation.105 An appropriate 
distribution of anisotropic charge or the peptide bond itself, because of its dipole nature, can 
cause protein-protein interactions to become attractive and aggregation to occur.20   At high salt 
concentrations and depending on the salt type, there may be preferential binding of ions to the 
protein, which can destabilize the native conformation and increase solubility20 (i.e., chaotropic 
effect). Divalent cationic salt ions could also bind to surface amino acid side chains or cross-link 
residues to provide increased conformational stabilization yet potentially increase aggregation.105 
Protein therapeutics come into contact with many different solid-liquid and air-liquid 
interfaces throughout production.  There have been many instances where syringe surfaces107-110, 
containers111,112, or stoppers112 have led to particle formation.  When mAb solutions were 
agitated in the presence of siliconized syringe walls with air bubbles, subvisible particles were 
observed consisting of silicone oil droplets and aggregated proteins. The combination of effects 
from the stress and interaction with the silicone-oil water interface and air-water interface led to 
the observed particles.109  
Even stainless steel particles that sometimes are shed during some types of filling 
processes, can serve as heterogeneous nuclei for microparticle formation.113,114 Heterogeneous 
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particles have also arisen from interaction with tungsten115 or silicon oil107, used in the 
production of prefilled syringes. In one study, vials, which were filled with an IgG formulation 
using a piston pump, showed an increase in subvisible particle formation (1.5-3µm) consisting of 
protein with no structural changes.  It was hypothesized that nanoparticles that were being shed 
from the pump were heterogeneous nucleation sites for formation of protein microparticles.114 A 
similar study was performed to further look at the effect of filling pumps to cause particulation.  
It was found that the rotary piston pump formed many more IgG microparticles upon filling of a 
mAb solution than a rolling diaphragm pump, peristaltic pump, and time-pressure filler 
pumps.113 Tungsten, which may be present in prefilled syringes, seemed to induce large particles 
but this was highly dependent on solution pH, probably due to electrostatic interactions between 
protein and tungsten molecules.115   
1.5 MAB PARTICLE CHARACTERIZATION 
 
A better understanding of protein aggregation can only be gained by developing robust 
analytical techniques for monitoring its occurrence and the nature of the aggregates.  Protein 
aggregates can be classified into multiple categories by 1) size, 2) reversibility, 3) conformation, 
4) covalent modification, and 5) morphology.116  Various techniques used to look at these 
aggregate characteristics will be briefly described.  However, the user of any technique must 
always be aware of the potential pitfalls of each and every technique since not every method is 
useful for all types of protein particle samples.27,110,117 Techniques for sizing and counting of 
aggregates will be briefly discussed followed by discussion of commonly used protein particle 
characterization techniques.  
1.5.1 Particle Sizing and Counting 
 
 
 18 
Depending on environmental conditions, aggregates can form in various size ranges:  
soluble (<100 nm), submicrometer (100-1000 nm), subvisible (1-100 µm), and visible (>100 
µm).116 There is no single technique available that can be used to characterize this broad size 
range of aggregates.  Therefore a variety of analytical techniques must be used.110 Some of the 
most common analytical techniques used to size and count aggregates and particles are discussed 
below but an in-depth discussion of these techniques and their potential advantages and 
disadvantages are discussed elsewhere in the literature. 68,118,119  As mentioned earlier, protein 
particles between 0.1-10 µm in size have been receiving a lot more scrutiny over the past few 
years due to the hypothesis that they have an increased potential to cause untoward immunogenic 
responses.52  Therefore, in this chapter we will focus on this size range, but briefly summarize 
the techniques for quantification of small soluble aggregates.  
1.5.1.1 Soluble Aggregates (<100 nm) 
 
Information about small, soluble protein aggregates, while not the focus of this review, 
can be obtained from a variety of techniques. Most commonly used techniques are size exclusion 
chromatography (SEC), dynamic light scattering (DLS), analytical ultracentrifugation (AUC), 
and asymmetrical field flow fractionation (AFFF).  Additionally, SEC can be coupled to a multi-
angle light scattering detector (MALS) to gain information on the absolute molecular weight of 
the aggregates. 120,121  
1.5.1.2 Submicron (100-1000 nm) 
 
Techniques like dynamic light scattering (DLS), Nanosight Particle Tracking Analysis 
(NTA), and Resonant Mass Measurement (RMM) cover this size range. DLS is a light scattering 
technique, which provides molecular weight information about aggregates in solution.  DLS is a 
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quick, often high throughput technique that determines the size of aggregates based on 
measurements of time-dependent fluctuations in scattered light intensity, which arise from 
random motions of molecules in solution. From this information and by knowledge of the 
viscosity and temperature of the solution, a diffusion coefficient can be determined, which can 
then be used to calculate the hydrodynamic radius by the use of the Stokes Einstein equation.  
The samples, however, need to be homogenous with low polydispersity since size determination 
can be biased towards large particles even if only a few large particles are present.  
NTA is a complementary technique to DLS used to monitor protein particle size, but has 
the advantage of being able to count particles as well. 122  It consists is an optical microscope 
linked to a light scattering detector, which allows visualization of the actual Brownian motion of 
nanometer-sized particles.  Unlike DLS, NTA has the capacity to track and monitor the 
diffusional movements of individual particles and calculate their size using a modified Stokes-
Einstein Equation,122 while DLS calculates the “average” diffusional coefficient from the entire 
ensemble of particles within the solution, NTA calculates size from individual particles.  This 
greatly diminishes the bias towards the contribution of larger particles, associated with many 
light scattering techniques.  Therefore NTA can better analyze polydisperse samples than DLS.  
The Resonant Mass Measurement (RMM) technique measures the size of particles between 
approximately 400 nm to 2 µm and has the ability to differentiate protein particles from silicone 
oil droplets. 123-125  The sensor consists of a suspended beam that resonates at a specific 
frequency.  When a protein particle passes through the microchannel resonator, the frequency 
changes.  The change in frequency is measured and is used to calculate the buoyant mass of the 
particle. By knowing the density of the fluid and approximating the density of the particle, the 
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dry mass of the particle and its corresponding diameter (assuming an equivalent spherical 
approximation) can be calculated.  
Turbidity and nephelometry can be used to measure the light transmitted through the 
sample solution or light scattered by the sample solution relative to formazin standards, 
respectively.   These techniques are not limited to any one size range of aggregates and thus can 
be used as an overall assessment of aggregation. Nephelometry measures the amount of light 
scattered, typically at 850 or 860 nm and at a scattering angle of 90°.  For turbidimetry, the 
transmitted light is measured using a UV/Visible spectrophotometer at a wavelength between 
320 to 800 nm (where proteins do not absorb light).  The measurement is simple to perform and 
nondestructive, yet it doesn’t provide quantitative information about the size, shape, or types of 
aggregates, so it more useful for comparative purposes.  Additionally, high turbidity can also 
arise from larger size aggregates or from the opalescence of high protein concentration solutions, 
which does not always indicate that there is a large amount of aggregates or particles present in 
the sample.119  
1.5.1.3 Micron (Subvisible) 
 
A combination of techniques such as Optical Microscopy, Coulter Counters, Light 
Obscuration, Flow-Imaging (MFI and Flowcam), and Fluorescent Activated Cell Sorter (FACS) 
can be used to count, size and characterize subvisible particles in the range of 1-100 µm.   
 Optical microscopy is a compendial method that requires samples to be filtered onto a 
membrane and visually analyzed.  This technique, however, requires a large sample volume. The 
filtration step can potentially alter protein aggregates. In addition, protein particles may be 
difficult to visualize without additional staining steps.  This requires manual evaluation of the 
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filtered particles, which can be very time-consuming.  Because of this, it is seldomly used on its 
own as a characterization tool, but is used in conjunction with other characterization techniques.   
Flow Imaging Microscopy (Flowcam) and Microflow-Imaging (MFI) are similar 
techniques.  In both methods, particles pass through a flow cell past a high-powered charge-
coupled device (CCD) camera where high resolution images of the particles are captured and 
stored into databases.  The particle images are analyzed by specialized software to provide 
information about size, count, and various morphological parameters, such as aspect ratio or 
transparency of the particles. Unfortunately, protein particles can adhere to the glass surface of 
the flow cells, and can often be very difficult to remove thus requiring careful sample preparation 
and cleaning procedures.  These techniques allow the user to perform operations that were too 
complex previously such as examining how the morphology of the protein particles varies with 
formulation, solution, and stress conditions.  Additionally, these morphological parameters allow 
easy differentiation of protein from non-proteinaceous particles, such as air bubbles or silicone-
oil droplets 126.  Unlike it’s light obscuration counterpart, these two orthogonal techniques are 
more likely to detect translucent protein particles.126  
Light obscuration is a compendial technique that measures the amount of light blocked by a 
particle as it passes through a laser beam. This blocked light intensity is proportional to the 
cross-sectional area of an equivalently sized sphere, which can then be used to calculate the size 
of a particle.  While this technique is easy to perform, it cannot differentiate between bubbles, oil 
droplets, or dust particles. In addition, it often under counts transparent protein particles since 
they do not block light to the same extent as the polystyrene beads used to calibrate the 
instrument. Finally, light obscuration methods often require high sample volumes, although 
lower volume compendial methods for biotechnology products have recently become 
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available.119   
Coulter Counters, or electrical sensing zone methods, rely on the change in electrical 
resistance of a particle as it passes through an electrical sensing zone to calculate particle size 
(based on equivalent spherical diameter).  However, the solution generally needs to be highly 
conductive to measure electric current and the technique can often underestimate the smaller 
sizes.  These conductive solutions can pose some problems for protein solutions that are highly 
sensitive to ionic strength.  This technique can cover a broad size range, from 0.5 µm to 1000 
µm, if multiple apertures and different conductive solutions are used. While this technique does 
not provide morphological information, it does not have some of the limitations that other optical 
detectors face regarding issues concerning refractive index, shape, and compactness. 119  
A Fluorescent Activated Cell Sorter (FACS) is a flow cytometry instrument with sorting 
capabilities.  It can be used to sort fluorescently labeled particles or can be used without 
fluorescence labeling to detect, quantitate, and collect micron sized particles by measuring light 
scattering.  FACS can monitor individual particles and gives very reliable size distribution data.  
The advantage of this technique is that particles of interest can be detected and captured for 
further analysis.  Unfortunately, this technique dilutes particles significantly during analysis 
making the sample recovery difficult during routine use.   
1.5.1.4 Visible (> 100 µm) 
 
 Larger particles can be detected visually without any instrument, although well-defined 
viewing parameters are essential to obtain reproducible results. The United States Pharmacopeia 
(USP) requires parenteral preparations to be “essentially free from visible particles,” while the 
European Pharmacopoeia (Ph.Eur.), states injections have to be “practically free from particles.”  
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The Ph. Eur. chapter provides specific methods for visual assessment of particles, under defined 
background and lighting conditions.30  Even though extensive training is required to perform this 
operation, the results are still based on viewer’s judgment.  Some manual visual inspection 
procedure use a scale provided in the Deutscher Arzneimittel Codex that describes the presence 
of visible particles from a scale of 0 (no particles) to 10 (particles visible immediately in large 
amounts) within 5 s.119 
1.5.2 Protein Particle Characterization 
Aggregates not only vary by size and counts, but also by their morphology and composition 
including conformation and covalent modifications of protein within the particles.79,116 The 
conformation of the protein can be described by its secondary and tertiary structures and by its 
surface hydrophobicity, and can range from being native, partially unfolded, or extensively 
unfolded. Aggregates can also have various covalent linkages, some resulting from disulfide 
cross-linking, which are reducible, and other crosslinks that are not be reducible.  Additionally, 
amino acid residues can be modified by chemical reactions which lead to formation of thioether 
and dityrosine covalent bonds, oxidation of methionines or cysteines, or deamidation reactions, 
etc.116   The morphology of protein molecules within particles and aggregates can be studied by a 
variety of techniques and can range from amorphous to fibrillar in structure.   Characterizing 
aggregates with respect to these traits is potentially just as important as being able to size and 
count them.  Protein particles containing many of these physicochemical aspects have been 
implicated in different immunogenic responses.35,127,128 
 
1.5.2.1 Conformational Alterations 
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Biophysical techniques such as Circular Dichroism (CD), Fourier Transform Infrared 
Spectroscopy (FTIR), Raman Spectroscopy, and Fluorescence Spectroscopy can be used to study 
conformational changes in proteins leading to aggregation.  These techniques will be briefly 
discussed, but detailed information can be obtained from other sources.129,130  
CD is a measure of the unequal absorption of right and left-handed circularly polarized 
light.  Near-UV CD is used to monitor wavelengths between 250-350 nm and can give 
information regarding the tertiary structure characteristics of a protein by monitoring certain 
amino acid residues.  Far-UV CD can be used to study changes in secondary structure of the 
protein, by examining wavelengths between 170-250 nm to monitor the protein polypeptide 
backbone conformation, such as alpha helices, beta sheets, or random coil.  However, larger 
protein particles or turbid solutions can give inconsistent results from absorption flattening and 
differential scattering effects, but recent developments are being made to look at the structure of 
protein within immobilized particles using a rotating cylindrical sample cell and ultrathin path 
length cells.119,131  
Fourier Transform Infrared Spectroscopy (FTIR) analysis can provide an estimate of the 
amount of various secondary structure components in a protein solution by looking at the 
vibration characteristics of the bonds in the protein backbone, especially in the Amide I region 
between 1600-1700cm-1. 79,132-134  The use of FTIR Microscopy allows increased sensitivity and 
makes it possible to determine the composition of protein molecules within a single protein 
particle 126.  The advantage of FTIR analysis of proteins is that it can be performed in optically 
clear and turbid solutions or with solid samples.  Unfortunately, the sensitivity is fairly low and a 
relatively large amount of aggregate needs to be present to detect changes in the protein higher 
order structure.  Raman spectroscopy gives similar and complementary information as FTIR, 
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based on inelastic Raman scattering. Proteinaceous and nonproteinaceous particles can also be 
analyzed by Raman spectroscopy.  Similar to FTIR microscopy, it also requires a lot of 
aggregated sample to detect structural changes.135   
Fluorescence spectroscopy relies on monitoring the emission of photons from certain 
high energy states to certain low energy states.  It can be used to study changes in tertiary 
structure of proteins by monitoring changes in environment around aromatic amino acid 
residues, primarily Trp, but minimally near Tyr residues.  This approach, which monitors the 
environment around aromatic residues is called intrinsic fluorescence spectroscopy. In extrinsic 
fluorescence spectroscopy, fluorescent dyes such as 1,8 anilinonapthalene sulfonic acid, 
thioflavin T, sypro orange, nile red, or congo red, whose florescence properties change upon 
exposure to more apolar environments, are used to monitor changes in surface hydrophobicities 
or levels of aggregates in protein samples.136,137  The dyes, however, can also interfere with the 
aggregates present in solution and may either cause more aggregation or disrupt the aggregates 
present by their own binding to regions on the protein. Perhaps the best method using 
fluorescence with individual protein particles employs FACS equipped with fluorescent detectors 
(described above).  Mach et al have used this technique with a monoclonal antibody and showed 
that is simple to differentiate proteinaceous particles after staining them with a fluorescent 
hydrophobic dye.138   
1.5.2.2 Covalent Modifications 
 
SDS-PAGE is the simplest and fastest technique used to look for the presence of 
reducible or non-reducible covalent linkages (i.e., disulfide bonds) in protein samples.  The 
technique uses an electric field to separate molecules based primarily on their molecular weight 
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by unfolding and coating protein molecules with a highly negatively charged detergent. 
However, the sample preparation itself (adding sodium-dodecyl sulfate solution and extensive 
heating) may modify the aggregates and cause non-covalent aggregates to dissociate, leading to 
inaccurate quantitation of the resulting bands. A similar technique can be performed using a 
capillary based system (CE-SDS) to determine the amount of covalent, disulfide linkages in 
aggregates. 139 It has been performed with several mAbs and used for detection of 
aggregates.140,141 
Peptide mapping can also be used to determine if any chemical modifications occurred on 
the primary sequence of a mAb.  First, the protein is treated enzymatically to produce peptide 
fragments which are then separated, monitored and identified using a combination of UPLC 
techniques in conjunction with UV and mass spectrometry.  Using this method, a mAb, subjected 
to extended storage, was analyzed for the extent of deamidation and methionine oxidation.142  In 
another study, a mAb was subjected to mechanical, chemical, and thermal stress treatment and 
then analyzed for chemical modifications.78  It was shown that different types of aggregates 
contained varying levels of different types of chemical modifications.78 
1.5.2.3 Morphology and Composition 
 
 The simplest way of obtaining morphological information is by using MFI, described 
above.  The technique provides digital images of protein particles and calculates a variety of 
morphological parameters (area, intensity, equivalent circular diameter, perimeter, circularity, 
maximum ferret diameter, aspect ratio, and edge particles) of particles in solution.  This 
technique is fast and requires minimal sample preparation. For additional images, one can rely on 
an FTIR microscope, which often is accompanied with an optical microscope (described above). 
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The highest resolution images, however, and the greatest morphological information can be 
gained from Atomic Force Microscopy (AFM), Scanning Electron Microscopy (SEM), or 
Transmission Electron Microscopy (SEM).143 AFM can be used to obtain the surface topology of 
protein aggregates by using a small cantilever that moves directly over the surface of the sample 
with automatic height adjustments.  The utility of the method is illustrated by a recent study with 
stressed mAbs.144  SEM can be used to visualize aggregates from a few nanometers to several 
microns in size by striking the sample with a beam of electrons, which scan the surface, giving 
information about the composition and topology of the sample. Sample preparation for SEM 
often requires coating the surface of aggregates with a conductive material, which may destroy 
or modify the aggregates.  Transmission Electron Microscopy145 can also be a viable technique 
for visualizing aggregates down to nanometers in size.  Unlike SEM, the electron beam directly 
interacts and passes through the sample to form an image.  While sample preparation generally 
requires staining with uranyl acetate, samples can also be analyzed with minimal sample 
preparation, using a Cryo-electronic Microscopy (Cryo-EM).146 This technique also provides 
morphological information of the sample, but unlike SEM or TEM, the sample can be visualized 
in its native state. 147 Composition of protein aggregates can be obtained by performing Energy-
dispersive X-ray spectroscopy (usually in conjunction with SEM or TEM) to obtain elemental 
information of protein within aggregates or particles. 126,148 The signal is obtained when a beam 
of electrons interacts with the sample. The beam of electrons can collide and eject electrons of 
different elements located in distinct energy levels to create a “hole”.  When another electron, 
from a higher energy state, occupies the empty electron “hole,” the difference in energy to fill the 
position is released as an x-ray signal, measured by an energy-dispersive spectrometer.  These x-
ray signals emitted are characteristic of certain elements which can then be easily determined.149   
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It is extremely valuable to understand the uses and drawbacks for each of these 
techniques when interpreting data.  Additionally, it is very important to always mention the 
method used in conjunction with the results since each technique is performed by relying on 
different scientific principles. Assumptions about shape, refractive index, and density of protein 
particles are made and using polystyrene standards for various measurement techniques, 
although convenient, may not accurately reflect the comparative properties of protein particles.  
Currently there are no standards available that adequately mimic protein particles in terms of 
these parameters, even though extensive work is underway to develop them.   
 
1.6 MAB PARTICLE PREVENTION 
 
While there are many ways in which mAbs can aggregate and form particles, there are 
also many approaches that have been developed to minimize and ultimately prevent particle 
formation. The first step is often to predict the aggregation potential of a protein based on 
computer modeling, by finding aggregation “hotspots” and minimizing them by modification of 
amino acid sequences.30 However, this can be problematic as it may introduce a foreign epitope 
or cause the protein to alter its biological activity.   
The most common excipients used to stabilize protein molecules are amino acid 
derivatives, sugars, osmolytes, or salts.106 Some amino acids, such as proline or arginine, are 
often added to decrease aggregation, probably due to their contribution to inter-molecular self-
association due to hydrophobic stacking or by preferential exclusion mechanism.106   Osmolytes 
stabilize protein structure by preferential hydration mechanism and solvophobic effects.106  Salts 
can increase or decrease stability of the protein through nonspecific interactions and these effects 
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can vary depending on their concentration.  For long term storage, anti-microbials may be added 
to the formulation to extend their lifetime but studies have shown that the presence of these can 
lead, in some cases, to partial unfolding of a protein and consequent aggregation.150 
In the early stages of drug development, it is necessary to determine a protein’s 
aggregation behavior as it is subjected to freeze-thaw, agitation, heat, or mechanical stresses. 
Conditions similar to this will often be encountered during the production and handling of a 
protein drug.  For these kinds of conditions, various additives can be included in the formulation 
to prevent aggregation. These stabilizers generally function by minimizing conformational 
changes of the native protein to suppress aggregation.  For possible shaking stress that may occur 
during shipping or during freeze-thaw, non-ionic surfactants are often added to compete with the 
protein for air-water interfaces and to decrease the protein’s surface adsorption on these 
interfaces. Surfactants minimize ice-protein interactions by reducing surface adsorption, but if 
they are contaminated with peroxides or exposed to a sufficient amount of light, they can 
degrade and cause oxidation reactions.  In such cases, methionine or tryptophan is often included 
in the formulations to prevent or reduce oxidation reactions due to polysorbate degradation.  
Surfactants could also cover exposed hydrophobic sites of the protein itself and thus prevent 
aggregation.67  Polysorbates have been used in many mAb formulations such as Rituxan, 
Remicade, ReoPro and Humira.151  In both freezing and shaking stresses, surface adsorption to 
various interfaces is one major source of aggregation.  Therefore minimizing the surface area of 
the interface can decrease aggregation. During freeze-thawing, it is common to employ a slow 
freezing rate since this will generate larger crystals, with a lower surface area. Additionally, 
increasing the protein concentration can be beneficial, especially for preventing freezing and 
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shaking-related aggregates, since higher protein concentration would lead to a smaller fraction of 
protein being adsorbed at the interface than if the formulation was more dilute.  
Prevention against thermal stress can also be accomplished by addition of sugars (e.g., 
sucrose, trehalose) since they stabilize the protein by preferential exclusion. Sugars also can have 
more affinity for the native state than for the non-native state. Arginine can also be included to 
increase the solubility of aggregation-prone molecules.  It is in fact known to suppress heat-
induced aggregation of mAbs.106  
 
1.7. ATTRIBUTES OF AGGREGATES THAT MAY BE LINKED TO INCREASED 
IMMUNE RESPONSE 
 
Some aggregate characteristics may impact immune responses more than others. 
Specifically increased uptake of particles by antigen presenting cells (APCs) or extended 
exposure of them to T cells could play a role in the immune response,152-155 especially since the 
first step in inducing an immunogenic response is by APCs.  In fact, protein aggregates activate 
APCs and can be easily phagocytized155. However, while APC uptake is a requirement for 
immunogenicity, it does warrant it, but is good for predictive purposes.  APC binding and uptake 
of the antigen can be modulated by altering size, surface molecule organization, 
hydrophobicity/hydrophilicity, shape, surface charge, and conformation.156,157 Additionally, it 
appears that the type of aggregate itself may be an important factor as well.   
The size of antigens is thought to play one of the largest roles in their immunogenicity.  
Soluble aggregates do not seem to cause significant immune responses.158  Even though there is 
no clear conclusion concerning what size of particles seem to be optimal for phagocytosis157, it is 
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known that APCs have evolved to process antigens that were similar in size to viruses (20-100 
nm) and bacteria (a few micrometers).157,159  It is also believed that subvisible (micron) sized 
particles can act as adjuvants and enhance T cell responses by attracting dendritic cells, which 
uptake aggregates. 42,160-163 Due to their larger size, microparticles can also present multiple 
copies of antigens on their surface, facilitating B cell activation.163 However, interpretation of 
some of this data needs to be taken with caution as many studies looking at the impact of size 
were performed using different types of beads to carry the antigen and were not pure protein 
particles. Therefore, how accurately these results correlate with actual protein particles remains 
to be seen.  
The structure of aggregates themselves is very important as well.  Native-like aggregates 
appear to be more capable of producing ADAs that could cross-react with the native monomer. 
42,164   Additionally, molecular weight, mass, and solubility of the aggregates can play a role in 
the immunogenicity of a biotherapeutic. Protein self-assembly into virus like particles display 
repeating, equally spaced epitopes, which mimic those present in viruses or bacteria.  The 
immune system has evolved to target these repetitive patterns and mount a strong immune 
response.30,157,165 Other pathogen-associated molecular patterns such as the exposure of 
hydrophobic portions of biological molecule have become evolutionary danger signals to the 
immune system to recruit cells for repair, destruction, or increased immunity.156  In some studies, 
microspheres with hydrophobic surfaces were more readily phagocytized than those with 
hydrophilic surfaces.159,166,167  
Particle shape and geometry may influence attachment and internalization and impact the 
overall rate of phagocytosis by macrophages.168,169 Tabata et al showed that phagocytosis of 
oblate ellipsoids is better than phagocytosis of prolate ellipsoids or spheres, but attachment of 
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prolate ellipsoids is better than that of oblate ellipsoids of certain volumes.166 Those with the 
longest dimensions close to 2-3 microns have the highest attachment.166 They described their 
findings by mentioning that phagocytosis is an energy intensive process requiring actin 
reorganization.  The oblate ellipsoid, which requires the least actin remodeling by the 
cytoskeleton, will be internalized faster. In addition to influencing binding and uptake, aggregate 
morphology may influence how it becomes accessible for peptide processing.128  
Surface charge is another factor that may influence APC uptake.  Cationic microparticles 
can be taken up, often non-specifically, by macrophages and dendritic cells (DC), 167,170,171 
although, this is not always the case.170  The cell surface in vivo is usually negatively charged 
due to the presence of sulfated proteoglycans.  Thus, ionic attraction between cationic 
microparticles and the negatively charged surface often can lead to binding and internalization. 
159  
The type of aggregate may be an important immunogenic factor.  Specifically oxidized 
samples have often showed higher immune response in many studies.  This could be because a 
large amount of reactive oxidized species in biological pathways may be considered as danger 
signal by the immune system.172  Oxidized mAbs in one case showed a relatively high immune 
response 173, whereas, in another study, two oxidized IgG2 mAbs did not.174 As discussed above, 
it has been shown that high immunogenic responses were apparent from protein samples 
consisting of a large number of subvisible particles, various levels of native conformation, and 
those oxidized either by metal-catalyzed42,164,175,176 or hydrogen peroxide.175 Therefore the type 
of chemical modifications and the extent of structural alterations in proteins within 
aggregates/particles can determine immunogenic potential in conjunction with aggregate size and 
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number.  Surface charge and morphology of protein particles has also been shown to play a role 
in some cases.   
1.8 CHAPTER REVIEWS 
 
1.8.1 Structural Characterization of IgG1 mAb Aggregates and Particles Generated 
Under Various Stress Conditions (Chapter 2) 
Chapter 2 presents a case study looking at protein particle formation of an IgG1 mAb 
using different analytical techniques to study the effect of four different stresses (freeze-thaw, 
shaking, stirring, and heating) and the effect of salt on the size, number, and nature of 
aggregates/particles.  Initially, aggregates and particles were sized and counted by SEC, NTA, 
MFI, turbidity, and visual assessments.  Particle morphology was examined by MFI and TEM. 
The protein within the particles that formed under the same four stresses, but in the presence of 
150 mM NaCl, was analyzed for covalent crosslinking (by SDS-PAGE), secondary structure 
content (FTIR in solution/FTIR Microscopy), and surface hydrophobicity (extrinsic fluorescence 
using 1,8 ANS).  Radar plots, generated from MFI data, were also utilized as a data visualization 
tool to study the effects of the stress and salt on particle size distribution and morphology of 
subvisible particles.   
The possible causes for aggregation and particle formation under each stress condition is 
discussed and compared with other similar studies using monoclonal antibodies.  These 
comparisons showed that aggregate and particle formation varies with the protein, type of stress, 
and solution conditions.  Freeze-thaw was the mildest condition.   Only in the presence of NaCl, 
some subvisible particles containing protein with native secondary structure and low surface 
hydrophobicity were formed.  Shaking generated predominantly transparent and amorphous 
 
 34 
micron-sized particles, a combination of fiber-like and spherical-like nanometer sized particles. 
These particles contained protein that had largely native like secondary structure and low surface 
hydrophobicity with very little covalent crosslinking. Both stirring and heating in the presence of 
salt were harsher conditions.  Stirring generated a large quantity of submicron, micron, and 
visible particles.  In the absence of NaCl, more spherical nanometer particles were observed 
compared to the other NaCl-stressed samples. Insoluble protein, isolated after centrifugation, was 
more highly covalently linked and displayed greater surface hydrophobicity than the protein in 
the soluble fraction. The subvisible particles contained protein with some decrease in native like 
secondary structure. Heating of an IgG1 sample in the absence of NaCl was generally a mild 
stress and did not form a large number of soluble aggregates or nanometer and micron-sized 
particles. Heating in the presence of NaCl, however, generated particles of all sizes in great 
abundance. Nanometer particles were fibrillar in morphology. The insoluble aggregates, 
separated by centrifugation, contained a higher level of covalently linked aggregates than the 
protein in the supernatant but both demonstrated high levels of ANS binding.  Subvisible 
particles contained protein with non-native like secondary structure. The heat stressed samples 
had very highly non-native-like secondary structure. The combination of structural changes from 
the heating stress (conformation effects) and decreased shielding of repulsive charges (colloidal 
effects) by the NaCl led to the large amounts of aggregate and particle formation.   
Our work follows some general trends but some exceptions are also noted.  All stresses 
showed increased aggregation in the presence of NaCl but in different size ranges.  This 
observation highlights the fact that protein aggregate formation cannot always be detected by one 
technique and a range of analytical tools need to be used for full characterization.   
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1.8.2. Characterization of the Physical Stability of a Lyophilized IgG1 mAb after 
Accelerated Shipping-like Stress (Chapter 3)  
The impact of mechanical stress on the stability of lyophilized protein therapeutics has 
not previously been studied in detail.  This chapter focuses on understanding if shaking stress, 
mimicking the transportation and shipping conditions that a lyophilized protein may encounter, 
can decrease the physical stability of the protein upon reconstitution.  We implemented a stress 
shipping test based on guidelines from ASTM International Standard Test Methods for Vibration 
Testing of Shipping Containers 177.  Our initial studies showed that the physical stability of both 
a liquid and lyophilized formulation of an IgG1 mAb during shaking was similar, contrary to our 
notion that the lyophilized sample should be more stable.  The lyophilized sample displayed 
physical instability upon reconstitution upon shaking stress.  This was an interesting result and 
was further investigated.   
An array of analytical techniques were utilized to size and count protein aggregates and 
particles forming over a broad size range using SEC, DLS, NTA, RMM, MFI, and solution 
turbidity.  The morphology and composition of these particles were further examined using radar 
chart analysis of MFI data, SDS-PAGE and FTIR Microscopy.  Interestingly, shaking stress only 
led to increases in turbidity and subvisible particle counts (as assessed by MFI).  In conjunction 
with analyzing the effect of mechanical stress on the physical stability of this mAb, we also 
analyzed the effect of moisture content, reconstitution medium type and addition rate, storage 
duration, storage temperature, and cake structure on the physical stability of this mAb.  In all 
cases, shake-stressing of the lyophilized mAb, followed by reconstitution, led to increases in 
turbidity and subvisible particle formation.  Minimal changes in conformation or covalent 
linking of protein within the particles was detected by FTIR analysis or SDS-PAGE upon stress 
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and reconstitution. The effect of moisture content and reconstitution addition rate were minimal 
on the stressed mAb.  However, the reconstitution of the shake-stressed sample took longer than 
the unstressed lyophilized sample. Reconstitution medium was an important factor impacting the 
physical stability of this protein upon stress.  The potential causes of increased subvisible particle 
counts and the effect of reconstitution medium upon shaking stress are discussed. Significant 
differences in physical stability were not observed when the effect of extent of shaking on 
subsequent storage stability of the lyophilized IgG mAb was analyzed.  Solution turbidity and 
subvisible particle concentration increased with increasing storage duration and with increasing 
temperature of storage.  The cake integrity, resulting from the shake stress, did impact the extent 
of degradation.  As the mechanical stress applied to the lyophilized cake was increased (with 
more cake collapse), subsequent storage stability decreased.   
This case study highlights that post-lyophilization mechanical stress, which may be 
encountered by the lyophilized protein during shipping and transportation, can result in physical 
instability of the lyophilized protein.  This study highlights the importance of monitoring shake 
sensitivity of lyophilized protein cakes as part of formulation development strategies.  Future 
work requiring more lyophilized proteins to be characterized in this manner is suggested.   
1.8.3. Physical characterization and in vitro biological impact of highly aggregated 
antibodies separated into size enriched populations by FACS  (Chapter 4) 
The goal of this chapter is to study the impact of protein aggregate size on the in vitro 
early and late phase immune response using stir stressed IgG2 mAb particles (mAb2) and an In 
Vitro Comparative Immunogenicity Assessment Assay (IVCIA), which was developed by our 
scientific collaborators at Amgen. 
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To study the impact of protein particle size in the IVCIA assay, a mAb2 solution was 
stirred to generate protein particles of varying sizes.  The protein particles were first separated 
into various size populations using either (1) low speed centrifugation to enrich for nanometer 
vs. micron sized particles, or (2) the Fluorescence Activated Cell Sorter (FACS) to separate and 
collect enriched fractions of different micron-sized protein particles.  The enriched fractions 
were assessed for their immunogenic potential in the IVCIA but due to the dilute nature of FACS 
sorted particles, the sample prepared immediately before FACS separation was biophysically 
characterized.  We were able, however, to examine particle morphology and composition of the 
FACS isolated particles by a combination of MFI, TEM and SEM-EDX.  
In an initial set of experiments, we showed that micron sized protein particles, compared 
to nanometer-sized particles, displayed the highest cytokine signature readout in the IVCIA 
assay. The FACS separation did not dramatically alter the properties of the stir stressed sample 
and the enrichment was high even after the necessary two freeze thaws.  The sample just prior to 
FACS separation contained particles that were amorphous containing some alteration in overall 
secondary structure with increased surface hydrophobicity.  Interestingly, particles generated by 
stirring contained fluorine as measured by SEM-EDX; the element was not present in the buffer, 
control mAb2 or heated mAb2.  Its impact in our assay needs to be assessed in the future.  
Limitations and advantages of using FACS for sorting subvisible particles are discussed. We also 
highlighted that both protein mass and number of particles are important factors for 
consideration in monitoring their ability to generate cytokine responses in this assay.  Even 
though the PBMC response was low due to the dilute nature of the particles, it appeared that in 
this assay, with this mAb, 5-10 µm sized protein particles displayed relatively elevated levels of 
cytokine responses compared to the other sized protein particles tested.   
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1.8.4. Summary, conclusions, and future directions (Chapter 5) 
 Chapter 5 summarizes the observations and understanding gained from studying three 
different monoclonal antibodies.  In the first study, presented in Chapter 2, the effects of 
different stresses on the aggregation behavior of a mAb were characterized by a host of different 
techniques. Different stresses led to formation of aggregates with very different characteristics.  
It is suggested that it is not enough to just count and size aggregates and particles but it is 
necessary to thoroughly characterize them as well. The second study, presented in Chapter 3, 
looked at the physical stability of a lyophilized mAb undergoing agitation stress, which mimics 
the stress encountered by the protein during transportation and shipping.  The objective here was 
to bring attention to the fact that mechanical stress that a lyophilized protein may encounter 
during transportation may lead to increased particle formation.  Since this kind of work has not 
been done before, a detailed mechanism is lacking.  Strategies are described on how to better 
understand this occurrence. In the final study, presented in Chapter 4, a new application for 
FACS is described and the potential of an in-vitro assay, based on human immune cells, was 
presented. The advantages and limitations of FACS and the capacity of the cell-based assay to 
rank relative immunogenic potential of various stressed samples are discussed.  While future 
work is suggested to get a clearer understanding of this very complex topic, some insight into the 
impact of protein particle size in this in vitro cell-based immunogenicity model system is 
obtained.  
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2.1 INTRODUCTION 
 
A current concern with the use of monoclonal antibody-based therapeutics is their 
tendency to aggregate and form particles during long-term storage and/or during accidental 
exposure to environmental stresses.  The formation of aggregates and particles may lead to an 
increase in immune response 1-3  or a decrease in efficacy of the drug.2,4  Protein aggregation can 
occur during many stages of production (purification, formulation, and filling), or during long-
term storage, shipping, and even administration to the patient.5  Therefore it is important to better 
understand the reasons for aggregation and particle formation due to different stresses and 
formulation conditions in order to develop strategies to minimize its occurrence.   
Aggregation and particle formation in therapeutic protein formulations can be caused by 
a variety of environmental stresses or by formulation conditions such as concentration,6-8 
solution pH,6,9,10 and the presence or absence of certain excipients.6,7,9  Freezing can not only 
lead to changes in the formulation pH6,11,12 and concentration of proteins and excipients,6 but 
also to the formation of ice/water interfaces6,13-15 where protein adsorption can induce partial 
protein unfolding and subsequent aggregation.6,9,15-17  Proteins subjected to heating undergo 
conformational changes that can lead to the formation of aggregates and particles.9,18 Mechanical 
stresses may cause shear or interfacial effects in which the protein adsorbs to the air-water 
interface, leading to structural alterations which can initiate aggregation as well.9,16,19,20   Stirring 
and shaking are both mechanical stresses that can also cause cavitation, local thermal effects, 
bubble entrapment, and transportation of the aggregated protein from the air-water or air-
container interface into the bulk solution.6,21-23  
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One major challenge in studying protein aggregation experimentally is that a wide variety 
of analytical techniques are required to characterize the formation of protein aggregates and 
particles over a broad size range (from few nanometer to hundreds of microns).24  In addition, it 
is also important to have complimentary, orthogonal techniques for analyzing aggregates of 
similar size ranges since results can differ based on the principles and setup of each technique.6  
In this work, we follow the previously proposed definitions of protein aggregates, across the size 
ranges of few nanometers to 100s of microns.25  In this case study, size exclusion 
chromatography (SEC) is used to analyze smaller aggregates in the size range of tens of 
nanometers. Although it is a powerful analytical tool for monitoring small nanometer-sized 
soluble aggregates, upon injection of sample into the column, aggregates can potentially 
dissociate upon mixing with mobile phase or adhere to the column thereby requiring careful 
method development and use of orthogonal techniques.26  For sizing submicron particles (0.1 to 
1 µm), Nanosight Tracking Analysis (NTA) is used while for micron (1-100 µm) size particles, 
Microflow-Imaging technique (MFI) is employed.  NTA tracks and sizes individual particles 
(unlike its DLS counterpart), but has limited sensitivity in detecting low numbers of submicron 
particles. In addition to sizing and counting particles like light obscuration, MFI also has digital 
imaging capabilities that can provide morphological information allowing differentiation 
between silicone and protein particles.  To detect visible particles larger than 100 µm, visual 
assessments are employed.  Turbidity is also used as a general method to monitor the formation 
of aggregates and particles in solution across the various size ranges.  Although visual inspection 
is a commonly used technique, even under pre-defined conditions and with extensive analyst 
training, results may vary between different analysts. Turbidity provides semi-quantitative 
information for comparisons of the overall aggregation state of a sample, but it does not provide 
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information regarding the size or number of particles. Detailed discussions of the strengths and 
limitations of these analytical techniques are described more thoroughly elsewhere.27,28 
Recently, there has been an increased emphasis on characterizing the morphology and 
composition of particles in addition to counting and sizing them.27   As a starting point for this 
work, MFI analysis, in addition to sizing and counting of subvisible particles, is used for 
morphological analysis by utilizing parameters such as aspect ratio and intensity of the digital 
images.29,30 For visualization of small, nanometer-sized aggregates, transmission electron 
microscopy (TEM) is used.31  SDS-PAGE is used to determine the extent of covalent, disulfide 
linkages present in aggregates.32 Extrinsic fluorescence spectroscopy with 8-anilino-1-
naphthalene sulfonate (ANS) probe provides information concerning the surface hydrophobicity 
of aggregates.33;34,35  FTIR provides insights into the secondary structure of native protein and 
aggregates in solution,6,36-38 with the use of a FTIR microscope allowing for selection of 
individual protein particles for secondary structure analysis.29   
This paper is a “protein particle formation” case study by utilizing a variety of analytical 
techniques to examine the effect of four different environmental stresses (freeze-thaw, shaking, 
stirring, and heating) and formulation composition (salt concentration) on the number, size range 
morphology, and compositional nature of the IgG1 aggregates/particles formed from stressing 
the mAb solutions. Additionally, a new data visualization method consisting of radar plot 
analysis39 was used to better evaluate the effects of environmental stress and salt concentration 
on particle size distributions as well as changes in certain morphological parameters measured by 
MFI.  The trends observed in terms of types and amounts of particles formed under the different 
stress conditions are discussed, along with some comparisons to previous studies with different 
monoclonal antibodies.    
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2.2 EXPERIMENTAL SECTION 
2.2.1 Materials 
Purified monoclonal human IgG1 (mAb) was obtained from Janssen Biotech (Radnor, 
PA) at 40 mg/mL.  The reagents and stir bars required for sample preparation were purchased 
from Sigma Aldrich (St. Louis, MO), and Fisher Scientific (Pittsburgh, PA).  The 3 mL vials and 
rubber stoppers used to generate protein aggregates were purchased from West Pharmaceuticals 
(Lionville, PA).  For counting and sizing of aggregates (using SEC, NTA, MFI, turbidity, visual 
assessments), the mAb was diluted to 1 mg/mL using 10 mM sodium acetate buffer, pH 5 ± 150 
mM NaCl.22 This condition was also used for morphological analysis of particles by MFI.  For 
structural and morphological analysis of the aggregates (using TEM, MFI, SDS-PAGE, FTIR-
Microscopy, ANS-Fluorescence), the mAb was diluted to 1 mg/ml in 10 mM sodium acetate 
buffer, pH 5 containing 150 mM NaCl.  
2.2.2  Methods 
 
2.2.2.1 Generation of Aggregates 
 
 The 40 mg/mL IgG1 mAb solution was diluted to 1 mg/mL in 10 mM sodium acetate 
buffer, pH 5 ± 150 mM NaCl and then subjected to a variety of accelerated stress conditions.  
These conditions were selected to match pH solution conditions used previously with a different 
set of IgG mAbs22,40  In each case, the buffer controls were stressed similarly to the protein 
samples and analyzed using various sizing, counting, and characterization techniques.  Since the 
buffer controls showed very low particle counts, the data were not included in the figures.  For 
freeze-thaw stress, the mAb was frozen and thawed one to three times (indicated as cycles) at -
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80°C and room temperature, respectively (labeled FT-C1 and FT-C3).  For shaking stress, the 
mAb was agitated at 300 rpm (using an IKA AS260.1 shaking platform) for 1-3 days (labeled 
shake-D1 and shake-D3).  For stirring stress, the mAb was stirred at an intermediate speed 
(setting 5) on a stirring plate (ThermoSci Pierce Reacti-Therm III #18823 Heating/Stirring 
Module) using Flea Micro Teflon coated magnets (Fisher Scientific) for 1-3 days (labeled stir-
D1 and stir-D3).  For thermal stress, the mAb was incubated at 60¹C in an incubator (Revco 
Ultima II) for 1-3 days (labeled heat-D1 and heat-D3).  
2.2.2.2 Size-Exclusion Chromatography 
 
 A Shimadzu Prominence HPLC system equipped with a diode-array detector was 
employed with a Tosoh Bioscience TSK-Gel Bioassist G3SWXL (7.8 mm x 30.0 cm) PEEK 
column and a corresponding PEEK Guard column (TSK Guard Column SWXL, 6.0 mm x 4.0 cm) 
that were preconditioned with BSA as described previously.26  Molecular weight standards 
(Biorad Laboratories; Hercules, CA) were run to test for efficiency of separation and resolution.  
Both the column and guard column were equilibrated at 30¹C for 1 hour using the mobile phase 
comprised of 0.2 M sodium phosphate, pH 6.8 at a flow rate of 0.7 ml/min.  Aggregated samples 
were centrifuged at 16,000g (851 rotor on an IEC Micromax 3593) for 5 min and 10 µL of 
supernatant was injected for analysis and monitored simultaneously at 214 and 280 nm for each 
30 min sample run.26  Multimers, dimers, monomer, and fragment peaks were quantified using 
the LC Solutions data analysis software provided with the instrument as described elsewhere.26   
2.2.2.3 Nanoparticle Tracking Analysis (NTA)  
 
 Submicron (nanometer) sized particles were measured using a Nanosight LM-14 
(Nanosight, Amesbury, UK) with a high resolution EMCCD camera.  Stressed mAb solutions 
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were centrifuged at 16,000g for 5 min and 300 uL of the supernatants were injected into the 
sample holder.  The stirred (with and without NaCl) and heat stressed (with NaCl only) samples 
were diluted by a factor of 100 prior to analysis.  Three 30 s movies were taken at ambient 
temperature for each sample at a viscosity of 0.95 cP.  Data analysis was completed using NTA 
2.3 software (Nanosight) with the required camera level and gain adjustments.  Dilution factors 
were accounted for in the data analysis.   
2.2.2.4 Micro-Flow Digital Imaging  
 
 Subvisible (micron sized) protein particles were analyzed and imaged using a MFI DPA 
4200 (Protein Simple, Santa Clara, CA).  Prior to each analysis, the instrument was primed with 
purified water to obtain a particle-free baseline.  Samples were gently swirled and 1 mL of each 
sample was removed using a low protein-binding pipette tip and loaded into a sample holder.  
Some of the samples (stir-D1 and D3 with and without NaCl; shake-D3 with NaCl; and heat-D3 
with NaCl) were diluted by a factor of 100 prior to being passed through the instrument at a flow 
rate of 0.1m/min.   The data were obtained as described previously by Kumru et al.41  
2.2.2.5 Data Visualization with Radar Plots  
 
 To generate MFI particle size distribution radar plots, subvisible particle concentrations 
and sizes for both unstressed and stressed samples were obtained from MFI’s MVAS 1.3 
software. Similarly, MFI particle morphology radar charts were created using the average mean 
intensity and aspect ratio values for each sample. All samples were run independently three times 
(n=3).  The data were pre-processed in Excel and two radar plots (one showing average values 
and one showing variability in the runs) were generated using the MiddaughSuite software 
created in our lab.42  The two radar charts were superimposed using Adobe Photoshop CS6.  See 
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Kalonia et al. 2013 and Kim et al. 2012 for a more detailed description of this data visualization 
methodology as applied to protein aggregation and conformational stability data, 
respectively.39,42   
2.2.2.6 SDS-PAGE 
 
 Samples were centrifuged at 16,000g for 5 min to separate the soluble fraction 
(supernatant) from the insoluble fraction (pellet).  Both fractions were dissolved in NuPAGE 
LDS sample buffer (Life Technologies, Carlsbad, CA) with and without 50 mM DTT (BioRad) 
and incubated at 80¹C for 90 s.  Approximately 10 µg of each sample was separated on a 3-8% 
Tris-Acetate gel using Tris-Acetate running buffer (Life Technologies) for 65 min at 150V.  A 
Hi-Mark unstained molecular weight ladder was used as a reference (Life Technologies).  The 
starting protein concentration for the supernatant of one sample (stir-D3) was low so a maximum 
of 20 µL was loaded.  Protein bands were visualized by staining with Bio-Safe Coomassie blue 
(BioRad). 
2.2.2.7 Turbidity 
 
 A HACH 2100 AN turbidimeter was used to monitor the turbidity of each of the samples.  
Prior to running the aggregated samples, NTU calibration standards were used to generate a 
standard curve.    
2.2.2.8 Transmission Electron Microscopy (TEM)   
 
 Carbon-coated grids were dipped into methylene chloride for 10 s to remove the top 
carbon layer and were dried for a few minutes.  The images were obtained by uranyl acetate 
staining and by following the procedure by Kumru et al.41   
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2.2.2.9 Free Thiol Quantitation 
 
 Samples were centrifuged at 16,000g for 5 min to separate the soluble (supernatant) and 
the insoluble (pellet) fractions.  The pellet was dissolved in 6M guanidine hydrochloride (Fisher 
Scientific).  The amount of free thiol in the samples as well as in the appropriate controls was 
measured using the protocol described in the Measure-iT Thiol Assay Kit (Molecular Probes) 
with a SpectraMax MS plate reader (Molecular Devices; Sunnyvale, CA).  
2.2.2.10 Extrinsic Fluorescence Spectroscopy  
 
 Samples were centrifuged at 16,000g for 5 min to separate the soluble and insoluble 
fractions.  The pellet was resuspended in 10 mM sodium acetate, 150mM NaCl, pH 5.  The 
protein concentration of each of these supernatant and pellet components was measured using a 
Nanodrop spectrometer (Thermo Scientific) with light scattering correction.  The samples were 
diluted to 0.1 mg/mL in 10 mM sodium acetate, 150 mM NaCl, pH 5.  8-Anilinonaphthalene-1-
sulfonate (ANS; Sigma-Aldrich, St. Louis, MO) was added and the ANS fluorescence of the 
samples were recorded according to Kumru et al.41  The signal from the buffer with equivalent 
amount of ANS was subtracted from all measurements. 
2.2.2.11 Fourier Transform Infrared Microscopy  
 
 Five µm gold filters (Pall Corporation) were used for analyzing the aggregated samples. 
Filters were equilibrated by washing with 0.1 M NaOH.  The samples were then filtered, washed 
with ultrapure water, and dried overnight.  A Bruker Hyperion FTIR Microscope with a 15X 
objective was used to image individual particles.  Two-hundred-fifty-six scans were recorded 
from 600-4000 cm-1 with a viewing area of about 100 µm x 100 µm.  To observe the maximum 
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change in secondary structure due to heating, a 1 mg/mL sample in acetate buffer (10 mM 
sodium acetate, 150 mM NaCl, pH 5) was heated for 20 min at 80¹C.  This heated sample 
(labeled heated control) was also filtered onto the 5 µm gold filter and dried overnight.  OPUS 
(V6.5) software was used for baseline and atmospheric correction.  The second derivative spectra 
were obtained using a nine-point Savitzky-Golay smoothing function.   
2.2.2.12 Fourier Transform Infrared Spectroscopy  
 
 The unstressed mAb at 1 and 10 mg/mL in 10 mM sodium acetate, 150 mM NaCl, pH 5 
were analyzed with a Bruker Tensor 27 FTIR Spectrometer and a Bio-ATR cell.  Two-hundred-
fifty-six scans were recorded from 600-4000 cm-1 at a resolution of 4 cm-1.  To observe changes 
in secondary structure as a function of temperature, unstressed sample at 10 mg/mL was heated 
from 10 to 87.5¹C at 4 cm-1 resolution and 120 s equilibration time with 2.5¹C increments for 
256 scans.   
 
2.3 RESULTS 
 
2.3.1 Counting and Sizing of Aggregates and Particles Formed under Accelerated Stress 
Conditions 
2.3.1.1 SEC (soluble aggregates, <100 nm) 
To determine the amount of smaller (soluble) nanometer aggregates, the stressed IgG1 
mAb samples were centrifuged and the resulting supernatants were analyzed by SEC.  The 
amount of protein material that did not elute from the SEC (referred to as insoluble aggregates) 
was indirectly determined by monitoring the decrease in the total area of the chromatogram 
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peaks between unstressed (D0) and the stressed samples.  The earliest eluted peak was labeled as 
multimer, the second peak as dimer, the third and largest peak as monomer, and the final peak as 
fragment based on the estimated molecular weights.  In the absence of salt, heat stressed samples 
produced more fragments, dimers, and insoluble aggregates compared to the unstressed sample 
(Fig. 2.1A, 2.1I).  Stirring formed more multimers and insoluble aggregates (Fig. 2.1G), while 
freeze-thaw formed a very small amount of multimers and dimers (Fig. 2.1A), compared to the 
unstressed sample.  Shaking (Fig. 2.1E) did not show an increase in any species relative to the 
unstressed sample.  In the presence of 0.15M NaCl, protein was further destabilized and 
generally resulted in the formation of more aggregates.  Heat-stressed mAb in the presence of 
NaCl (Fig. 2.1J) showed more insoluble aggregates, a larger decrease in monomer, and an 
increase in multimer compared to its NaCl-free counterpart, which showed some fragment 
formation and lower levels of impurity (Fig. 2.1I).  Stirring the mAb solution in the presence of 
salt resulted in a large increase in insoluble aggregate and a concurrent decrease in monomer 
content (Fig. 2.1G vs.2.1 H).  Freeze-thaw and shaking did not show changes in any species, but 
in the presence of NaCl, a slight increase in insoluble aggregate was observed (Fig 2.1D, 2.1F).  
2.3.1.2 Nanoparticle Tracking Analysis (NTA) (50-1000 nm particles) 
NTA was used to assess the concentration and size distribution of nanometer sized 
particles (also referred to as submicron particles) formed in stressed and unstressed samples. 
Stirring of the mAb solution in the absence of NaCl (Fig. 2.2A and 2.2C) generated the largest 
number of nanometer sized particles (between ~150-250 nm).  In contrast, in the presence of salt, 
heating generated the most nanometer sized particles (Fig. 2.2B and 2.2D). The concentration of 
nanometer particles present in the unstressed controls was below the instrument’s quantitation 
limit (data not shown).   
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2.3.1.3 MFI (2-100 µm particles)  
Subvisible particle data (concentration and size range of micron size particles) obtained 
from MFI measurements of stressed and unstressed samples were visualized using radar plots 
(Fig. 2.3 and Fig. 2.9). This novel data visualization method for MFI data is described in detail 
elsewhere.39  As shown in the key to Figure 2.3, the concentric circles represent concentration of 
particles, with the lowest concentration (102) being the innermost circle, and highest 
concentration (>107) being the outermost.  The 5 corners of the polygon within the circles 
represent the particle size bins.  An increase in size of the polygon towards one corner represents 
an increase in concentration of particles in that size bin (e.g., stretching of a corner from the 
innermost concentric circle to the outermost circle in size bin number 3 indicates that there is an 
increase in the ≥10<25 µm particles from 102 to >107 particles/mL).   
As shown in Figure 2.3, the size and concentration of subvisible particles formed is 
highly dependent on the type of stress. In the absence of NaCl, freeze-thaw and heat stressed 
mAb samples showed the lowest concentration of particles even after 3 cycles/days of stress, 
while shaking and stirring showed a higher concentration of particles. Stirring produced the most 
subvisible particles, especially in the 2-25 µm size range.  In the presence of NaCl, a higher 
concentration of particles, especially in the 2-25 µm size range, was observed in all of the 
stressed mAb samples.  The heated mAb showed a large difference in both particle number and 
size in the presence and absence of salt that increased from day 1 to day 3.  A large variability in 
the larger particles was observed (the lighter shading on the radar plots reflects the standard 
deviation of the measurements).  In general, shaking the mAb solution containing NaCl 
generated the largest subvisible particles (2-50 µm) (Fig. 2.3).   Particle counts of controls were 
negligible.  
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2.3.1.4 Turbidity and Visual Assessment  
Results of turbidity measurements and visual observations of the stressed mAb solutions 
are shown in Table 2.1.  In samples lacking NaCl, agitation and stirring resulted in the highest 
number of >100 µm (referred to as visible particles, VP), with stirring producing the greatest 
turbidity.  No major NaCl effect was seen for the freeze-thaw stress.  Agitation, stirring, and 
heating stresses on the mAb formed more VP and higher turbidity in the presence of NaCl than 
in the absence of it.  The highest turbidity levels were measured for stir-D3 samples, followed by 
stir-D1, and heat-D3.  In addition, the presence of NaCl increased the turbidity for the heated 
(heat-D1 and heat-D3) protein compared to the corresponding heat stressed mAb samples 
without NaCl.  Shaken or stirred mAb samples formed a large number of visible particles 
regardless of the presence or absence of NaCl.  
2.3.2 Structural Characterization of Aggregates and Particles 
2.3.2.1 Particle Morphology 
As an initial step in characterizing the nature and composition of the particles formed 
under different stresses, MFI was used to elucidate morphological information (intensity and 
aspect ratio parameters) of the subvisible particles generated after three days of stress (Fig. 2.3 
and Fig. 2.9).  Aspect ratio is a ratio of width of the particle relative to the height and intensity is 
related to the particle absorption characteristics.   Data were visualized in the form of a radar plot 
(Fig. 2.4). Figure 2.4 shows the different stresses applied to mAb solutions with and without 
NaCl on the x-axis and the MFI morphology parameters, intensity and aspect ratio, on the y-axis.  
The top and bottom radar charts describe the intensity and aspect ratio, respectively, of the 
particles as a function of stress and solution condition.  As shown in the key to Figure 2.4, the 
aspect ratio of the micron particles varies from ~0.35 (elongated) to 0.85 (more circular) and the 
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intensity from about 350 (opaque) to 850 (highly transparent) intensity level units (ILU).  It 
should be emphasized that the concentric circles here do not represent concentration, but rather a 
change in particle morphology with the outermost circle representing elongated, opaque 
particles, and the innermost circle representing transparent, circular particles.  The corners of the 
5-sided polygon represent distinct particle size bins (labeled 1-5 in the figure). The pink-shaded 
region indicates that an insufficient number of particles were collected in that size range for 
accurate morphological analysis.   
In the absence of NaCl, the shaking of the mAb solution over 3 days resulted in particles 
that appeared transparent (Fig. 2.4A) and elongated (Fig. 2.4B) over all particle size ranges.  In 
the presence of NaCl under the same stress condition, the particles formed are less transparent 
(i.e., more opaque) and less elongated (i.e., more circular in shape) over a narrower size range.  
Stirring-induced mAb particles formed in the presence or absence of NaCl do not show notable 
differences in intensity or aspect ratio.  The concentration of particles in the freeze-thaw and 
heated samples without NaCl was lower (Fig. 2.3) and an accurate comparison of the 
morphology change across the size ranges was limited (as shown by the shaded areas in Figure 
2.4).   
To characterize the morphology of smaller particles, TEM was used to examine the shape 
of nanometer sized aggregates generated from 3 days of different stresses in the presence of 0.15 
M NaCl.  Some representative TEM images are shown in Figure 2.5.  It can be seen that the type 
of stress to which the mAb solution was subjected influences the morphology of the aggregates 
generated.  Freeze-thaw and heated aggregates appear very fibrillar, while agitated-induced 
aggregates appear fibrillar with some spherical aggregates.  The stirring-induced aggregates were 
predominantly spherical in nature in this size range.   
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2.3.2.2 Non-native disulphide cross-linking 
  SDS-PAGE was used to study the formation of non-native covalent crosslinking in the 
stressed mAb.  Results for the stirring and heating stressed mAb containing NaCl are shown in 
Figure 2.6.A and 2.6.B (non-reduced and reduced, respectively).  These samples were first 
centrifuged to separate the supernatant (S) and pellet components (P) prior to electrophoresis.  
The non-reduced supernatants contained predominantly monomers while the pellets contained 
high molecular weight species above 500 kDa (i.e., larger than tetramer).  Upon reduction of the 
supernatant and pellet, a complete loss in the high molecular weight material was observed with 
the light and heavy chains bands of the mAb visible as the primary species.  The pellet for stir-
D1 and D3, heat-D1 and D3 contained significant amounts of non-native disulfide linked 
aggregates.  The supernatant of heat-D1 protein contained some of these non-native disulfide 
linked aggregates as well.  No disulfide-linked aggregates were detected in freeze-thaw and 
agitation stressed mAb samples (data not shown).  The number of free sulfhydryl groups in the 
mAb samples was also measured, and virtually no free thiols were present in control or stressed 
samples (data not shown).   
2.3.2.3 Overall secondary structure content 
The secondary structure of the aggregated samples was studied using FTIR spectroscopy 
of control mAb samples and FTIR microscopy of individual particles formed by stress in 10 mM 
acetate, 150 mM NaCl, pH 5. Representative spectra are shown in Figure 2.7 along with 
wavelength values from multiple measurements including standard deviations.  Two mAb 
controls were prepared for comparison to the particles formed from stressed samples: an 
unstressed mAb with native conformation (Figure 2.7A in the form of second derivative FTIR 
spectra) and particles isolated from an extensively heated mAb sample with some degree of 
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structural perturbations (Figure 2.7B). Figures 2.7C-2.7F show microscopic images and the 
corresponding FTIR spectra of isolated amorphous mAb particles generated under different 
stresses.   
In the Amide I region of the second derivative FTIR spectra of the native mAb, two 
minima at 1637 cm-1 and 1690 cm-1 were observed (Figure 2.7A).  This result is consistent with 
the predominantly intramolecular beta sheets present in native IgGs. 9,43,44  For the isolated mAb 
particles from the extensively heat stressed control, severely altered secondary structure 
displaying extensive loss of intramolecular beta sheet structure (as shown by loss of the two 
minima seen in the native mAb control, and the appearance of intermolecular beta sheets with 
minima at 1617 cm-1, and 1693 cm-1 (Figure 2.7B)) is seen.  For the isolated mAb particles 
produced by three days of heating at 60¹C, the spectra show the sample is more similar to the 
extensively heated control as evidenced by the presence of the two minima at 1624 cm-1 and 
1694 cm-1.45,46  The mAb particles isolated after three freeze-thaw cycles and three days of 
agitation have FTIR spectra with primarily native-like structure as seen by the second derivative 
minima at 1634 cm-1 and 1691 cm-1 and  1635 cm-1 and 1692 cm-1, respectively.  The stirred 
aggregates show reproducibly shifted minima in the main second derivative peak to 1631 cm-1 
indicating some alteration in secondary structure. 
2.3.2.4 Surface hydrophobicity  
To examine any changes in the exposure of apolar regions in the stressed samples 
containing NaCl due to structural perturbations or aggregation/self-association, ANS extrinsic 
fluorescence spectroscopy was used.  Stress induced aggregated mAb samples were centrifuged 
and separated into supernatant and pellet components.  They were analyzed along with two 
controls: the unstressed mAb (D0) and a positive control (Heat-melt). As a positive control to 
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determine the greatest extent of apolar binding of ANS, the mAb solution was heated from 10 to 
87.5°C in the presence of ANS.  From the emission spectrum, it was determined that the 
maximum binding of ANS to the mAb occurred at 72°C suggesting maximal ANS access to 
apolar sites at high temperature.  Representative spectra are shown in Figure 2.8.  The control 
mAb solution (D0) along with supernatants from the FT, shake, and stir-D1 samples (Fig. 2.8A 
and 2.8B) show very little fluorescence intensity indicating that in these samples, ANS has very 
little access to the apolar regions of the mAb.  In the stir-D1 pellet, slightly higher fluorescence 
intensity was observed, which suggests some exposure of apolar sites in these aggregates (Fig. 
2.8A and 2.8B). The heat-D1 supernatant and pellet show the largest ANS fluorescence intensity 
increase suggesting the greatest exposure of apolar regions.  The heat stressed mAb samples 
containing NaCl displayed a similar magnitude of fluorescence intensity as the positive control 
(heat-melt) indicating that this stress condition may also generate samples with extensively 
apolar exposed regions.  
 
2.4 DISCUSSION 
As an initial set of experiments, we first counted and sized protein particles generated 
under accelerated stress conditions employing an IgG1 mAb solution with and without 0.15 M 
NaCl.  A summary of the counting and sizing results from SEC, NTA, MFI, Turbidity, and 
Visual Assessments are presented in Table 2.2.  Different stresses (in the presence and absence 
of NaCl) result in the formation of mAb aggregates and particles of varying sizes that cannot be 
measured by a single analytical method.  As shown in Table 2.2, using multiple techniques is 
therefore very important for analyzing the formation of a broad size range of aggregates.  For 
example, SEC showed that the formation of soluble aggregates was influenced by the presence 
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of NaCl across the four stresses.  NTA results demonstrated that the presence of NaCl affected 
the extent of nanometer particle formation in the freeze-thaw and heat stressed samples, but not 
for the agitated and stirred stressed samples.  Similarly, MFI detected that NaCl enhanced the 
formation of micron particles only for the freeze-thaw stressed mAb sample.  Finally, turbidity 
and visual assessments showed changes in particle formation (due to the presence or absence of 
NaCl) with heat stressed mAb solutions.   
Freeze-thaw stress was observed to be the mildest condition in solutions without NaCl 
since essentially no detectable aggregates or particles were seen (Table 2.2, first row).  Upon 
addition of NaCl (Table 2.2, second row), some insoluble aggregates (detected as a loss of total 
mass by SEC) and some nanometer and micron particles were detected by NTA and MFI.  
Shaking the mAb solution with and without NaCl (third and fourth row in Table 2.2) generated a 
turbid solution with primarily micron (2 to >100 µm) size particles observed by MFI and visual 
inspection. The shaken solution in presence of NaCl was more turbid with some insoluble 
aggregates, and a larger number of micron-sized particles 2 to >100 µm.  Stirring without NaCl 
produced a moderately turbid solution consisting of some insoluble aggregates, submicron, 
micron, as well as a large number of visible entities.  Stirring the mAb solutions, in the presence 
of NaCl, generated the most turbid solutions consisting of a very large amount of insoluble 
aggregates (20% after day 1 and around 60% after 3 days of stress, as quantified by SEC).  The 
largest differences in aggregate and particle formation were observed due to heating the mAb 
solution (Table 2.2; rows seven and eight).  Heating in the absence of NaCl generated a fairly 
clear solution consisting of primarily monomers with a very small amount of insoluble 
aggregates and fragments (SEC), little to no nanometer-sized (NTA), micron (MFI), and visible 
particles even after three days of stress.  In the presence of NaCl, however, a highly turbid 
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solution formed containing much more insoluble and multimer aggregates as well as a large 
increase in the number of nanometer, micron, and visible sized particles.  
Comparison of these results to other studies shows similar trends in which mAb 
aggregate and particle formation depends on the type of stress and solution conditions.  For an 
IgG1 mAb with a basic pI range formulated at lower solution pH such as pH 5.0, the addition of 
NaCl (<0.15 M) may promote protein aggregation and particle formation during environmental 
stress by a combination of effects resulting from neutralizing protein surface charge and 
decreasing electrostatic interactions.  These effects may promote protein-protein interactions 
(colloidal stability) or decrease the structural integrity and stability of the protein 
(conformational stability).9,47  The last column of Table 2.2 describes the impact of NaCl on 
various stresses using eight analytical readouts obtained from four instruments.  For a given 
stress, column values can potentially range from 0/8, indicating NaCl had no impact on the 
aggregation behavior, to 8/8 where NaCl impacted the aggregation behavior of the mAb as 
measured by all of these analytical methods.  Agitation and stirring stresses of the mAb solution 
were least influenced by the presence of NaCl (1 out of 8).  Although the two stresses themselves 
were damaging to the protein, the addition of NaCl minimally increased mAb instability (as 
manifested in detectable changes in SEC for percent insoluble aggregate and monomer content 
for agitation and stirring stresses, respectively).  Aggregation of the mAb under freeze-thaw 
stress was more influenced by the presence of NaCl (3 out of 8).  Although freeze-thaw stress 
does not seem to cause alterations in the conformation of the mAb (see below), increases in 
percent insoluble and soluble aggregate, as well as nanometer and micron sized particles (by 
SEC, NTA, and MFI, respectively) were noted due to the presence of NaCl, indicating decreased 
colloidal stability.  Finally, heat stress showed the largest effect of NaCl on mAb instability (6 
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out of 8).  Although heating of the mAb solution in the absence of salt alters the conformational 
stability of the protein, it does not result in extensive aggregate or particle formation.  With the 
addition of NaCl, however, there is now a large colloidal component to the mAb instability.   
Despite the availability of new analytical methods to accurately and precisely count and 
size protein particles in the submicron and subvisible size range,27,28,48-51 biophysical 
characterization of the nature, composition and structural integrity of the protein within these 
particles remains a major analytical challenge. The focus of this work was to characterize 
aggregates and particles formed in an IgG1 mAb in the presence of 0.15M NaCl as a function of 
various stresses (freeze-thaw, shaking, stirring and heating).  The primary goal was to 
characterize the morphology, structural integrity and composition of the IgG1 particles formed in 
0.15M NaCl containing solutions by probing the extent of non-native covalent cross-linking, 
changes in overall protein secondary structure, and alterations in surface hydrophobicity within 
the particles as formed by each type of stress applied to the mAb solutions.   Additionally, we 
also evaluated the morphology of these particles by TEM and by a newly developed approach 
from our laboratory to analyze MFI size distribution and morphological data using radar plots.39  
These plots are commonly used to summarize large sets of protein data from multiple 
biophysical techniques. Radar plots are used to better visualize particle size distribution and 
morphological parameters of the particles.39  
The freeze-thaw stress appeared to be mild and essentially did not change the overall 
higher order structure or covalent crosslinking of the protein within the aggregates.  Particles, 
isolated onto a gold filter, showed no detectable alterations in overall secondary structure relative 
to the native IgG sample, even after three freeze thaw cycles.  The nanometer sized aggregates 
appeared to have a fibrillar morphology by TEM.  The micron sized particles (10-50µm) were 
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opaque (less transparent) and more elongated.  Similarly, freeze-thaw samples showed very low 
surface hydrophobicity almost equal to that of the native protein.  There appeared to be no 
covalent cross-linking present in the sample and no corresponding higher molecular weight 
aggregates seen on SDS-PAGE gels (data not shown). Results obtained from similar experiments 
by Joubert et al.22 as well as Barnard et al52 and Zhang et al.53 with different mAbs were 
consistent with our observations. 
For mAb solutions stressed by shaking, a common stress encountered by many protein 
drugs during transportation, generated predominantly fibrillar and slightly spherical nanometer 
particles, while the micron sized particles were more opaque and circular than the samples 
shaken without NaCl, as shown in Figures 2.4 and 2.5. These stressed samples contained little to 
no covalently linked aggregates with largely native-like secondary structure and low surface 
hydrophobicity (Figs 2.6-2.8) even after three days of shaking stress. While shaking generated 
higher number of aggregates and particles than freeze-thaw, there were not many differences in 
the biophysical characteristics of the aggregates generated by these two stresses compared to the 
unstressed, native protein.  This result is similar to data published previously with other 
proteins.17,22,54   
Stirring stress was a harsher condition on the IgG1 compared to freeze-thaw and shaking.  
In addition, the particles generated from this stress were predominantly spherical in morphology 
which was not observed with other stresses. From the MFI morphology data, NaCl did not 
notably affect particle morphology (in terms of aspect ratio and intensity) of the stirred samples 
in the micron size range as shown by the radar chart analysis in Figure 2.4.  Biophysical 
differences were also observed in protein from the pellet fraction and supernatant fraction of the 
centrifuged stirred IgG mAb samples.  The protein in the pellet fraction displayed greater surface 
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hydrophobicity (Figure 2.8) and contained an increased amount of reducible high molecular 
weight covalently linked aggregates (Figure 2.6) than the supernatant fraction.  The ANS 
fluorescence data suggest that the population of aggregates present in the pellet may be more 
structurally altered compared to the aggregates present in the supernatant. The isolated stir-
stressed particles showed some loss in overall intramolecular beta sheet structure content and 
some increase in the formation of intermolecular beta sheet structures (non-native, aggregated 
structures) as shown by FTIR analysis (Figure 2.7). One study with a different mAb reported that 
the overall secondary structure of the stirred sample was similar to that of the unstressed sample, 
contrary to our results with this IgG.17 In addition to rapid transportation of aggregates into bulk 
solution from the interface, protein also encounters the harsh shear force of the stir-bar and the 
resulting thermal and cavitation effects.17,55 All of these factors could account for higher 
aggregation and particulation with stirring stress compared to shaking.   
For the heated samples of the IgG mAb, the supernatant fraction contained less non-
native covalently linked aggregates compared to the pellet fraction which possessed higher levels 
of this type of disulfide cross-linked aggregate as measured by SDS-PAGE (Figure 2.6). The 
variability in the micron particle concentration was very high due to heating, so it is difficult to 
make definitive conclusions about the aspect ratio or intensity of these particles, although more 
elongated and more opaque particles were seen in the presence of NaCl (Figure 2.4).  In the 
presence of NaCl, nanometer sized particles seen by TEM appeared fibrillar in morphology 
(Figure 2.5).  The heat stressed samples displayed a highly perturbed overall secondary structure 
content consisting of predominantly intermolecular beta sheets as measured by FTIR (Figure 
2.7).  The increased ANS binding in both the supernatant and pellet of the centrifuged heated 
samples suggests significant exposure of apolar moieties in both fractions.  Hawe et al. noted that 
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the heat generated aggregates contained non-native covalent cross-linking with significantly 
increased ANS binding (increase in surface hydrophobicity), as well as a large perturbation in 
the secondary structure 18,22  Zhang et al. conducted a similar experiment with Bevacizumab and 
determined that heat generated aggregates had significantly altered structure from their ANS and 
intrinsic Trp fluorescence data.53  These results are consistent with our observations  
In summary, while there has been a vast growth in our ability to count and size protein 
aggregates and particles over a wide size range during the past ~5 years, our analytical 
capabilities to describe the morphology, structural integrity and composition of the protein 
within these particles is still limited.  The goal of this study was to provide a case study to 
examine the effect of different environmental stresses on an IgG1 mAb solution in terms of the 
morphology of particles formed as well the extent of structural alterations of the protein within 
the particles. We confirmed results of previous studies 17,18,22,52,55 that the type of stress a mAb 
solution experiences greatly influences many of its physical properties in distinct ways. There are 
still many gaps in our understanding that need to be addressed, 56  especially if there is a 
relationship between a particular particle count, particle size range, particle weight or perhaps the 
physicochemical or morphological trait(s) of protein particles/aggregates and their potential to 
generate an immune response in vivo.56-62  
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2.5 TABLES AND FIGURES 
Table 2.1.  Turbidity measurements and visual assessments of visible particles for control and 
stressed IgG1 mAb samples. Samples contained 1 mg/mL antibody in 10 mM sodium acetate, 
pH 5 in absence and presence of 150 mM NaCl.   The turbidity data are an average of three 
independent experiments (n=3) with standard deviation.  For visual assessments of visible 
particles, “-“ is no change observed relative to unstressed sample; “+” is some change observed 
relative to unstressed sample (2-5 particles detected); “++” notable change observed relative to 
unstressed sample (> 5 particles detected).   
  No NaCl With 150mM NaCl 
  Turbidity (NTU) 
Visual 
Assessment Turbidity (NTU) 
Visual 
Assessment 
mAb 
Samples Average Stdev   Average Stdev   
 
Buffer Alone 
(no mAb) 0.2 0.1 - 0.7 0.6 - 
 
Day 0 0.6 0.1 - 0.7 0.1 - 
Freeze-Thaw 
Cycle 1 1.3 0.3 - 0.7 0.1 - 
Freeze-Thaw 
Cycle 3 1.5 0.5 - 1.6 0.2 - 
Agitation 
Day 1 8.1 1.6 ++ 22.4 2.1 ++ 
Agitation 
Day 3  7.6 0.4 ++ 25.0 10.5 ++ 
Stirring 
Day1 13.2 5.4 ++ 217.7 17.0 ++ 
Stirring 
Day3 64.4 7 ++ 756.7 71.9 ++ 
Heating 
Day1 0.9 0.1 - 82.4 3.4 + 
Heating 
Day3 0.9 0.1 - 212.3 5.9 ++ 
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Table 2.2.  Summary of formation of soluble aggregates and nanometer, subvisible (microns), 
and visible (>100µm) sized particles in IgG1 mAb solutions as measured by SEC, NTA, MFI, 
Turbidity, and Visual Assessments, respectively. Symbols describe whether a change was 
observed (+) or not observed (-) compared to the unstressed mAb sample with the given 
analytical technique. Eight types of measurements are shown in the table and the last column 
summarizes, for each stress, the number of notable effects (+ vs. -) due to the presence versus 
absence of NaCl. Samples contained 1 mg/mL antibody in 10 mM sodium acetate, pH 5 in 
absence and presence of 150 mM NaCl.   
 
  
 SECa NTA MFI Turbidity 
  
Visual 
Assessment  
# Results 
Differing 
due to 
NaCl   
  %M %I %A %F          
Freeze/Thaw            
-NaCl  - - - - - - - -  
+NaCl  - + - - + + - - 3/8 
Agitation            
-NaCl  - - - - - + + +  
+NaCl  - + - - - + + + 1/8 
Stirring            
-NaCl  - + - - + + + +  
+NaCl  + + - - + + + + 1/8 
Heating            
-NaCl  - + - + - + - -  
+NaCl  + + + - + + + + 6/8 
 
a  %M, %I, %A, %F correspond to percent monomer, insoluble aggregate, soluble aggregate, and 
fragment, respectively.   
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Figure 2.1.  Formation of soluble and insoluble aggregates in IgG1 mAb solutions exposed to 
different stresses as measured by SEC. Representative SEC chromatograms monitored at 214 nm 
of 1 mg/mL antibody in 10 mM sodium acetate, pH 5 in absence (a) and presence (b) of 150 mM 
NaCl.  Key: day 0 control (    ), F/T cycle 3 (    ), agitation day 3 (    ), stirring day 3    (   ), 
heating day 3 (   ).  Plots of monomer loss and changes in amounts of impurities as a function of 
different stresses are shown: freeze-thaw cycles (c) without NaCl and (d) with NaCl; days of 
agitation (e) without NaCl and (f) with NaCl; days of stirring (g) without NaCl and (h) with 
NaCl; days of heating (i) without NaCl and (j) with NaCl.    Key for c-j:   -% monomer; 
impurity:  - % insoluble; - % multimer;  - % dimer; -  % fragment.  Each graph 
represents the average of three separate experiments (n=3).  Error bars represent one standard 
deviation. 
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Figure 2.2.  Formation of submicron-sized particles in IgG1 mAb solutions exposed to different 
stresses as measured by NTA.  Representative NTA data showing the formation of nanometer 
sized particles due to four indicated stresses applied to 1 mg/mL antibody solution in 10 mM 
sodium acetate, pH 5 in the (a) absence of NaCl and (b) in the presence of NaCl.  Concentration 
of nanometer-sized protein particles formed due to each stress at day 1 (D1) and (D3) in the (c) 
absence and (d) presence of NaCl.  Each data set is the average of three separate experiments 
(n=3) and the error bars for each data point represents one standard deviation.   
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Figure 2.3. Radar plots for visualizing formation of subvisible particles (concentration and size 
distributions) in IgG1 mAb solutions exposed to different stresses as measured by MFI.  Radar 
plots show MFI particle concentration and size data distributions as generated by four indicated 
stresses when applied to 1 mg/mL antibody solution in 10 mM sodium acetate, pH 5 with and 
without 150 mM NaCl.  See the text for details of radar plot analysis.  The data shown are the 
average of three separate experiments (n=3) and the error represents one standard deviation.   
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Figure 2.4. Radar plots for visualizing morphology parameters of subvisible particles (aspect 
ratio and intensity) in IgG1 mAb solutions exposed to different stresses as measured by MFI.  
Radar plots show MFI morphology data distributions as generated by four indicated stresses 
when applied to 1 mg/mL antibody solution in 10 mM sodium acetate, pH 5 with and without 
150 mM NaCl.  See text for details of radar plot analysis.  The data shown are the average of 
three separate experiments (n=3) and the error represents one standard deviation.   
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Figure 2.5.  Representative TEM images of IgG1 mAb aggregates and particles formed after 
three freeze-thaw cycles or three days of each indicated stress.  Particles were isolated from 1 
mg/mL antibody solution in 10 mM sodium acetate, 150 mM NaCl, pH 5.   
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Figure 2.6.   Reduced and non-reduced SDS-PAGE gels of IgG1 mAb samples exposed to four 
different stresses.  Samples contained 1 mg/ml antibody in 10 mM sodium acetate, 150 mM 
NaCl, pH 5.  High molecular weight aggregates formed by disulfide linkages were observed in 
pellet of stir-day 1, stir-day 3, heat-day 1 and heat-day 3 samples.  Stressed samples were 
centrifuged to separate supernatant (S) from pellet (P), run on SDS-PAGE, and stained as 
described in the Methods section.  
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Figure 2.7.  FTIR analysis of overall secondary structure of IgG mAb solutions and isolated 
particles as generated from four indicated stresses. Samples contained 1 mg/ml antibody in 10 
mM sodium acetate, 150 mM NaCl, pH 5.  Second derivative FTIR spectrum of (a) native, 
unstressed protein in solution, and (b) particle isolated from mAb heated at 80°C for 20 min to 
determine the maximum extent of secondary structure loss in solution. (c-f) Representative 
optical images of isolated mAb particles (by passing through gold filter) as generated from the 
four indicated stresses and their corresponding second derivative FTIR spectra from FTIR 
microscope.  Numerical values are the average of three separate experiments (n=3) with error 
associated with the wavenumbers representing one standard deviation.   
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Figure 2.8.   ANS extrinsic fluorescence analysis of IgG1 mAb samples (supernatant and pellet 
components) before and after indicated stress was applied to samples. Samples contained 1 
mg/ml mAb in 10 mM sodium acetate, 150 mM NaCl, pH 5.  (a) Representative ANS spectra, 
and (b) ANS fluorescence intensity values (at 480 nm) for each stressed mAb sample compared 
to the two controls: unstressed (D0) and extensively heated samples (heat-melt).  The average 
intensities shown are based on three separate experiments (n=3).  The error bars represent one 
standard deviation.   
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Figure 2.9.  Total concentration of subvisible particles (greater than 2 µm as measured by MFI) 
formed in IgG1 mAb solutions as generated by indicated stress at different time points.  Samples 
contained 1 mg/ml antibody in 10 mM sodium acetate, pH 5 in the absence (A) or presence (B) 
of 150 mM NaCl.  The MFI particle data shown are the average of three separate experiments 
(n=3) and the error bars represent one standard deviation.   
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CHAPTER 3: Characterization of the Physical Stability of a Lyophilized IgG1 mAb After 
Accelerated Shipping-like Stress 
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3.1 INTRODUCTION 
When a protein therapeutic is appropriately lyophilized with stabilizing excipients, the 
solid dosage form typically displays increased physicochemical stability during storage and 
shipping, compared to a liquid formulation counterpart, resulting in a longer shelf life including a 
lower propensity toward aggregation.1-3 Many proteins, including monoclonal antibodies 
(mAbs), have been shown to be more stable during exposure to elevated temperatures in the 
lyophilized than in the liquid state1,4-7, although there are some exceptions to this general rule.6  
Despite protein lyophilization being a relatively well-established formulation technology, there 
remains numerous challenges both in terms of developing an improved  understanding of protein 
degradation pathways in the solid state as well as better optimizing lyophilization process design 
and scale-up 1,5,8,9.   
The lyophilization process typically consists of freezing, primary and secondary drying, 
and reconstitution steps, each of which may structurally damage proteins10-14.  Freezing of bulk 
water in a protein solution can cause cryoconcentration of protein and excipients, pH changes, 
and/or adsorption of protein to the surface of ice crystals10,13,14.  Primary drying removes the 
frozen bulk water and further concentrates the protein and stabilizers, allowing the possibility of 
unfavorable interactions 5,11.  Protein instability is also possible during secondary drying, during 
which the non-frozen water bound to the protein or excipients is removed.  The composition of 
the reconstitution medium and it’s rate of addition may also affect the stability of a lyophilized 
protein upon reconstitution back into the liquid state15.  For example, if the reconstitution 
medium is added too rapidly, the dried protein may not be given sufficient time to rehydrate and 
assume its native conformation, and the presence of this improperly rehydrated protein may lead 
to aggregation. 6,16.  The aggregation of monoclonal antibodies in the lyophilized state, and/or 
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upon reconstitution, has also been correlated with formation of non-native intermolecular 
disulfide bonds17 as well as the appearance of aggregates of different sizes including an increased 
number of subvisible particles18.   
A freeze-dried cake’s physical structure and moisture level are typically optimized as part 
of protein lyophilization development, since either can potentially affect the extent to which a 
protein may aggregate in the solid state 6,19-21.  These parameters can be interrelated since 
changes in residual moisture content may affect not only protein structure, but also the physical 
integrity of the lyophilized cake itself (i.e., a change from a viscous to a rubbery state where 
molecular mobility increases7).  Some lyophilized protein preparations with high moisture 
content have shown increased chemical degradation due to increased mobility and the ability of 
water to participate in chemical reactions.22,23 However, a bell shaped relationship between 
moisture content and physical stability (aggregation) has also been observed, e.g., lyophilized 
recombinant human albumin displayed maximum aggregation at ~50% moisture content. 24  In 
terms of the effect of the physical integrity of a freeze-dried cake on protein stability, it has been 
shown that when a lyophilized cake of an IgG1 mAb is physically collapsed to different extents 
by using different amounts of stabilizers and bulking agents during the freeze-drying process, the 
mAb can still remain stable in the different preparations.19-21  The method of cake collapse, 
however, either during the freeze-drying cycle or during storage at elevated temperatures, has 
been shown to potentially be an important factor in determining protein stability during 
subsequent storage.21   
The effect of mechanical stress on the stability of lyophilized proteins has not been as 
widely examined.  In this work, to examine the potential of shipping stress to cause protein 
aggregation, we implemented a stress shipping test based on considering guidelines in the 
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vibration testing document D999 proposed by ASTM International Standard Test Methods for 
Vibration Testing of Shipping Containers25.  Currently, there are no guidance documents 
available that are specific for pharmaceutical products that outline the testing criteria to use when 
evaluating product quality impact of shipping-related stress.  Initially, we examined the physical 
stability of an IgG1 mAb formulation in both a liquid and lyophilized state after exposure to 
shaking stress with the expectation that the protein in the lyophilized state would be more stable 
in terms of aggregation and particle formation.  Surprisingly, the lyophilized preparation also 
displayed mAb physical instability (upon reconstitution).   
The focus of this work was to better understand the effect of shaking stress, used to 
mimic extreme shipping conditions, on the physical stability of a lyophilized mAb preparation.  
A wide variety of analytical characterization techniques were used to size and count protein 
aggregates and particles across a wide size range including size-exclusion chromatography 
(SEC), dynamic light scattering (DLS), Nanoparticle Tracking Analysis (NTA), Resonant Mass 
Measurement (Archimedes), Microflow-Imaging (MFI), and turbidity.  We also used data 
visualization tools (e.g., radar plots) to display and compare the number and size of protein 
particles formed under different conditions.  The composition of the protein found in particles 
was further examined using SDS-PAGE and FTIR Microscopy.  We determined how 
formulation variables such as residual moisture content, reconstitution speed, and composition of 
the reconstitution medium affected the formation of subvisible particles and solution turbidity 
when the lyophilized mAb was exposed not only to shaking stress, but also to subsequent storage 
for three months at various temperatures.   
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3.2 EXPERIMENTAL SECTION  
3.2.1 Materials 
Lyophilized IgG1 mAb samples prepared at 0.6% and 6.8% moisture content, and their 
corresponding matching placebos without protein, were supplied in stoppered 20 mL glass vials 
by Human Genome Sciences (currently GlaxoSmithKline).  Upon reconstitution with 5 mL of 
deionized water from Water Pro PS Station (Labconco, Kansas City, MO), the target 
concentration was approximately 30 mg/mL protein, in a formulation consisting of 0.08 mg/mL 
citric acid monohydrate (Avantor Performance Materials, JT Baker 0115, Center Valley, PA), 
1.6 mg/mL sodium citrate dihydrate (Avantor Performance Materials, JT Baker 3647), 11 
mg/mL glycine (Avantor Performance Materials, JT Baker 0581), 3 mg/mL sucrose (Avantor 
Performance Materials, JT Baker 4005), and 0.12 mg/mL polysorbate-80 (Croda International, 
SR48833, England) at pH 6.5.  Lyophilized samples were stored at 4 °C unless otherwise 
indicated.  The IgG1 mAb has a pI of ~8.4 and protein concentrations were determined by UV 
spectroscopy at 280 nm with an extinction coefficient of  ε 0.1% =1.58 (g/100mL)-1 cm-1.   
3.2.2 Methods 
3.2.2.1 Shaking stress studies 
Glass vials containing lyophilized and liquid IgG1 protein samples and corresponding 
placebo controls were taped horizontally inside of a lightweight, cryogenic box (13 x 13 x 5 cm) 
, which was then taped to the cuphead of a 4.9 mm orbit Fisher Scientific Analog Vortex Mixer 
(Waltham, MA) and shaken vigorously at 3200 rpm for different periods of times at ambient 
temperature. Depending on the experiment, the shake-stressed samples were either in the 
lyophilized (solid) state or in the reconstituted (liquid) state.  Unstressed and stressed samples of 
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lyophilized protein and placebos were reconstituted with 5 mL of deionized water (Labconco) 
over 10 s, unless otherwise noted.  To prepare the liquid samples, the lyophilized protein 
formulation was reconstituted with 5 mL of deionized water (Labconco) prior to shaking.  
To study the effect of reconstitution medium type and addition rate, shake-stressed (for 
24 h) and unstressed lyophilized IgG1 mAb samples were reconstituted by adding 5 mL of four 
different diluents (deionized water, 150 mM NaCl, 150 mM NaCl + 0.05% polysorbate 80, and 
500 mM NaCl) at two rates (5 mL injected over 10 s and 5 mL injected over 2.5 min).   To study 
the effect of shake-stress on subsequent storage stability, lyophilized mAb samples in stoppered 
glass vials were shaken for 2.5 min or 24 h and placed at 4, 40, or 55°C for up to 3 months at 
ambient humidity.  Intact, unstressed samples (no cake breakage) were also stored up to 3 
months at these temperatures.  At time zero in the stability study, intact cake samples, 2.5 min 
shaking, and 24 h shaking samples were analyzed immediately (no storage).  Placebos were also 
analyzed after 3 months storage at 55°C.  
3.2.2.2 Turbidity 
To monitor solution turbidity of samples, a HACH 2100 AN turbidimeter (HACH, 
Loveland, CO) was used.  Prior to analyzing the experimental samples, StableCal calibration 
standards (Hach, Loveland, CO), ranging from <0.1 to 4000 Nephelometric Turbidity Units 
(NTU), containing hexamethylenetetramine and demineralized water, were used for generating a 
standard curve.  The method is based on comparing intensity of light scattered by a sample under 
defined conditions with the intensity of light scattered by a standard reference suspension. 
Samples were not centrifuged or diluted for analysis.  
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3.2.2.3 Size-exclusion HPLC (SE-HPLC) 
 A Shimadzu UFLC HPLC system equipped with a diode-array detector and a Tosoh 
Bioscience (Tokyo, Japan) TSK-Gel G3000SWXL (7.8 mm ID x 30.0 cm, 5µm) and the 
corresponding guard column (TSK-Gel Guard Column SWXL, 6.0 mm ID x 4.0 cm, 7µm) were 
used to monitor for the presence of soluble aggregates (< 100 nm).  Prior to sample runs, the 
columns were rinsed for 60 min with deionized water followed by equilibration at 30¹C for 1 h 
using mobile phase (10 mM sodium phosphate, 450 mM sodium chloride, pH 7.4) at a flow rate 
of 0.5 ml/min. Molecular weight standards (Biorad Laboratories, Hercules, CA) were run to test 
for efficacy of separation and resolution.  Samples were centrifuged at 16,000 x g for 5 min and 
10µL of supernatant was injected for analysis and monitored at 280 nm for each 35 min sample 
run.  Aggregates, monomers, and fragment peaks were quantified using the LC Solutions data 
analysis software provided with the instrument.   
3.2.2.4 Nanoparticle Tracking Analysis (NTA) 
 Submicron sized particles (50-1000 nm) were measured using a Nanosight LM-14 
(Nanosight, Amesbury, UK) with a CCD camera.  Stressed samples and controls were 
centrifuged at 16,000 x g for 5 min, to separate larger aggregates outside the instrument sizing 
range.  The supernatant was diluted 100 fold in formulation buffer (η=1.08 mpa. S for 
formulation buffer and η=1.36 mpa. S for the unstressed sample).  Three hundred microliters of 
the 100 fold diluted supernatants were injected into the sample holder.  Three 30 s movies were 
taken at ambient temperature for each sample.  All samples were corrected for dilution.  Data 
analysis was performed using the NTA 2.3 software, provided with the instrument, with 
detection threshold of 16, a screen gain of 7, and a minimum expected particle size of 50 nm.   
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3.2.2.5 Dynamic Light Scattering (DLS) 
 DLS measurements were performed to monitor small nanometer sized particles (1-
1000nm) using a DynaPro™ Plate Reader (Wyatt Technologies, Santa Barbara, CA). Prior to 
analysis, the protein samples and controls were centrifuged at 16,000 x g for 5 min to remove 
large aggregates.  The supernatant was separated and 30µL of the supernatant was loaded into a 
clear bottom 384 well assay plate (Corning Incorporated, Corning, NY).  The plate was then 
centrifuged at 1177 x g for 3 min to remove air bubbles. Measurements were performed at 20°C 
with auto attenuation using the globular protein model and with the viscosity values determined 
using an Anton Parr Stabinger Viscometer 3000 (Anton Parr Inc., Ashland, VA).  The data were 
collected using the Dynamics V 7.1.6 software, provided with the instrument, and analyzed using 
multimodal analysis.   
3.2.2.6 Resonant Mass Measurements 
 Analysis of 0.25 to 3 micron sized particles was accomplished using an Archimedes 
particle metrology system (Affinity Biosciences, Santa Barbara, California).  The instrument was 
first calibrated with NIST standard 1  µm polystyrene beads prior to analyzing experimental 
samples. To prevent clogging of the Hi-Q micro sensors, samples were centrifuged at 16,000 x g 
for 5 min and supernatants were analyzed.  Triplicates of each sample were allowed to run until 
500 particles were counted to obtain statistically significant data.  Particle Lab software, 
provided with the instrument, was used to obtain particle size and concentration.   
3.2.2.7 Micro-flow Digital Imaging and Radar Chart Analysis 
 Micron sized subvisible particles (2-100 µm) were analyzed and imaged using an MFI 
DPA-4200 (Protein Simple, Santa Clara, CA).  See the method described in Telikepalli et al. 
201426 for further details.  Protein containing samples were diluted 100 fold prior to analysis and 
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this dilution factor was accounted to determine particle concentration.  MFI’s MVAS 1.3 
software was used to collect particle imaging data, which was then analyzed by radar plots to 
assess the particle size and concentration distribution for the unstressed and stressed samples 
using in-house software (Middaugh Suite) as described in detail elsewhere26-28.   Additional radar 
plot analysis was performed in which the particle concentrations in each size bin for the stressed 
samples were normalized relative to its “control,” an unstressed sample that is similar in all other 
parameters.  This normalization helps in visualizing and rank ordering the relative impact of a 
particular formulation parameter (e.g., stress) on the relative extent and size distribution of 
particle formation.   
3.2.2.8 SDS-PAGE 
 Samples were mixed with 4X NuPAGE LDS sample buffer (Life Technologies, 
Carlsbad, CA) with and without, 50mM dithiothreitol (BioRad Laboratories, Hercules, CA) and 
incubated at 80¹C for 90 s.  Approximately 10 µg of each sample was separated on a 3-8% Tris-
Acetate gel using Tris-Acetate Buffer (Life Technologies, Carlsbad, CA). Hi-Mark Unstained 
Protein Standard (Life Technologies, Carlsbad, CA) was used as a molecular weight ladder.  
Protein bands were visualized by staining the gels with Bio-safe Coomassie Blue G250 stain 
(BioRad Laboratories, Hercules, CA).  
3.2.2.9 FTIR 
 Unstressed lyophilized mAb, after being reconstituted with 5 mL deionized water over 10 
s, was analyzed for overall secondary structure content as a function of temperature by Fourier 
transform infrared spectroscopy (FTIR) using instrumentation and methodology presented in 
Telikepalli et al. 201426.   
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3.2.2.10 FTIR Microscopy-15X Objective-Reflectance mode 
 The method from Telikepalli et al. 201426 was used to prepare and isolate protein 
particles from stressed samples, and then to perform overall secondary structure analysis of 
proteins within individual isolated particles using a Bruker Hyperion FTIR Microscope (Bruker 
Biosciences, Billerica, MA) with a 15X objective in reflectance mode to image individual 
particles on gold coated filters (Pall Corporation, Port Washington, NY).   
 
3.3 RESULTS 
3.3.1 Comparison of the physical stability of an IgG1 mAb formulation in the solid and 
liquid state during shaking 
Samples of the IgG1 mAb were shaken (to simulate extreme shipping stress conditions) 
in the same formulation in the liquid or solid state for 5 min, 2h, 6h, and 15 h. Upon shaking, the 
solid state lyophilized cake increasingly turned into a finer, broken down powder after each of 
these shaking conditions.  The physical stability of the mAb was assessed by a combination of 
analytical techniques including SE-HPLC, DLS, NTA, MFI, and turbidity.  These techniques 
were used to determine differences in the aggregation behavior of protein from lyophilized and 
liquid shake-stressed samples across a wide aggregate size range of nanometers to hundreds of 
microns29. Aggregate formation in the size range of 1-1000 nm (detectable by a combination of 
SE-HPLC, DLS, and NTA) was minimal with similar results in both types of stressed samples 
(data not shown).  For example, with SE-HPLC, approximately 99% monomer and 1% aggregate 
was noted at time zero with no change after shake-stress.  Additionally, no changes in the total 
area of the SEC peaks were observed, suggesting no detectable change in the total protein 
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concentration by this method.  DLS showed predominantly monomers (approximately 5 nm 
radius), with no changes in hydrodynamic size of protein in these samples after shake-stress.  For 
NTA analysis, submicron sized particles in the range of 100-300 nm were observed in the 
samples with no changes noted in particle concentration and size distribution as a function of 
shake-stress (data not shown).    
In contrast, differences in solution turbidity and micron size particle concentrations 
(detected by MFI) were observed between the liquid and lyophilized mAb samples after shaking 
as shown in Figure 3.1A and 3.1B, respectively.  The turbidity of the liquid sample does not 
appear to change even after 15 h of shaking.  In contrast, for the lyophilized sample, the turbidity 
of the solution (upon reconstitution) increases as a function of shaking time (Figure 3.1A).  After 
stressing the liquid and lyophilized samples for 5 min up to 15 h, the liquid and lyophilized 
samples both showed a small increase in the total number of micron sized particles as measured 
by MFI (Figure 3.1B).  Given the variability in the particle concentration determinations, it was 
concluded that both the liquid and lyophilized stressed samples generated similar levels of 
micron particles, with the 15 h time point showing a trend such that the lyophilized stressed 
sample may actually produce a greater number of micron sized particles than the liquid stressed 
samples.  
The relative instability of the lyophilized protein was not anticipated.  In fact, it was 
assumed that the protein in liquid state would be more susceptible to physical degradation by 
shaking, compared to the lyophilized state, even though the formulation contained polysorbate 
80, a non-ionic surfactant which is known to stabilize against shaking-induced degradation in 
liquid formulations. To better understand these observations, a series of experiments were 
performed as described below to examine the effect of shaking the lyophilized formulation on 
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the physical stability of the IgG1 mAb (measured upon reconstitution) as determined by solution 
turbidity and formation of micron sized particles (MFI). 
3.3.2 Characterization of particle formation in shake stressed lyophilized mAb samples  
 In an initial set of experiments, the effect of moisture content on the physical stability of 
the lyophilized mAb after shaking was assessed. Both “low” moisture (0.6%) and “high” 
moisture (6.8%) freeze-dried samples were prepared and then shaken for 24 h, turning both 
lyophilized samples into broken apart, finer powders, prior to reconstitution. No increases in size 
or in concentration of soluble aggregates or submicron particles were observed as a function of 
stress or moisture content by SE-HPLC and NTA, respectively (data not shown).  In addition, 
DLS analysis did not show the presence of species other than the monomer across the four 
samples (data not shown).  Twenty-four hours of shaking increased the solution turbidity and 
micron sized particle counts for both samples (Figure 3.2).  The shake-stressed 6.8% moisture 
lyophilized mAb sample showed somewhat increased levels of turbidity and particle counts 
when compared to the 0.6% moisture samples.   
 The MFI total particle concentration data displayed in Figure 3.2 were further analyzed 
and displayed as a radar chart to better visualize the particle size distributions in the four samples 
as shown in Figure 3.3.  Two different scales, shown on the right side of the figure, are used to 
analyze these MFI data.  The “particle number” scale, used to display the actual MFI particle size 
and concentration data for samples at time 0 and after 24 hours of shaking, has the innermost 
circle representing the lowest particle concentration of ~0 particles/mL and the outermost 
corresponding to the highest concentration of ~2.5 x 106 particles /mL. The 2-5 µm size bin starts 
at the top and increases clockwise up to a 25-40 µm size bin. The “normalized” scale shows 
particle concentrations of the stressed sample relative to its unstressed control for each size bin.  
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Thus the scale increases from 0x (innermost circle) to 50x (outermost circle), where the latter 
indicates the number of particles in a size bin after shake-stressing are 50x greater than the 
number of particles in the same size bin at time 0 (no shaking).  
 For both the low and high moisture samples, the lyophilized mAb shows a low number of 
micron-sized particles upon reconstitution. After 24 h of shaking, the number of 2-5 µm particles 
increased (along with a small increase in 5-10 µm particles) in both moisture level samples.  
However, the 6.8% moisture samples formed more 2-5 µm particles than the 0.6% samples after 
shaking.  This effect is more clearly reflected in the normalized radar plots where, it can be seen 
that the shake-stressed 6.8% moisture sample shows a larger relative increase in particles 
compared to its control than the shake-stressed 0.6% moisture sample.  For example, there is an 
~40 fold increase in the formation of 2-5 µm particles compared to the unstressed control for the 
6.8% moisture sample, but only about a 10 fold increase of the 2-5 µm for the shaken 0.6% 
moisture sample.  Similarly, a larger relative increase is observed for the formation of 5-10 µm 
sized particles, with an almost 35 fold increase for the higher moisture sample after shaking. 
 In addition to sizing and counting particles, the nature of the protein within the particles 
formed was examined by SDS-PAGE and FTIR analysis.  In both the control and shake-stressed 
lyophilized samples at the two different moisture levels, non-reduced and reduced SDS-PAGE 
gels were compared.  In the non-reduced gel, mostly IgG1 monomers with some fragments and 
dimers were observed.  Upon reduction with dithiothreitol, however, dimers were reduced and 
only heavy and light chains of the IgG1 can be seen (see Figure 3.9).  However, it appeared that 
these dimers were not forming as a function of the shake-stress and were present in all of the 
samples.  Additionally, upon centrifugation of samples into supernatant and pellet components, 
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no notable differences were seen in both the non-reduced and reduced SDS-PAGE gels for the 
supernatant, pellet, or the non-centrifuged samples. 
FTIR and FTIR Microscopy were used for the evaluation of overall secondary structure 
of the mAb in solution and of the mAb within the particles formed as a function of shaking stress 
in the lyophilized samples, respectively.  Representative FTIR spectra, and corresponding 
wavenumber positions from triplicate measurements, are shown for two control samples and for 
the 0.6% and 6.8% moisture lyophilized mAb samples in Figures 3.4A and 3.4B, respectively.  
The solid black line corresponds to the FTIR second derivative spectrum of the Amide I band of 
the unstressed, control mAb in solution and shows spectra with minima around 1636 and 1690 
cm-1, which correspond to the intramolecular beta sheets that are in the main secondary structure 
of antibodies.  To determine the extent of secondary structure loss that is possible with this mAb, 
the mAb solution was extensively heated and the resulting isolated particles were analyzed by 
FTIR Microscopy.  The second derivative spectra, depicted as blue dotted graphs, possess 
minima at 1622 cm-1 and 1619 cm-1 and 1692 cm-1 and 1693 cm-1 indicating loss of intra-
molecular beta sheets and formation of inter-molecular beta sheets (i.e., aggregation).  The red 
dotted lines are the second derivative spectra of the isolated protein particles obtained from each 
of the two shake-stressed samples by FTIR Microscopy (after reconstitution of the low and high 
moisture lyophilized mAb samples followed by filtration and capture of particles on a gold 
filter).  Compared to the two control samples (unstressed sample in solution and heat control), 
the IgG1 in the protein particle from the T=24 h shake-stressed sample has similar overall 
secondary structure to the unstressed control.  However, these isolated protein particles may have 
a slightly altered overall secondary structure content compared to the protein in the unstressed 
sample since their spectra show a small shift in the average minima around 1633 cm-1 and 1691 
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cm-1.  Importantly, the particles obtained from the 0.6 and 6.8% moisture samples showed 
similar levels of change in protein secondary structure indicating that for this IgG1 mAb, 
moisture content in conjunction with shake stress do not seem to largely impact the secondary 
structure of the protein within the particles.   
3.3.3  Characterization of particle formation in shake stressed lyophilized mAb samples 
as function of reconstitution medium type and addition time.    
 For both the low and high moisture containing lyophilized mAb samples, the control 
(unstressed) vials fully reconstituted in about 30 s, while the shake-stressed vials took ~ 1.5 min.  
This was similar regardless of the medium type or medium addition rate.  There was no 
difference in reconstitution time as a result of moisture content, so the effect of medium type and 
addition rate were further examined with the low moisture lyophilized sample.  The 0.6% 
moisture lyophilized sample was shaken for 24 h and reconstituted with 5 mL of different 
mediums at two different rates and then monitored for their effects on physical stability of the 
mAb by measuring solution turbidity and the concentration of micron-sized particles.  As shown 
in Figures 3.5A and 3.5B, the shake stressed lyophilized samples were more turbid and contained 
higher concentrations of micron-sized particles than the non-shaken samples upon reconstitution.  
Reconstitution with water consistently led to higher solution turbidity and higher micron-sized 
particle concentrations than reconstitution with the other diluents.  In addition, the role of 
medium addition rate was examined and no effects were observed for most of the conditions 
with two exceptions:  (1) for the 24 h shake-stressed lyophilized samples reconstituted at a slow 
rate with 150 mM NaCl + 0.05% polysorbate 80, higher turbidity and increased particle counts 
were observed compared to the fast addition of this medium, and (2) while the turbidity did not 
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change, reconstituting the shake-stressed lyophilized sample slowly with 150 mM NaCl solution 
produced more micron-sized particles than the same sample reconstituted at the fast rate.  
 Radar plot analysis of the MFI particle data showed some distinct relative changes in 
particle size distribution depending on the medium selection and the rate of addition (Figures 3.6 
for water as the medium and Figure 3.7 for the other diluents; note the scale differences in the 
two figures).  Regardless of medium type, predominantly 2-5 µm particles are formed upon 
shake-stress lyophilized samples upon both the slow and fast medium addition.  When water was 
used as the reconstitution medium (Figure 3.6), there was almost a 15 fold increase in the 
formation of 5-10 µm particles upon slow reconstitution compared to the unstressed sample 
similarly reconstituted.   In contrast, rapid addition of water resulted in a smaller relative increase 
in particles formed in this same size range.  For the other medium types, the addition rate was 
found to have some effect on the micron particle concentration as shown in Figure 3.7.  Slow 
reconstitution of the shake-stressed lyophilized samples with 150 mM NaCl and 150 mM 
NaCl+0.05% polysorbate 80 produced a larger relative increase (as seen by the normalized plot) 
in the formation of micron particles across the size bins. Such a relative increase in particle 
formation was not observed upon more rapid addition of these reconstitution media.   
3.3.4  Effect of shake stressing lyophilized mAb samples on subsequent storage stability.   
A three month stability study was performed using the lyophilized mAb samples (0.6% 
moisture) after exposure to different amounts of shake stress.  Intact lyophilized cakes 
(unstressed controls), slightly broken cakes (shaken for 2.5 min) and completely broken 
lyophilized cakes (shaken for 24 h) were stored at 4, 40, and 55¹C for 3 months (at ambient 
humidity) in stoppered glass vials. Representative pictures of the physical integrity of these 
lyophilized cakes corresponding to the varying levels of shake stress are shown in Figure 3.8A.  
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Upon fast addition with 5 mL deionized water, samples were analyzed by a combination of 
NTA, MFI, and turbidity.  NTA showed no changes in aggregation due to stress (data not 
shown).  In contrast, solution turbidity (Figure 3.8A) and micron-sized particles measured by 
MFI (Figure 3.8B) did reveal some stability differences as a function of shake stress and storage 
temperature (in addition, at the higher temperatures and longer time periods, slight yellow color 
changes were noted in all of the samples upon reconstitution; data not shown).  As shown in 
Figure 3.8A, all samples showed an increase in turbidity with increasing storage temperature 
(4°C < 40°C < 55°C).  If samples stored for identical time periods are considered, turbidity did 
not significantly increase in the intact and 2.5 min shaken samples.  The samples stored at 55°C 
were the most turbid, followed by the samples stored at 40°C (4°C < 40°C < 55°C).  Figures 
3.8C and 3.8D show normalized turbidity and normalized micron particle concentrations 
obtained by taking a ratio of turbidity (or micron particle concentration) of the stressed sample to 
its control (T=0) for a given shaking duration.  This shows the change in turbidity or number of 
micron particles in a sample relative to its unstressed control.  At 40°C, after three months of 
storage, the relative change in turbidity and total subvisible particle concentration for all shaken 
samples is approximately 1.5x and 2-3x, respectively.  At 55°C after three months, the relative 
change for the shaken samples is about 3.5-5x and 7-15x for turbidity and total micron particle 
concentration, respectively. 
In summary, Figures 3.8A and 3.8B show increasing turbidity and particle counts with 
increasing shaking duration, storage time, and temperature.  However, the T=0 samples 
themselves show an increase in turbidity and micron sized particle counts with increasing 
shaking duration (T=0 Intact cake < T=0 2.5 min shaking < T=0 24 h shaking).  Higher 
temperatures and longer storage show an increase in turbidity and particle counts relative to the 
 
 105 
control (4°C < 40°C < 55°C and T=0 ~ T=1 month < T=3 months) within each shaking time.  
When different shaking times are compared, in terms of relative changes versus time zero 
(Figures 3.8C and 3.8D), however, both relative turbidity and relative micron particle 
concentration changes stay constant or even decrease, especially for the samples stored at 55°C 
for three months as the cake structure is increasingly collapsed.  
 
3.4 DISCUSSIONS  
 The focus of this work was to better characterize how shaking of a freeze-dried IgG1 
mAb formulation can affect protein stability upon reconstitution.  We first examined the 
lyophilized IgG1 mAb control (no shake-stress), which showed minimal levels of physical 
instability after reconstitution.  These initial results indicated the formulation composition and 
lyophilization cycle resulted in a stable protein preparation. While there is a plethora of literature 
on how to effectively formulate and stabilize protein drugs during the lyophilization process and 
subsequent long term storage,1,5,17,24,30 the effect of subsequent mechanical stresses applied to the 
lyophilized dosage form on physical stability and aggregation of mAb, which could potentially 
occur during shipping and handling, has not been examined to the same extent.   
3.4.1  Physical stability of shake-stressed mAb in lyophilized state 
In this work, mechanical shaking-stress was applied to the liquid and lyophilized state of 
an IgG1 mAb formulation, and a variety of analytical techniques were used to assess the physical 
stability of the mAb. These results highlight the need to examine protein aggregation across a 
wide size range since no one analytical approach covers the different size ranges of protein 
aggregates and particles that may form26,29,31.  SEC and DLS, two very commonly used 
techniques to monitor soluble, nanometer sized aggregates, along with NTA, to detect submicron 
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sized particles, showed no differences in particle levels between control (unstressed) and shake-
stressed samples across the various experiments.  Interestingly, although the shaking stress had 
minimal effects on the formation of soluble aggregates and smaller submicron sized particles, 
physical instability was detected by turbidity measurements and by formation of larger micron 
size particles (as shown by MFI). Thus, shake-stressing the lyophilized mAb, followed by 
reconstitution, led to increased levels of protein particles in the subvisible size range (~2-100 
microns) but not in the smaller, submicron size ranges.  These results highlight the need to 
examine protein aggregation across a wide size range since no one analytical approach covers the 
different size ranges of protein aggregates and particles that may form26,29,31 
The shake-stress had minor effects on the conformation and composition of the protein 
contained within these particles as evidenced by SDS-PAGE and FTIR analysis. Upon shake 
stressing freeze-dried cakes, the resulting protein particles, formed in two different moisture 
level samples, showed similar levels of non-native disulfide crosslinks (SDS-PAGE) and the 
presence of slightly altered overall secondary structure content compared to the native protein 
(FTIR analysis). In contrast, the role of non-native disulfide bond formation in the generation of 
aggregates appears less influential than has been observed previously with other lyophilized 
mAbs17. A recent study performed in our laboratory studied the aggregation behavior of a mAb 
undergoing shaking stress.  While this was a different IgG1 mAb, in a liquid solution and in a 
different formulation, shake stress also led to formation of particles with only minor changes in 
overall conformational integrity of the protein within the particles as seen by SDS-PAGE, FTIR 
and by ANS fluorescence spectroscopy26.   
 The effect of the residual moisture content of the lyophilized cake on the physical 
stability of the mAb after shake-stress was also evaluated. There is an abundance of literature 
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describing the effects of moisture content on the stability of lyophilized protein therapeutics19-22  
Improved protein stability is often observed at lower moisture contents of a lyophilized cake, 
with values not exceeding 2.0% 6, However, exceptions have been noted. For example, when the 
stability of a lyophilized humanized mAb produced with varying moisture contents and stored at 
elevated temperatures up to a year was analyzed,22 no cake collapse or changes in protein 
secondary structure were observed22 but the intermediate moisture level samples were more 
resistant to aggregation. The relationship between moisture content and protein aggregation 
potential is complex and may be very dependent on the protein itself, formulation composition 
and freeze-drying conditions1,5-7,22.  In our study with an IgG1 mAb, the physical stability of the 
6.8% moisture sample was not drastically different than the 0.6% moisture sample during 
lyophilization or upon exposure to subsequent mechanical stress.  
3.4.2  Effect of reconstitution on shake-stressed degradation of lyophilized mAb 
The choice of medium used to reconstitute the lyophilized IgG mAb was an important 
factor in this study6,32. Using water as the diluent for both the unstressed and shake-stressed 
lyophilized mAb samples resulted in higher solution turbidity, and in an increased concentration 
of micron sized particles, compared to the use of other diluents.  The addition of sodium chloride 
solutions partially inhibited the formation of micron particles in our studies probably because the 
sodium chloride reduces protein-protein colloidal interactions.6 33   Previous studies have shown 
the importance of ionic strength in reconstitution solutions where either increased or decreased 
ionic strength of the reconstitution medium inhibited protein aggregation, highlighting the 
protein and formulation specific nature of these observations. 32-36  However, sodium chloride 
containing diluents result in reconstituted mAb solutions with higher solution osmolality, which 
might be a concern depending on the route of administration (e.g., subcutaneous injection into 
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the patient).    The presence of polysorbate 80 in the reconstitution buffer perhaps had a small  
stabilizing effect on the formation of subvisible particles upon reconstitution. Numerous studies 
have shown that polysorbate can decrease aggregation when used in the reconstitution 
medium.33,34,37-39.  It has been suggested that surfactants may increase wettability of powders 
leading to increased dissolution rate of lyophilized powders, inhibit surface induced denaturation 
during reconstitution, or stabilize the native state of the protein by increasing the free energy of 
unfolding. 34,37,39 Stabilizing compounds, such as polysorbate 80 or NaCl, in the diluent may 
prevent or reduce protein-protein interactions, and/or the physical dilution imparted by their 
addition can lead to separation of protein molecules and hinder aggregation7.  
Upon reconstitution, the type of diluent and the rate of diluent addition can affect not 
only protein stability 6,36, but also reconstitution times.  The rate of diluent addition on the 
physical stability of the reconstituted, lyophilized IgG1 mAb in this study was, in general, not an 
important factor.  However, the time required for reconstitution was longer for the shake-stressed 
lyophilized samples than the unstressed vials (approx. 0.5 vs. 1.5 minutes), regardless of the rate 
of addition or the type of diluent used. Since the physical state of the lyophilized mAb impacts 
dissolution time upon reconstitution, it is possible this results in differences in local protein or 
excipient concentrations and subsequently to the observed differences in subvisible particle 
formation.  The higher surface area and porosity present in the lyophilized cake, compared to the 
finer powder formed after shaking, may allow it to dissolve faster than the powder40.  However, 
disruption of lyophilized cake structure may not be the only destabilizing mechanism. 
Vibrational forces, or local heating effects generated from shaking itself, can potentially increase 
the contact area of powder particles allowing increased interactions between them41 leading to a 
cohesive powder that is “sticky.”42   
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These differences in reconstitution time did not change, however, when the samples were 
reconstituted at different rates and with different diluents.  While this lyophilized protein 
formulation had a relatively short reconstitution time, for other lyophilized protein samples in 
which the reconstitution time is longer and may be problematic during clinical administration, 
techniques mentioned by Cao et al15 could be beneficial.  For example, reconstituting under 
vacuum, adding wetting agents, and/or using low diluent volumes were observed to be methods 
that can decrease reconstitution times in a high concentration lyophilized formulation of a Fc-
fusion protein15.  Additionally, three reconstitution procedures were described, in which the 
reconstitution medium is added and the vial is gently swirled for different periods of time, 
resulting in different reconstitution times15.  In addition to reconstitution time, such 
reconstitution procedures could be evaluated in the future to assess their ability to minimize 
subvisible particle formation during reconstitution of shake stressed lyophilized protein powders. 
3.4.3 Storage of shake-stressed lyophilized mAb samples 
The effects of the extent of shaking stress on subsequent storage stability of the freeze 
dried IgG1 formulation were also analyzed in this work.  Lyophilized mAb samples were 
prepared as follows: (1) unstressed, physically intact cakes, (2) brief shaking (2.5 min) resulting 
in some cake breakage, and (3) extensive shaking (24 h) resulting in the cake being broken down 
to a powder.  These samples were stored at different temperatures over a three month period, and 
at each time point, were reconstituted rapidly with 5 mL of water. Increasing shaking stress on 
the freeze dried cake showed some small differences with increased levels in turbidity and 
subvisible particles. Solution turbidity and subvisible particle concentration increased with 
increasing storage (T=0 < T=1 month <T=3months), especially for the samples stored at 40°C 
and 55°C.  Similar to Schersch et al19-21, we also noticed a color change during storage of the 
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lyophilized protein at higher temperatures in this formulation, which they reasonably attributed 
to the well-known non-enzymatic browning (Malliard-type) reaction between reducing end 
sugars (potentially due to degraded sucrose) and lysine residues in the protein.  The turbidity 
levels and subvisible particle concentrations are highest for the 24h shaken samples compared to 
the intact and 2.5 min shaken samples (Intact ~ 2.5 min shaking < 24 h shaking).  Even though 
Figures 3.8A and 3.8B show increasing turbidity and particle counts with increasing shaking 
duration, storage time, and temperature, comparing samples to appropriate controls provides 
fuller understanding of the importance of shaking stress in inducing turbidity and micron particle 
formation.  Figure 3.8C and Figure 3.8D compare a particular sample with its relevant control 
(T=0).  Within each shaking time, higher temperatures and longer storage show increase in 
turbidity and particle counts relative to the control (4°C < 40°C < 55°C and T=0 ~ T=1 month < 
T=3 months).  When different shake times are compared, however, both turbidity and micron 
particle counts stay relatively constant or decrease, especially for the samples stored at 55°C for 
three months.  This is largely because the controls themselves (T=0) increase in both turbidity 
and particle counts with increasing shaking duration so the instability associated with storage 
temperature and storage duration appear less profound.   
In comparison, Schersch et al. have examined the effect of cake collapse (due to a variety 
of causes) during freeze-drying and subsequent storage at elevated temperatures on the stability 
of a different IgG1 mAb.19-21  For example, when lyophilized cakes were collapsed by using 
different amounts of excipients or by using different freeze-drying protocols, the stability of 
protein in the collapsed and non-collapsed cakes were not different from one another. In 
addition, conformational integrity of the IgG1, as measured by FTIR analysis of the overall 
secondary structure, was also not affected by cake collapse.19  Additionally, when the effect of 
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cake collapse on long-term storage at various temperatures ranging from 2-50°C up to 6 months 
was analyzed, protein stability was retained in the collapsed and non-collapsed cakes after 
storage.20  In addition, the stability of the freeze-dried samples that were collapsed during freeze-
drying vs. samples collapsed only during subsequent storage at 40 and 50°C for 3 months were 
compared to determine if the method of collapse affected protein stability.  In this case, the 
stability of the proteins in the collapsed lyophilized cakes (collapse due to freeze-drying) was 
better than the stability of protein in the storage-collapsed samples.  Overall, the authors 
concluded that the collapse (freeze-dried) samples appeared to be more stable than the collapsed 
(storage) samples.21    
The method of cake collapse could be another important parameter to consider as well in 
terms of effects on storage stability.  In this work, we mechanically stressed the samples to alter 
the cake integrity to different extents and then stored the cakes (with varying levels of physical 
collapse) at different temperatures. In comparison, Schersch et al. have examined in detail the 
effect of different methods of cake collapse on the stability of a different IgG mAb.19-21   The 
stability of the samples collapsed during freeze-drying compared to samples during subsequent 
storage at elevated temperatures showed that the stability of the protein in the freeze-drying 
collapsed cake was better than the protein in the storage-collapsed samples.  Overall, the authors 
concluded that the collapse (freeze-dried) samples appeared to be more stable than the collapsed 
(storage) samples21.  
 
3.5 CONCLUSIONS 
This case study highlights that post-lyophilization mechanical stresses, potentially 
encountered during shipping and transportation excursions, can result in physical instability of a 
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lyophilized protein upon reconstitution. For this particular IgG1 mAb formulation, a liquid 
dosage form (5 mL of a 30 mg/mL protein solution in a 20 mL stoppered glass vial) showed 
instability due to shaking stress, despite the presence of stabilizers including polysorbate 80.  The 
common sense approach of lyophilization did not successfully address the issue since the 
lyophilized dosage form of the same formulation was also shake-sensitive.  The increase in 
subvisible particle formation seen with the shake-stressed lyophilized IgG1 mAb upon 
reconstitution correlated with the formation of a finer powder and increased dissolution times, 
while no major differences in the structural integrity of the protein within the particles was noted.  
Thus, local differences in protein and excipient concentrations, upon the wetting and dissolution 
of the shake-stressed vs. control lyophilized cakes, likely contribute to these observations.  
It is acknowledged that the level of shake stress that the cakes were exposed to in this 
study was relatively high, but this was a useful means of rapidly characterizing various 
conditions with respect to product quality impact (e.g., cake moisture, reconstitution rate, 
medium type, etc).  The level of mechanical stress that a product will be exposed to during 
typical shipping and handling can be variable, and it is easier to interpret their effects by 
comparing to stressed, worst-case study designs.  In addition, within the general ASTM shipping 
guidance documents25, which are not specific for pharmaceutical products, the level of stress 
these documents suggest may be relatively high based on the schedule rating a user chooses to 
analyze.   
The observations highlight the importance of considering shake sensitivity of lyophilized 
cakes in terms of protein stability as part of formulation development activities including the 
formulation composition, lyophilization process and reconstitution medium selection.  Potential 
degradation is expected to be manageable by implementing an appropriate packaging and 
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shipping configuration that will minimize or prevent extensive cake breakage. The use of 
orthogonal subvisible particle counting and sizing techniques such as light obscuration (HIAC) 
and/or coulter counters are suggested for future work for comparison to the MFI analytical 
results. Additional work is also required to further elucidate the nature of the physical 
degradation pathway(s) leading to protein particle formation during reconstitution of shake-
stressed lyophilized mAb preparations, as well as to evaluate how this physical instability may 
vary with different IgG mAbs, other proteins and in the presence of different excipients and 
stabilizers.    
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3.6  FIGURES 
 
 
 
 
 
 
Figure 3.1. Physical instability of an IgG1 mAb formulation after shaking in the solid (freeze-
dried cake) or liquid state for 5 min, 2h, 6h, and 15h.  Samples were monitored by (A) solution 
turbidity and (B) total concentration of subvisible particles (≥2 µm as measured by MFI).  
Lyophilized samples were reconstituted prior to analysis.  Each graph represents the average of 
three separate experiments (n=3) and error bars represent one standard deviation.  Placebo 
samples were measured after 15 h of shaking showed negligible turbidity and concentration of 
micron sized particles compared to the protein containing samples. 
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Figure 3.2.  Physical instability of a lyophilized IgG1 mAb samples prepared with 0.6% and 
6.8% moisture content and shake-stressed for 24 h in the solid state.  Samples were reconstituted 
with water and monitored for solution turbidity (left Y- axis) and subvisible particles by MFI 
(right Y-axis).  Placebo samples were measured after 24 h of shaking and showed negligible 
turbidity and concentration of micron sized particles compared to the protein containing samples.  
The graph represents the average of three separate experiments (n=3) and error bars represent 
one standard deviation. 
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Figure 3.3.  Radar plot analysis of MFI particle concentration and size distribution results before 
and after shake-stressing lyophilized mAb samples.  IgG1 mAb lyophilized samples were 
prepared with 0.6% and 6.8% moisture content, shake-stressed for 24 h, reconstituted with water, 
and subvisible particle levels were measured by MFI (See Figure 3.2).  The “particle # scale” 
radar plot shows actual particle concentration values in different size ranges and the “normalized 
scale” radar plot shows relative change in subvisible particle concentration and size distribution 
of shake stressed samples compared to the corresponding T=0 sample (unstressed control).  
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Figure 3.4.  Representative second-derivative FTIR spectra of protein particles isolated from  
lyophilized IgG1 mAb samples containing 0.6% and 6.8% moisture levels after shake-stress.  
Samples include: native, unstressed protein in solution (T=0); protein particles isolated from 
shake stressed lyophilized mAb (a) 0.6% and b) 6.8% moisture) after reconstitution (T=24h); and 
particles isolated from mAb solution heated at 80°C for 20 min (heat control).  The characteristic 
peaks in the Amide I region indicative of intra and inter molecular beta sheet secondary structure 
are shown in the table. Values in table represent the average of three separate experiments (n=3) 
along with one standard deviation.   
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Figure 3.5. Effect of reconstitution medium and addition rate on the physical instability of a 
lyophilized IgG1 mAb samples reconstituted after shaking.  Lyophilized IgG1 mAb samples 
were shake-stressed for 24 h and reconstituted slow (5 mL over 2.5 minutes) or fast (5 mL over 
10 seconds) conditions with the following mediums: (1) deionized H20, (2) 150 mM NaCl, (3) 
150 mM NaCl containing 0.05% polysorbate 80, and (4) 500 mM NaCl.  The resulting (A) 
solution turbidity and (B) total concentration of subvisible particles  (≥2 µm as measured by 
MFI) values are shown.  Each graph represents the average of three separate experiments (n=3) 
and error bars represent one standard deviation.  
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Figure 3.6.  Radar plot analysis of MFI particle concentration and size distribution results as a 
function of the rate of reconstitution of shaking-stressed lyophilized mAb samples. Lyophilized 
IgG1 mAb samples (without shaking, T=0) and 24 h of shaking (T=24) were reconstituted with 
deionized H20 slowly (5 mL over 2.5 min) or rapidly (5 mL over 10 s) are shown.  The “particle 
# scale” radar plot shows actual particle concentration values in different size ranges and the 
“normalized scale” radar plot shows relative change in subvisible particle concentration and size 
distribution of shake stressed samples compared to the corresponding T=0 sample (unstressed 
control).  
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Figure 3.7.  Radar plot analysis of MFI particle concentration and size distribution results as a 
function of diluent type used to reconstitute shake-stressed lyophilized mAb samples.   
Lyophilized IgG1 mAb samples (without shaking, T=0) and 24 hours of shaking (T=24) were 
reconstituted with various mediums under slow (5 mL over 2.5 min) or fast (5 mL over 10 s) 
conditions as indicated in the figure.  Reconstitution diluents included:   (1) 5 mL of 150 mM 
NaCl, (2) 5 mL of 150mM NaCl + 0.05% Polysorbate 80, and (3) 5 mL 500 mM NaCl.   The 
“particle # scale” radar plot shows actual particle concentration values in different size ranges 
and the “normalized scale” radar plot shows relative change in subvisible particle concentration 
and size distribution of shake stressed samples compared to the corresponding T=0 sample 
(unstressed control).  
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Figure 3.8.  Storage stability of lyophilized IgG1 mAb samples as a function of cake integrity.  
Lyophilized samples included unstressed control (Intact cake), shake stressed for 2.5 min, and 
shake stressed for 24 hrs.  Representative pictures of intact cake, 2.5 min shaking, and 24h shake 
stressed cakes at time zero are shown.  Samples were then stored for up to 3 months at three 
different temperatures (4, 40, 55°C), reconstituted and  monitored for (A) solution turbidity and 
(B) total concentration of subvisible particles (≥2 µm as measured by MFI).  Stressed samples, 
which have been shaken for a certain amount of time and stored at different temperatures, were 
compared to controls (T=0, but with shaking) and resulting C) normalized turbidity or D) 
normalized subvisible particle concentrations are shown.  The y-axis values for both (C) and (D) 
were obtained by dividing the turbidity values (or micron particle concentration) of a stored 
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sample by its relevant control at time zero experiencing similar duration of shaking.  Each graph 
represents the average of three separate experiments (n=3) and error bars represent one standard 
deviation. Placebo samples were measured after 3 months storage at 55°C h and showed low 
turbidity (~1 NTU) and a relatively low number of micron sized particles ( ~12,000 
particles/mL).    
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Figure 3.9.  Nonreduced and reduced SDS-PAGE gels of lyophilized shake-stressed (T=24 h) 
and unstressed (T=0) IgG1 mAb samples prepared with 0.6% and 6.8% moisture levels are 
shown.  Samples were also centrifuged to separate supernatant from pellet and run on SDS-
PAGE and stained as described in the Methods section.  See text for description of results.  
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CHAPTER 4: Physical characterization and in vitro biological impact of highly aggregated 
antibodies separated into size enriched populations by FACS 
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4.1 INTRODUCTION 
The presence of aggregates in recombinant protein therapeutics is a serious concern due 
to their potential immunogenicity risk in patients.1-10 The most notable clinical examples of 
immunogenicity include Factor VIII7, and human growth hormone (hGH),8 and most likely 
erythropoietin (EPO). 2,3  Unfortunately, exactly how aggregates produce an immune response, 
and the extent of their impact in in-vivo responses, is not fully understood. Aggregates can arise 
at all steps of protein production: fermentation, expression, purification, formulation, filling, 
transport, storage, and administration.11,12  Since each protein is different, it may aggregate 
differently depending on the environmental stresses and solution conditions, which may expose 
various epitopes that may be more immune reactive than others.  For example, different solution 
conditions can lead to formation of different types and sizes of aggregates and particles.13-15  
Various environmental stresses including interfaces, temperatures, freeze-thaw, containers, pH, 
ionic strength, excipients, and concentration can all lead to protein aggregation.16-22         
Our knowledge of the immunogenic potential of protein therapeutics is confounded by 
the fact that in addition to the presence of aggregates, immunogenicity risk can be contributed by 
factors that may arise from many patient related factors such as genetics, age, disease-related 
factors, and other concomitant medications the patient may be taking.  The route of 
administration, dose, and the frequency of administration are also important factors.  Product 
related factors such as non-human T-cell epitope content in sequence, origin of the active 
substance, process related contaminants, and formulation can impact immunogenicity as well. 23-
26  The presence of so many variables complicates our understanding of the immunogenic 
potential of various therapeutic proteins.  Therefore, determining the potential impact of 
aggregates by themselves on immunogenicity is very challenging.  Despite these obstacles, a 
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combination of in silico predictions 27-30, in vitro cell-based assays27,31-33, and in vivo transgenic 
animal models34-38 are currently being extensively evaluated to assess the relative potential of 
different protein aggregates and particles to elicit immune responses in humans.   
One particularly promising in vitro approach is the use of human Peripheral Blood 
Mononuclear Cells (PBMC) derived from a healthy donor population with heterozygous MHC 
genotypes to screen antigens or mAb candidates for their propensity to stimulate certain features 
of the immune system1.   In-vitro models have been previously used to examine the 
immunogenicity of recombinant human erythropoietin-alpha39, recombinant Factor VIII39 and 
IgG mAbs40 with a certain degree of success. The correlation of clinical immunogenicity with 
the in vitro PBMC output was also investigated for immunogenic human fusion protein.  
Subjects that induced IFN-gamma secreting T cells in PBMC were associated with a higher 
magnitude of immune response (as detected by binding and neutralizing anti-drug antibody) in 
clinical trials.31  These in-vitro assays are relatively cheaper and faster to perform than in-vivo 
animal model based studies, can incorporate the diversity of the genetic polymorphism of alleles 
in the representative human population, can be used to screen a large number of candidate 
biotherapeutic mAbs during early development, and can be employed to compare the relative 
immunogenicity of different pharmaceuticals.27,31-33  
Most of the studies to date have focused on evaluation of immune activation by 
challenging with heterogeneous sized aggregates.  However, there is still a gap where the actual 
aggregate size associated with the immune activation has not been as thoroughly addressed.  
Previous work using three different IgG mAbs, including the one used in this study, were 
stressed by a variety of different methods and the resulting particles were characterized in terms 
of size, particle counts, conformation, morphology, and reversibility.13,41 Different types of 
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aggregates formed depending on the type of stress applied. 13  These different stressed mAbs 
were tested in an in vitro system to compare their relative response in human PBMC.40  It was 
found that aggregates, prepared by stirring for all three mAbs, displayed the highest response 
compared to the aggregates generated by all the other stresses tested.40  These results indicated 
that the presence of a high number of 2-10 µm particles, which were partially reversible, with 
retention of some folded structure in the stir-induced sample may be responsible for the 
increased PBMC response.40   
The purpose of this study was to further examine the impact of protein particle size on 
signature cytokine secretions of human PBMC at different stages of the immune response.40  An 
IgG2 monoclonal antibody (mAb2) solution was stirred to generate protein particles of varying 
sizes.  The mAb2 particles were then separated into various size enriched populations using (1) 
low speed centrifugation to enrich for nanometer vs. micron sized particles, and (2) Fluorescence 
Activated Cell Sorting (FACS) to separate enriched fractions of micron-sized protein particles.  
FACS is a promising approach for protein particle characterization as recently described by 
Rombach-Riegraf et al 42 for size separation and for related applications such as to detect and 
differentiate subvisible protein particles from silicone oil protein particles. 43-45 46  The stirring 
induced mAb particles were also physically characterized, before and after FACS separation, in 
terms of their particle number, size distribution, mass distribution, morphology and composition 
using a combination of techniques including Microflow imaging (MFI) with radar chart analysis, 
FTIR microscopy, and multiple electron microscopy analyses (TEM and SEM-EDS).  
 
 
 
 131 
4.2 EXPERIMENTAL SECTION 
4.2.1 Materials 
The IgG2 mAb, subsequently referred to as mAb2, was supplied by Amgen Inc. at 10.1 
mg/mL. This mAb has been used previously to characterize the immune potential of different 
mAbs and their aggregates.40,47  The antibody was highly purified48 and endotoxin levels were 
confirmed to be in an acceptable range (< 1.00 EU/mL) for use in these cell based assays. The 
stock mAb2 solution was stored at 4 °C prior to use. 
4.2.2 Methods 
4.2.2.1 Generation of aggregates 
The stock mAb2 was diluted to 1 mg/mL with 10 mM sodium acetate pH 5.0 (A5 buffer) 
and stressed by stirring (referred to as stir-20h) as described previously by Joubert et al.13  
Stirring stress was chosen since previous work showed that stirring of this IgG mAb produced 
aggregates that induced the highest response from PBMC.40  Additionally, for biophysical 
comparison purposes, a 1 mg/mL solution of mAb2 was heated extensively at 90°C for 30 min 
(labeled heat control).   
4.2.2.2 Size separation of mAb particles 
Two techniques were used to enrich different size populations of stirring induced 
particles: (1) slow speed centrifugation, and (2) gravitational settling of the samples combined 
with Fluorescence Activated Cell Sorting (FACS), subsequently referred to as “FACS”.  For 
method (1), one mL of stir-20h mAb2 sample was centrifuged at 2500 RCF using a Baxter 
Hereaus Biofuge 15 Model 3604 (Deerfield, IL) for 5 min.  The supernatant was removed and 
the pellet was resuspended in one mL of A5 buffer.  For method (2), 5 mL of stir-20h mAb2 
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sample was gently pipetted into 12x75mm polypropylene tubes and allowed to settle in a 
disturbance-free environment for 3 h at room temperature. After 3 h, 200 uL aliquots were 
removed carefully from the top to the bottom using a pipetteman with gel loading tips and 
collected into eppendorf tubes. The last aliquot in the tube (referred to as “bottom”) contained a 
greater number of larger micron-sized particles and this sample was then further size fractionated 
by FACS as described below.  
4.2.2.3 Fluorescent Activated Cell Sorting (FACS) 
A Beckman Coulter MoFlo XDP (Brea, CA) was set up as described in the 
instrumentation manual with calibrations done according to the manufacturer’s specifications. A 
flow cytometry size calibration kit from Invitrogen (Molecular Probes, Carlsbad, CA) was used 
for general size correlation between reference beads and protein particles.  The bottom sample 
was filtered through a 70 µm nylon mesh filter into a 12 x 75 mm polypropylene tube, and then 
diluted 15-20x with A5 buffer (called “pre-sort”). Four polypropylene tubes, each containing 200 
uL of A5 were placed at 4°C in a sterile FACS sorting chamber.  Samples were FACS sorted 
under the purify mode using a ceramic 70 µm nozzle tip at a pressure of 60 psi and at a speed of 
5000-10,000 events/sec. The gain and sensitivity values of the detectors were optimized to 
maximize the protein particle detection and threshold.  The charge plates were set to 4000V.   
Intellisort I was used to determine drop delay using flow check fluorospheres.  All experiments 
used phosphate buffered saline (PBS) at pH 7.2, as the sheath fluid, daily prepared using 
deionized water (Labconco, Kansas City, MO) under aseptic conditions.  The sheath fluid passed 
through an inline 0.22 µm filter just prior to mixture with pre-sort.  Endotoxin levels were tested 
in each part of the instrument and were found to be at an acceptable range after the rigorous 
cleaning procedure as described below.  Summit software version 5.2 (Beckman Coulter) was 
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used for data collection and data analysis was performed using Kaluza Flow Analysis (Beckman 
Coulter).   
4.2.2.4 Endotoxin cleaning and testing 
4.2.2.4.a Removing endotoxins 
Prior to using the stir-stressed mAb samples in the in-vitro cell-based assay, the samples 
were tested for endotoxins.  High levels of endotoxins (>10 EU/mL) were present in the FACS 
sorted samples despite sterilization of all instrument components and use of aseptic procedures.  
Therefore a protocol was developed to remove endotoxins by washing the instrument and all of 
its components with various solutions in the following sequence: 1) 10% bleach for 2 hours 2) 
deionized (Labconco) water for 2 hours 3) 70% ethanol for 2 hours 4) deionized water for 2 
hours, 5) 1% Triton-X 114 (Sigma, St. Louis, MO) for 2 hours, 6) deionized water for 3 hours 7) 
approximately 1 mg/mL polymyxin B sulfate solution (Sigma, St. Louis, MO) for 3 hours, and 8) 
final flushing with deionized water for 3 hours.  
4.2.2.4.b Endotoxin testing 
All protein samples and buffers were assessed for endotoxin levels by a LAL (Limulus 
amebocyte lysate) test with the Charles River Endosafe®-PTS™(Charles River, Wilmington, 
MA) system prior to being used in the biological assay.  The analysis was performed according 
to the manufacturer’s instructions.    
4.2.2.5 Particle counting and sizing of mAb particles 
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4.2.2.5.a HIAC-Royco Liquid Particle Counter 
HIAC/Royco liquid particle counter model 9703 with a HRLD-150 sensor and 
PharmSpec software PharmSpec (HACH Ultra Analytics, Grants Pass, OR) was used for 
obtaining particle counts and size distribution in some experiments.  The HIAC method is 
described in detail by Joubert et al.13,40   
4.2.2.5.b MicroFlow Imaging (MFI) 
Particle images, size distribution, and counts were obtained using MFI System DPA4200 
(Protein Simple, Santa Clara, CA). For analysis, stir-stressed mAb2 samples, generated at 
1mg/mL, were diluted 100x in A5 buffer.  Unstressed, buffer, and FACS sorted sample were not 
diluted, while the heat generated sample was diluted 25x prior MFI analysis.  After obtaining a 
clean base line, three hundred microliters of each sample was loaded using the peristaltic pump. 
No notable differences were observed in degassed versus non-treated samples (data not shown), 
so samples were not degassed for these studies.   
4.2.2.5.c MFI data analysis 
MFI particle concentration data are displayed as either bar charts or radar carts, all 
corrected for all dilution factors.  Additionally, a plot of % Particles vs Sample (size bin) is 
displayed.  The percentage of particles as detected by MFI was calculated by dividing the 
concentration of particles of a certain size range by the total number of particles in all size 
ranges.  This percentage is referred to as “enrichment” throughout this manuscript.  MFI 
morphology radar charts were generated in the size ranges 2-5, 5-10, and >10 µm to evaluate 
changes in particle intensity and aspect ratios as described previously.15,49  Finally, MFI particle 
data were used to calculate the estimated mass of protein within the particles, in the following 
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four size bins: 1-2, 2-5, and 5-10, >10µm, using the ellipsoid volume method recently 
described.50    
4.2.2.5.d Resonant Mass Measurement (RMM) 
A Particle Metrology System (Affinity Biosensors, Santa Barbara, California) was used 
with a Hi-Q micro sensor to quantify submicron and small micron particles from 0.2 to 1.85 µm. 
Sensor calibration and reference solution preparations were done according to the manufacturer’s 
instructions.  After a clean frequency trace was obtained, protein sample was loaded for 30 s, 
with a stop trigger of 200 particles. This limit of detection was empirically determined and used 
throughout the study. A density value for mAb of 1.41 g/mL was used. 
4.2.2.6 Biological testing of mAb particles using PBMC (in vitro comparative 
immunogenicity assessment assay, IVCIA) 
4.2.2.6.a Isolating Peripheral Blood Mononuclear Cells (PBMC) 
PBMC from healthy human donors were obtained from Amgen’s environmental health 
and safety department.  PBMC were isolated according to the procedure described previously.40 
4.2.2.6.b. Challenging PBMC with protein samples and controls 
PBMC from up to 8 donors were plated and acclimatized in 96-well culture plates as 
described previously.40 Acclimatized cells were then challenged with control (unstressed), and 
stir-20h mAb2 samples at equal volume, equal protein concentration at 40 µg/ml (total protein in 
solution determined by OD280 measurements), or equal particle number (based on light 
obscuration or MFI measurements). Negative controls, consisting of buffers isolated by FACS or 
medium-treated cells, and positive controls, such as lipopolysaccharide (LPS) or 
phytohemagglutinin (PHA).  LPS and PHA were controls at the early or late-stage immune 
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response, respectively.  Samples were incubated for either 20 h or 7 days, to assess an early stage 
or late stage immune response, respectively, as described by Joubert et al.40     
4.2.2.6.c. Meso-Scale Discovery Assay  
A 96-well human cytokine electro-chemiluminescence assay kit K151AYB-1 (Meso-
Scale Discovery, Gaithersburg, MD) was used, according to the manufacturer’s instructions, to 
quantify the concentration of monocyte chemotactic protein-1 (MCP-1) that was secreted by 
PBMC in response to the samples.  The 96 well plates were analyzed using an MSD Sector 
Imager 6000 instrument (Meso Scale Discovery, Gaithersburg, MD) and MSD Discovery 
Workbench Software 4.0 (Meso Scale Discovery).  SoftMax Pro was used for data analysis to 
convert the output luminescent units into protein concentration (pg/mL) using a standard curve.  
Responses were presented in terms of concentration of MCP-1 secreted and percentage of 
responding donors.  To determine the percentage of responding donors, the stimulation index 
(SI) was also calculated.  The SI was calculated by dividing the amount of cytokine detected 
(pg/mL) in the sample of interest by the cytokine detected in the unstressed sample.  For these 
studies, a response was considered to be positive if the SI ≥ 2.0 (i.e., response of the PBMC to 
the stressed sample is at least 2 fold higher than the control).  The percentage of donors (% 
donors) that responded was calculated by taking the total number of donors that had an SI ≥ 2.0 
as a percentage of the total number of donors tested.  The cutoff of SI ≥ 2.0 was determined by 
statistical analysis as described elsewhere.40   
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4.2.2.6.d. Multiplex Cytokine Analysis   
Quantification of cytokines released from PBMC was performed using a multiplex plate 
format using Milliplex (EMD Millipore, Billerica, MA) human panel kits and a Luminex 
Multiplexing instrument (specifically a Luminex FLEXMAP 3D instrument from EMD 
Millipore) as described by Joubert et al.40  For analysis of the PBMC supernatants at the early 
phase (after 20h incubation), the following cytokines were monitored: IL-10, IL-1ra, IL-1α, IL-
1β, IL-6, IL-8, MCP-1, MIP-1α, MIP-1β, TNF-α, and TNF-β.  For analysis of the PBMC 
supernatants at the late phase (after 7 days of incubation), the following cytokines were 
monitored: IFN-γ, IL-10, IL-12p40, IL-12p70, IL-13, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, and 
TNF-α.  A robust PBMC response was difficult to obtain due to the dilute nature of the FACS 
purified samples.  Therefore, the concentration of cytokines released by the PBMC was directly 
reported and the percentage of responding donors was calculated differently than for the MSD 
results. The cytokine response was analyzed as follows: for each cytokine monitored, the number 
of donors, who responded the highest (by releasing the largest amount of that same cytokine) to a 
specific size-enriched particle-containing sample was determined.    The number of donors that 
responded highest to this size bin was then taken as a percentage of the total number of donors 
that were tested. In all cases, negative controls such as buffer isolated by FACS and medium-
treated cells showed minimal response and positive controls such as LPS and/or PHA showed a 
very high response (SI>>2.0; data not shown).  In all cases, PBMC responses induced by the 
mAb samples were much lower than those induced by the LPS or PHA positive controls (data 
not shown).   
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4.2.2.7 Biophysical characterization of mAb particles 
4.2.2.7.a Extrinsic fluorescence 
8-Anilino-1-naphthalene sulfonate (8,1-ANS) was used to study changes in the 
accessibility of apolar regions in the protein samples.  An Agilent 8453 (Santa Clara, CA) was 
used with baseline and light scattering corrections.51 Fluorescence data were obtained as 
described previously.15  A spectrum of buffer containing ANS was subtracted from each 
spectrum prior to data analysis using Microsoft Excel software.  ANS peak positions and 
intensities were monitored and compared to that of the control samples to compare relative 
similarities or differences in surface hydrophobicity among samples.   
4.2.2.7.b FTIR 
The control, heat, and stirred mAb2 samples in solution were analyzed with a Bruker 
Tensor 27 FTIR Spectrometer and Bio-ATR cell.  Two hundred fifty-six scans were recorded 
from 600 to 4000 cm-1 with a resolution of 4 cm-1 as described in detail in Telikepalli et al.15  For 
analyzing mAb particles, 3 µm gold filters (Pall Corporation, Port Washington, NY) were used 
to capture and wash protein particles and then analyzed by FTIR microscopy as described in 
detail elsewhere.15   
4.2.2.7.c SDS-PAGE 
Each sample other than the FACS sorted samples was dissolved in NuPAGE LDS sample 
buffer (Life Technologies, Carlsbad, California) with and without 50 mM dithiothreitol (BioRad 
Laboratories, Hercules, CA) and incubated at 90°C for 5 min.  Approximately 3 µg of each 
sample was separated on a 3-8% Tris-acetate gel using Tris-acetate running buffer (Life 
Technologies) for 65 min at 150V.  A Hi-Mark unstained molecular weight ladder was used as a 
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reference (Life Technologies).  Protein bands were visualized by staining with Colloidal 
Coomassie (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.   
4.2.2.7.d Transmission Electron Microscopy (TEM) 
Six microliters of samples were placed onto Lacey Carbon 300 Mesh Copper grids (Ted 
Pella, Redding, CA) and allowed to sit for 2 min, with the excess wicked off by a Kimwipe.  
Stir-20h and bottom samples were diluted 100x with A5 buffer prior to being loaded onto the 
TEM grids.  FACS sorted samples, heat-stressed, unstressed control, and buffers were loaded 
directly onto the TEM grids with no dilution.  The grids were then placed into filtered 2% uranyl 
acetate for 2 min and extra stain was removed with a Kimwipe. The wet grids were air-dried for 
several min prior to being examined by TEM.  Samples were imaged on an FEI Technai F20 XT 
Field Emission Transmission Electron Microscope (Hillsboro, OR) using 200 kV electron 
acceleration voltage.  Images were captured at a standardized, normative electron dose and at a 
constant defocus value from the carbon-coated surfaces52.  
4.2.2.7.e Scanning Electron Microscopy (SEM)/Energy-dispersive X-ray Spectroscopy 
(EDS) 
A FEI Versa 3D Dual Beam Scanning Electron Microscope/ Focused Ion Beam 
(Hillsboro, OR) with an XMAX silicon drift detector (Oxford Instruments, UK) was used to 
obtain information regarding the surface morphology, elemental composition, and distribution of 
elements of the protein samples.  SEM data was obtained at an acceleration voltage of 7 kV and 
a spot size of 4.0 using an Everthart Thornely (ET) detector for image collection. Elemental 
mapping and energy spectra were acquired and processed with AZtecEnergy software (Oxford 
Instruments, UK).  For sample preparation, a small square piece of ruby red mica sheet (Electron 
Microscopy Sciences, Hatfield, PA) was mounted onto a standard SEM pin stub specimen mount 
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(Ted Pella, Redding, CA).  The grids prepared for TEM analysis were placed on top of the mica 
and a thin coating (3 nm) of electrically conductive material (gold) was deposited on the sample 
by a low vacuum sputter coater (Quorum Technology, Laughton, UK).   
 
4.3 RESULTS 
4.3.1 Initial comparisons of nanometer vs. micron sized mAb particles in a PMBC assay 
As an initial experiment, the IgG2 mAb (mAb2) in 10 mM acetate buffer, pH 5 (A5 
buffer) was stirred for 20h and the particles generated were fractionated by slow speed 
centrifugation to separate the supernatant and pellet, containing enriched nanometer and micron-
sized particles, respectively.  Figure 4.1 shows the size distribution of nanometer and micron 
sized particles present in the supernatant and pellet components as measured by HIAC and 
RMM, respectively.   There was almost a ten-fold higher number of smaller nanometer sized 
particles (0.2 to 1.5 µm) in the supernatant than the pellet, which contained more of the micron 
sized particles (2-10 µm). The percentage values shown in Figure 4.1 were calculated by 
dividing the number of particles in either the supernatant or pellet by the total number of 
particles present in both supernatant and pellet in a particular size range.  Hence the percentages 
signify the enrichment of a given size range in the samples.  For example, 83% of all the 
particles detected in the 0.2-1.5 µm range are in the supernatant, while only 17% of particles in 
this size range are in the pellet.   In addition, 70% of the particles detected in the 2-10 µm range 
are in the pellet, but only 30% of the particles in this size range are in the supernatant.  To get a 
better estimate for the precision of each technique, relative standard deviations (RSD) were 
calculated by running the stir-stressed mAb2 multiple times (N=10) on RMM; the RSD over the 
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size range 0.2 – 1.5 µm was about 30%.  A similar experiment has been previously done to 
determine the RSD of particles from another mAb using HIAC, which showed an RSD of 1% for 
the 2-10 µm particles, and 8 % RSD for particles greater than 10 µm.53  These samples were then 
analyzed for their cytokine response using an in vitro comparative immunogenicity assessment 
assay (IVCIA),40  as described in the Methods section. 
For these initial IVCIA studies, we tested the propensity of the supernatant (enriched in 
nanometer sized particles) and the resuspended pellet (enriched in micron-sized particles) to 
elicit a response in PBMC by monitoring the level of MCP-1 secreted.  MCP-1 was chosen as a 
representative cytokine since we previously identified this cytokine as part of the cytokine 
signature that is released by PBMC in response to aggregates at the early phase.40  PBMC from 8 
naïve healthy human donors were challenged with the mAb2 stir-20h total, supernatant and pellet 
samples and the secretion of MCP-1 was assessed at the early phase (20 hours) by an electro-
chemiluminescence assay. These initial results are shown in Figure 4.2.  The Y-axis on the left 
and corresponding colored bars represent the average concentration of MCP-1 detected in 
response to the different samples, while the Y-axis on the right and the corresponding gray bars 
refer to the percentage of donors that responded at least two fold higher than the unstressed mAb 
sample (SI ≥ 2.0).  The dots represent the individual data points for the 8 human donors.  Figure 
4.2 highlights the variability of MCP-1 expression levels for individual donors as well as the 
variability in responsiveness to the different mAb samples.  
When the PBMC were challenged with equal sample volumes of the three particle-
containing mAb samples (stir-20h total, supernatant, and pellet), the stir-20h total sample (no 
fractionation) showed the highest response with respect to both the number of responding donors 
as well as by magnitude of secreted MCP-1 (Figure 4.2A).  The stir-20h pellet showed a higher 
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response than the corresponding supernatant in terms of number of responding donors and 
magnitude of cytokine concentration.  Similar experiments were performed in which PBMC 
were challenged with equal protein concentrations (Figure 4.2B) or equal particle numbers 
(Figure 4.2C) of stir-20h supernatant and stir-20h pellet samples. Even though MCP-1 was 
detected when PBMC were challenged with the supernatant sample, none of the 8 donors 
responded two fold higher than the control, unstressed sample (Figure 4.2B).  In all three cases, 
(Figure 4.2A-C) the pellet sample induced a higher response than the supernatant sample by both 
magnitude of cytokine secretion and number of responding donors, suggesting that micron size 
particles enhance the response of PBMC in vitro to a greater extent than nanometer size particles 
at the early phase.  The level of cytokine secretion induced by the mAb2 samples was, however, 
much lower than that induced by the positive control (lipopolysaccharide, LPS; data not shown).   
To further test the wider applicability of these trends, the supernatant and pellet fractions 
of a second IgG2 monoclonal antibody were also tested in the IVCIA assay (data not shown).  
For both mAbs, the pellet fraction induced a higher response than the supernatant fraction, 
indicating that micron size particles induce a more robust response as compared to nanometer 
sized particles at the early phase.  
4.3.2 Size enrichment of various micron sized particles using FACS 
Based on the IVCIA data from evaluating stirring induced nanometer vs. micron sized 
mAb particles, it was observed that the larger micron sized particles showed higher relative 
responses in the donor population used (see above).  We therefore set out to develop a method to 
size fractionate the micron sized mAb particles for further analysis.  A wide variety (>20 
conditions) of settling, centrifugation and filtration experiments were evaluated to size 
fractionate micron-sized, stirring-induced mAb2 particles with limited success (data not shown).  
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After much trial and error experimentation, a methodology was identified that utilized a 
combination of gravitational settling under specific conditions combined with FACS, to enrich 
distinct micron sized particle populations (Figure 4.3A).  
The stir-20h mAb2 sample was gravitationally sedimented for 3h under specific 
conditions (see Methods section).  The bottom fraction (referred to as the “bottom” sample) was 
then collected.  The particle concentration and enrichment factor of the bottom sample as 
measured by MFI, in comparison to the original stir stressed mAb2 sample, is shown in Figures 
4.3B and 4.3C, respectively.  The bottom sample was then passed through the FACS and the 
forward scattering area (FSC) vs. side scattering (SSC) area dot plots were obtained as shown in 
Figure 4.3D. Each dot represents a counted particle and the FSC signal is generally considered to 
be a good indicator of particle size.54  Based on some initial correlations between FACS gating 
schemes and MFI sizing data (data not shown), gating schemes were optimized for best size 
enrichment and are shown in Figure 4.3D as I, II, III, and IV.  Based on these four gatings, the 
stir-20h bottom samples were sorted and collected. These four sorted samples (I, II, III, and IV) 
were collected and analyzed by MFI as shown in Figures 4.3E and 4.3F.  Sort I contains enriched 
number of 1-2 µm particles, Sort II contains an enriched number of 2-5 µm particles, Sort III an 
enriched number of 5-10 µm particles, and Sort IV an enriched number of greater than 10 µm 
particles (>10 µm); all sizes were calculated based on equivalent circular diameter (ECD). 
Comparing MFI enrichment results in Figures 4.3C with 4.3F shows a distinct enrichment in all 
four size ranges with good reproducibility as indicated by error bars.  Comparing MFI counts in 
Figures 4.3B with 4.3E, however, shows a large decrease in particle concentration after FACS 
separation, due to an extensive dilution of the samples of over ~1000 fold.  In this case, the 
FACS analysis had to be run numerous times (~20 runs over several months) to collect a 
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sufficient volume of sample, for further analysis.  Since so many runs were required for use in 
the PBMC assay, the FACS samples had to be collected and frozen after each run.    
For logistical reasons, FACS samples had to undergo two freeze thaws cycles prior to 
being evaluated.  The frozen FACS sorted samples from each individual FACS run were thawed, 
pooled with other similar sorts, and frozen again.  It was these pooled frozen samples that were 
then subsequently thawed for biophysical and FACS analysis.  These FACS sorted samples 
contained predominantly subvisible particles in PBS buffer.  The overall protein levels were low 
since mAb particles had been largely separated from free protein by the FACS. For example, 
total protein levels were too low to be observed in the FACS samples containing mAb particles 
by OD 280nm measurements, SDS-PAGE or with a colorimetric BCA assay (data not shown).  
Therefore, protein levels within the subvisible mAb particles could only be estimated by 
calculation from MFI data.50  To initially characterize the size measurements with these samples, 
one of the FACS sorted samples that underwent two F/T cycles, was examined by MFI (N=9) to 
examine the precision of the MFI results with these FACS samples.  RSD values between 20-
25% were obtained for the first three size bins (1-2, 2-5, and 5-10 µm), 60% for the largest size 
bin analyzed, and 20% for the total MFI particle counts (Figure 4.4A).  These values give the 
relative error associated with each of these particle counts in these different size ranges.  
Additionally, the pools (Sort I, II, III, IV) that underwent 2 F/T cycles were directly analyzed by 
MFI (N=3).  The particle enrichment factor for each of these four FACS samples is maintained 
after two F/T treatments (See results in Figure 4.3F vs. Figure 4.4B).   
Table 4.1 summarizes subvisible particle number, size and mass characteristics, based on 
MFI analysis, for each of the pools of the four samples (Sort I, II, III, and IV) that went through 
two F/T cycles. The total particle concentration is shown including estimated ranges (based on 
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twice the calculated RSD values from Figure 4.4).  In addition, the particle concentration in each 
of the four size ranges (including enrichment values and estimated ranges) are shown.  It is 
apparent here that the experimentally determined total particle concentration results (column 3) 
falls within the range expected based on RSD calculations (column 4) for nearly all of the FACS 
Sorts.  In addition, the calculated mass of the protein particles in each size range, based on MFI 
morphology measurements and assumptions of protein particle density as described by Kalonia 
et al, 2014,50 is shown in Table 4.1. 
  
4.3.3 IVCIA testing of FACS size-enriched populations of micron sized mAb particles 
The four FACS samples described in Table 4.1 (Sort I, II, III, IV) were next evaluated in 
the IVCIA assay. PBMC from 7 human donors were challenged with equal volumes and similar 
particle counts of each of these four FACS samples. The response to these FACS enriched 
micron-sized mAb particles was monitored at two different times, in the early stage (20 h 
incubation) and late stage (7 days incubation).  Multiplex cytokine analysis was used to assess 
two different panels of cytokines that were specific for each stage of the incubation.  The 
resulting cytokine profiles are shown in Figures 4.5 and 4.6.  A head-to-head comparison of the 
PBMC response to Sort I (containing enriched 1-2 µm particles) and Sort III (containing 
enriched 5-10 µm particles) is shown in Figure 4.5 at both the early phase (20 h, Figures 4.5A, 
4.5B) and late phase (7 days, Figures 4.5C, 4.5D).  Since the overall particle counts in each Sort 
sample were low, the PBMC responses observed were also low (compared to results shown in 
Figure 4.2).  
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Comparison of results in Figures 4.5A with 4.5B show that the concentrations of 
cytokines released (colored bars corresponding to the left-hand Y-axis) by PBMC in response to 
Sort I vs. Sort III are similar. However, the percentage of donors that responded (shown on the 
right hand Y-axis) to Sort III is higher as compared to Sort I.  Although this result shows that 
most of the donors responded more to the particles in Sort III than Sort I, it is important to keep 
in mind that this was not a dramatic response and the donors responded only marginally higher 
overall.  Similar observations can be made by comparing results in Figures 4.5C with 4.5D at the 
late phase of the PBMC response, which shows additional T-cell effector cytokines that are more 
specific to the late phase of the immune response.  This subtle difference between Sort I and Sort 
III is thought to be partly due to the low particle counts, which prevented robust cytokine release.  
However, it is apparent that more donors consistently responded to the Sort III sample than the 
Sort I sample.  
 Since Sort I showed a lower response than Sort III (Figure 4.5), it was not assessed 
further.  Sorts II, III, and IV were further assessed (Figure 4.6).  PBMC from 8 human donors 
were challenged with similar particle counts of Sort II, III, and IV and the resulting cytokine 
profiles are shown in Figure 6 at both the early phase (Figure 4.6A, 4.6B, 4.6C) and the late 
phase (Figure 4.6D, 4.6E, 4.6F). The overall responses, in terms of cytokine concentrations, were 
low, probably for the same reasons described above in Figure 4.5.  Despite these limitations, a 
trend of a greater number of responding donors across the different cytokines was observed for 
the Sort III sample (enriched in 5-10 µm particles) for the PBMC at both the early and late phase 
of this in-vitro assay (Figure 4.6).  
 
 147 
4.3.4 Biophysical characterization of FACS size-enriched populations of micron-sized 
mAb particles  
The Sort I, II, III, IV size enriched samples from the FACS contained subvisible particles, 
but undetectable amount of free protein in solution (as detected by OD280, SDS-PAGE or BCA 
assay), in PBS buffer, so this provided an opportunity to characterize protein particles without 
the presence of IgG2 mAb in solution.  Consequently, due to these FACS samples’ low mAb 
particle concentration (and thus low protein concentration), only a limited number of physical 
assays could be used (see below).  Therefore, the IgG2 mAb sample generated just prior to 
FACS separation was first characterized (stirring followed by gravitational settling and selection 
of the “bottom” sample) to better understand the nature of the micron-sized particles going into 
the FACS separation.  These samples contained both protein particles and soluble IgG2 mAb. 
The biophysical analysis of the starting material for FACS analysis focused on four 
samples:  two controls (unstressed and extensively heated mAb2 solutions as negative and 
positive controls), the stirred antibody solution (stir-20h), and the “bottom” sample from the 
stirred sample after gravitational settling (i.e., the starting material for the FACS separation).  
Only the heat-stressed control contained high molecular weight aggregates containing reducible 
covalent, disulfide linkages, which were not present in the other three samples as measured by 
SDS-PAGE (Figure 4.10).  Figure 4.7 shows TEM, SEM, EDS, FTIR, and ANS fluorescence 
spectroscopy data for the four samples.  The unstressed control (Figure 4.7; first row) contained 
no particles that could be imaged by TEM and SEM-EDS (see Figures 4.12 and 4.13).  The 
unstressed mAb2 solution contains antibody with largely native secondary structure 
(intramolecular beta sheets) with characteristic positions of the two peaks at 1691.1 cm-1 and 
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1636.6 cm-1, as determined by second-derivative FTIR spectroscopy. It also shows virtually no 
extrinsic fluorescence intensity indicating limited exposure of apolar regions for ANS binding. 
Similar biophysical analysis was then performed on the subvisible particle containing 
samples of mAb2. Results from heat stressed, stir-20h, and the bottom samples are shown in 
Rows 2, 3 and 4 of Figure 4.7, respectively.  These particles were observed to be amorphous in 
nature by TEM and SEM and contained predominantly carbon, nitrogen, and oxygen by EDS 
analysis (as expected for protein).  All protein samples contained trace levels of elemental 
chlorine, presumably bound to the mAb protein during exposure to NaCl solutions during 
purification.  Interestingly, the stir-20h samples also contain fluorine, probably originating from 
the Teflon coated stir-bar, while the heated particles did not contain fluorine (unstressed and heat 
stressed samples also lacked fluorine; see Figures 4.12 and 4.13).  The heat control samples 
contained protein with structurally altered conformation, containing mAb with predominantly 
intermolecular beta sheets, as indicated by the 1620.7 cm-1 peak by FTIR, as well as increase in 
surface hydrophobicity relative to the unstressed control.  The major peak in FTIR spectra of the 
particles isolated from the two stirred samples (stir-20h and bottom samples) was between the 
two control samples, even though there was some increased variability in peak position.  The 
bottom sample showed the largest increase in ANS intensity indicating a relatively increased 
surface hydrophobicity (or aggregation) of protein within this sample (last row in Figure 4.7).  
Thus, there is some level of structural alteration of the protein contained in the stir-induced 
protein particles as well as increase in surface hydrophobicity relative to the unstressed and 
heated controls. 
The bottom sample was the starting material for the FACS separation, leading to 
collection of Sorts I, II, III, and IV containing size enriched micron sized particles. The protein 
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particles after FACS separation (Sorts I, II, III, and IV) were quite dilute compared to the 
samples described above, but were in sufficient number to be visualized by TEM and SEM 
(Figure 4.8).  Representative TEM images at two resolutions (200 nm and 1 µm) with protein 
particles represented by the darker gray regions are shown, while the lighter, smoother, gray 
regions are due to the TEM grids used for sample preparation. Representative SEM images (5 
µm resolution) are shown, and the protein particles appear lighter with unique shapes and are 
highlighted by the blue boxes.  These SEM images provide a unique visual representation of the 
morphology of the protein particles compared to TEM.  Aside from their size, the protein 
particles from the four FACS samples (Sorts I, II, III, IV) are similar morphologically.  This is 
especially apparent in the 1 and 5 µm resolution TEM and SEM images, respectively.  The 
proteins within the blue boxes in the SEM images were analyzed for chemical composition by 
EDS (last column).  Similar to the starting material used in the FACS separation, the FACS 
separated particles contain C, N, O, and trace amounts of chlorine and fluorine. Elemental 
mapping of these particles confirmed that the fluorine was present only in the particles and not in 
the background or control samples (Figure 4.13).   
 In addition, MFI data were used to compare the morphology of these purified particles by 
constructing radar charts.15,49,55  These radar charts are a data visualization technique, which 
facilitates comparisons of a specific morphological characteristic in a large number of samples 
such as their aspect ratio and transparency (intensity).  For example, MFI morphology radar chart 
analysis of the Sort I, II, III, IV FACS samples, and the bottom mAb2 sample (starting material 
for FACS separation) is shown in Figure 4.9. As shown in the key in Figure 4.9B, size bins start 
at 2-5 µm at the top of the circle and increase clockwise up to > 10 µm.  The outermost circle has 
four more concentric circles within it and consists of a triangle, located in the center, pointing to 
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three size bins.  The triangle can get larger or smaller within the circle towards one or more size 
bin.  Depending on whether the intensity parameter or aspect ratio parameter are being analyzed, 
the expanding triangle shows that the particles in that size bin are becoming elongated (aspect 
ratio; going from 1 to 0) or more opaque (intensity; going from 850 to 350 ILU).  
From Figure 4.9A, no differences were observed in intensity or aspect ratio of FACS 
sorted mAb particles in the 2-5 µm size range although these small sizes approach the limit of 
MFI resolution for morphology parameters (around 4 µm).  For 5-10 µm size bins, particles 
present in Sort I, III, and IV samples appear slightly more opaque than similarly sized particles in 
the bottom and Sort II samples. Particles larger than 10 µm in the bottom and Sort IV samples 
appear more opaque than similarly sized particles in Sort I, II, and III.  In terms of aspect ratio, 
the FACS sorted samples showed some more elongated particles in the largest size bin (>10 µm) 
compared to the bottom sample. Overall, these differences are relatively minor, and the 
morphological parameters among the particles in the four FACS samples were similar.   
 
4.4 DISCUSSION  
This work evaluated the immune activation potential of protein aggregates of varying size 
by examining size-enriched populations of stirring-induced mAb2 particles in an in-vitro cell 
based assay, known as IVCIA, with PBMC from human donors.  As an initial set of experiments, 
we showed that micron sized protein particles enhanced cytokine secretion in the IVCIA assay to 
a greater extent than nanometer-sized particles.  To determine which size subset of micron sized 
aggregates induced the greatest response, we utilized a combination of gravitational settling and 
FACS separation to obtain different micron size-enriched protein particles from a stirred solution 
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of mAb2.  FACS sorting resulted in isolated protein particles, with no detectable soluble protein 
in samples as measured by OD 280nm, SDS-PAGE or BCA analysis, offering the opportunity 
for additional biophysical characterization of isolated protein particles (in addition to testing 
these particles in the IVCIA assay).  
The mAb2 particles induced by stirring were shown, compared to untreated and heat 
stressed controls, to contain an amorphous morphology with protein within the particles having 
some structural alterations in their overall secondary structure and increased surface 
hydrophobicity, but retaining some of the native higher-order structures as well (Figure 4.7).  
The FACS separation results for these mAb2 particles are consistent with those of Nishi et al. in 
that this technique involves a relatively mild condition that do not disrupt particles to a 
detectable extent.45  In this work, even after two freeze-thaw cycles, significant size-enrichment 
of mAb particles is maintained within the FACS sorted samples. This result indicates either these 
aggregates are irreversible, or that the conditions used to enrich and isolate them do not disrupt 
the reversible interactions.  Previous characterization of aggregates of mAb2 generated by 
stirring demonstrated some reversibility upon dilution, supporting the second conclusion.40    
FACS separates particles by imparting a charge on the droplet containing them.  From 
our analysis of morphology of the FACS sorted samples, although minor differences from MFI 
radar chart analysis were noted, it appears FACS does not dramatically alter the overall nature of 
particles before and after FACS separation.  The small differences observed in the radar plots 
may actually primarily reflect the different amounts of particles in different size bins (Table 4.1).  
Thus when evaluating the average aspect ratio or intensity in a size bin, one also needs to 
consider the number of particles present in that bin as well. A combination of TEM, SEM-EDS 
and MFI analysis of the morphology and composition of mAb2 particles before and after FACS 
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separation showed no notable differences (Figure 4.7, 4.8, 4.9). Interestingly, particles generated 
by stirring contained fluorine as measured by SEM-EDS, and this element was not present in the 
buffer and control mAb2 (unstressed and heat stressed) samples indicating that it was originating 
from the stir-stress (Teflon-coated stir bars were used in this study) and carried with the particles 
through the FACS separation.  The presence of this element in protein particles and its impact on 
PBMC responses is a subject for investigation in future work.   This result also highlights that 
generating particles under accelerated conditions (i.e., extensive stirring with a Teflon coated stir 
bar) does not necessarily mimic mAb particle formation under real-time storage conditions. In 
fact, fluorine was not observed in control or heat-stressed mAb2 samples.   
There are some practical limitations of the FACS technique for preparative isolation of 
protein particles that need to be improved in the future.  First, FACS isolation results in 
significant dilution of the particle sample (~1000X in these studies) resulting in low particle 
yields (compare Figure 4.3B to Figure 4.3E).  In fact, to prepare sufficient amounts of size-
enriched mAb particle samples for biophysical and biological testing in this work, many months 
of almost continuous FACS runs were required.  This in turn required freezing of individual sorts 
from individual runs, followed by subsequent thawing, pooling and refreezing of particle 
preparations to obtain the Sorts I, II, III, and IV evaluated in this work.  Even then, low particle 
counts obtained (< 10,000 particles/mL) approached the lower limit of particles required for the 
IVCIA assay and consequently led to low PBMC responses.  In addition, it is also difficult to 
further concentrate the FACS separated particles without loss of material due to additional 
processing or inadvertently altering their size distribution.  Rombach-Riegraf showed that 
resorting IgG particle samples increases purity of distinct size bins42, which was not a viable 
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option in this work since it would have dramatically decreased particle concentration even more, 
making the samples unsuitable for the in-vitro assay or biophysical characterization.   
The dilution from the FACS could result in the loss of reversible aggregates, so that the 
samples assessed after FACS analysis might be primarily irreversible aggregates.  This should 
present a “worse case” for immunological potential assessment, but might not reflect the original 
aggregate population.  It was found that even after two freeze-thaws, the FACS sorted samples 
retained a similar distribution of subvisible particles counts, indicating that they are in fairly 
stable state where they do not appear to either dissociate or aggregate, indicating potential 
irreversibility. SDS-PAGE gels showed that the “bottom” sample, used as the starting material 
for FACS separation, did not contain covalently linked high molecular weight aggregates; 
unfortunately, due to the dilute nature of the FACS samples, they could not be assessed by this 
technique.  It is possible that the bottom sample contained either covalently or non-covalently 
linked aggregates that dissociated upon sample preparation.  In that case, the aggregates should 
be fairly reversible.  However, more work needs to be done to further characterize the 
reversibility nature of these FACS sorted samples.   
These IVCIA results are consistent with other studies that have examined the role of the 
size of subvisible particles in eliciting an immune response.35,40,56-63  For example, stressed 
conditions that generated high levels of subvisible particles elicited ADA titers in various mouse 
models with heat stressed allergens57, human growth hormone 58, and recombinant human 
interferon alpha 2b.35  Further evidence suggests that larger sized subvisible particles are more 
likely to elicit various immune responses.  For example, when high pressure was applied to 
aggregates of human or murine growth hormone, subvisible particle counts declined along with a 
corresponding decrease in immunogenicity in mice. 58,64  These results agree with prior work 
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using protein coated spheres as a model system for protein aggregates of different sizes where 
antibody-coated 5 µm microspheres induced a greater response in (1) the IVCIA assay compared 
to heterogeneous stress-induced aggregate populations40 , and (2) in a Xeno-het mouse model 
system compared to antibody-coated nanospheres (20-50 nm).47  In this work, 5-10 µm sized 
protein particles displayed elevated levels of cytokine responses compared to the other sized 
mAb2 particles tested in the same IVCIA assay.  
The role of structural integrity of protein molecules within particles on immune responses 
has also been widely studied. 35,40,56,57,59,61-63,65  Results from one of our laboratories have 
previously shown that aggregated solutions with high numbers of 2-10 µm particles and the 
retention of at least some folded protein structure caused the highest PBMC immune response. 40  
In another study, Filipe et al. subjected a fully human IgG1 to various stresses and found that the 
stress that formed the most micron sized particles, which were mostly native in structure, 
actually did not show a high immune response59.  Instead copper-catalyzed aggregates, 
containing little to no visible and micron sized particles, low surface hydrophobicity, and large 
changes in secondary and tertiary structures were the ones that showed the highest ADA 
response in transgenic mice.59  This aggregate type was shown to contain a high level of copper 
and histidine oxidation,13,14  a modification not found in other types of stress treated aggregates. 
These results highlight the importance of aggregate type in inducing an immune response, which 
may be more important than size, amount, or morphology of the aggregates.59  In our work, the 
stirring induced mAb2 particles contained protein structural alterations in secondary and tertiary 
structure as shown by FTIR microscopy and extrinsic ANS fluorescence spectroscopy, 
respectively.  Compared to the heat control, the stirred samples displayed some retention of 
native higher-order structures, which may be necessary for the observed PBMC response.  
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The inter-relationship of protein particle size, number and mass presents a challenge in 
determining the most important factors in generating an immune response.  Rombach-Riegraf 
showed that the mass of protein present in subvisible particles may be an important property.  
They saw a positive correlation between protein mass in subvisible particles, generated by 
stressing an IgG mAb, and the amount of antigen processed and presented by the dendritic cells 
(DC).61  The more subvisible particles there are, the greater the mass of protein, and 
consequently, the greater the presentation of peptide by DC, which can influence DC maturation 
and activation of CD4+ T cells61.  While we did not design the IVCIA assay to examine the 
effect of protein mass of the FACS sorted samples, we subsequently estimated the weight of 
protein particles in Sorts I-IV using MFI morphology data using a new method from one of our 
laboratories.50 As shown in Table 4.1, Sort III, which showed the greatest response in the IVCIA 
assay, contained both the highest number of particles and the highest mass of protein present in 
the 5-10 µm size range (Table 4.1).  Even then, roughly 25% of the total protein mass in this 
sample was estimated to be from the particles larger than 10 µm.  Additionally, even though Sort 
IV contained a significant mass of protein calculated from the 5-10 µm particles, this sample 
showed a lower relative response in this PBMC in-vitro assay. Sort IV contained an enriched 
number of particles greater than 10 µm, and consequently most of the mass of the protein was 
present in these particles. This highlights that both protein mass and number of particles are 
important factors for consideration in monitoring cytokine responses in this assay.   
In summary, we observed that size-enriched fractions of stirring-induced mAb2 particles 
greater than 2 µm, especially in the 5-10 µm range, elicited a relatively greater cytokine 
responses in a number of PBMC donors in the in-vitro assay.  However, many questions remain.  
In terms of physical characteristics of the mAb aggregates, it would be beneficial to use the 
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methods established in this work to perform additional case studies with FACS size-enriched 
mAb particle populations (e.g., with different mAbs and different stresses and thus different 
physicochemical characteristics) to determine if the trends in size and immune potential observed 
in this work are generally observed across different types of mAb aggregates.  In terms of 
biological readouts, even though this PBMC in-vitro model avoids the challenges associated with 
animal models, accounts for human genetic diversity, and mimics administration of the drug, it 
still requires a large number of particles, perhaps much more than clinically relevant, to obtain a 
strong signal.40  Additionally, it is important to note that the cytokines monitored in this study 
serve as biomarkers of early and late phases of the immune response in this in-vitro system.  
They are useful tools to assess the relative response of a diverse human population of PBMC and 
to rank responses relative to different types of aggregates.  However, how the PBMC cytokine 
responses correlate with various in-vivo immune processes or immunogenicity is currently 
unknown due to the complexities arising from the pleiotropic nature of cytokines and the 
complexity of the immune system where the T cell driven B cell response and consequent 
signaling and antibody formation cannot be reproduced in-vitro.  A combination of this in-vitro 
assay with other in-silico and in-vivo models, however, should result in enhanced predictive 
value in determining the relative immunogenic potential of different therapeutics.   
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4.5 TABLES AND FIGURES 
Table 4.1.   Various characteristics of the FACS sorted samples I, II, III, and IV used in the 
IVCIA assay are shown.  The average particle concentration, experimental concentration range 
obtained from N=2, and estimated concentration range based on 2RSD from N=9 from Figure 
4.4 measurements using the same protein are shown.  The average concentration, range of 
particles in each of the size bins (1-2, 2-5, 5-10, >10 µm), their corresponding enrichment values, 
mass of protein in each bin (as calculated from Kalonia et al50), and the range of mass of protein 
within those size bins is shown. 
 
 
Total particle conc. (#) 
Size 
bin Particle conc. & enrichment by size bin 
 
Calculated particle 
mass by size bin 
Sorts 
Avg 
conc. 
 
Exp. 
conc. 
range 
Est. conc. 
range 
based on 
(2 RSD) ECD 
Avg 
conc. 
Avg 
enrichment Conc. range 
Enrichment 
range 
 
Avg 
mass 
protein 
mass 
range 
protein  
(#/mL) 
(#/mL) 
N=2 
(#/mL) 
N=9 ( µm) (#/mL  (%) (#/mL) (%) 
 
(ng) (ng) 
           
I 71300 
61100-
81400 
49000-
110000 
1-2 67400 94 56000-79000 92-97 
 
2.9 2.4 - 3.3 
2-5 3500 5 2700-4400 3-7 
 
1.5 1.0-1.9 
5-10 280 0 60-500 0-1 
 
2.1 0.5-3.6 
>10 100 0 50-150 0 
 
5.1 2.4-7.8 
            
II 31000 
25500-
36500 
22000-
51000 
1-2 14400 47 12700-16000 44-50 
 
1 0.8-1.2 
2-5 16300 52 12400-20100 49-55 
 
9.6 6.8-12 
5-10 400 1 360-380 1 
 
1.3 1.2-1.4 
>10 20 0 13-30 0 
 
7.5 1.0-14 
            
III 110400 
85900-
13500 
81000-
190000 
1-2 30000 28 25200-34700 26-29 
 
1.7 1.4-2.0 
2-5 28200 26 23000-33800 25-26 
 
28 21-36 
5-10 48000 43 35300-60700 41-45 
 
345 241-449 
>10 4200 4 2900-5600 3-4 
 
119 90-147 
            
IV 46900 
32000-
62000 
37000-
87000 
1-2 21200 46 16100-26200 42-51 
 
1.2 0.9-1.5 
2-5 14300 31 10300-18300 30-32 
 
11 7.3-14 
5-10 8000 16 4100-12000 13-19 
 
71 32-110 
>10 3400 7 1400-5500 4-9 
 
103 45-162 
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Figure 4.1. Separation of nanometer vs. micron sized stirring induced particles of mAb2 by low 
speed centrifugation. (A) Schematic of experimental setup, (B) particle number and size 
distributions of the fractionated samples are shown in three different size ranges.  The 
concentration of smaller particles (0.2-1.5µm) for both supernatant and pellet were obtained by 
Resonant Mass Measurement (RMM; estimated RSD ~30 %, see text).  The concentration of 
particles 2 to >10 µm was obtained from light obscuration measurements (HIAC; estimated RSD 
1-8%, see text). The percentages were calculated by dividing the number of particles in either the 
supernatant or pellet by the total number of particles present in both supernatant and pellet at a 
particular size range.   
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Figure 4.2.  Peripheral blood mononuclear cells (PBMC) from 8 human donors were incubated 
with solutions of mAb2 particles (see Figure 4.1) and examined for the release of MCP-1.  MCP-
1 was measured by electro-chemiluminescence at the early phase (20 h incubation) at (A) equal 
sample volume, (B) equal protein concentration, and (C) equal particle numbers.  The average 
concentration (n=8, colored bars) of MCP-1 and percentage of donors that responded (gray bars) 
to the aggregated mAb (two fold above the unstressed mAb2) is shown.  The black dots 
represent the concentration of MCP-1 secreted by each individual donor.   Different aggregate 
samples are shown horizontally as follows; stir-20h total (red), stir-20h supernatant (enriched in 
nanometer size particles; light blue), and stir-20h pellet (enriched in micron sized particles; 
purple); see Figure 4.1.  The media and buffer-stressed controls responded far below the 
threshold, and the LPS positive control responded much more intensely (SI>>2.0) than the 
aggregated protein samples (data not shown).   
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Figure 4.3.  Enrichment of different micron sized mAb2 particle populations using FACS 
separation.  (A) Flowchart of experimental steps, (B) subvisible particle counts in stirred sample 
(stir-20h) and bottom fraction after gravitational settling (bottom sample) as measured by MFI, 
(C) the percentage of particles in each size bin for these same two samples.  (D) Upon FACS 
sorting the bottom sample, a two dimensional dot plot of response from forward vs side 
scattering signals (FSC Area vs. SSC Area) is generated with gatings labeled Sort I-IV, (E) Sorts 
I-IV were analyzed for subvisible particle distribution with MFI, and (F) the percentage of 
particles in each size bin were determined. The graphs represent the average of three separate 
experiments (N=3) with the error bars representing one standard deviation.  
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Figure 4.4.  Determination of relative standard deviation (% RSD) of MFI particle counting and 
determination of enrichment factors for FACS separated samples of mAb2 particles. (A) 
Representative FACS sorted sample of stir-induced aggregated mAb2, obtained as outlined in 
Figure 4.3 and having undergone two freeze-thaw cycles, was used for repeat MFI testing to 
determine % RSD as a function of particle size bins (N=9 with the error bars representing one 
standard deviation), and (B) Enrichment analysis of FACS sorted samples (Sort I, II, III, IV) 
after undergoing two freeze-thaw cycles. Data are an average of three separate experiments 
(N=3) with the error bars representing one standard deviation.   
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Figure 4.5.  Peripheral blood mononuclear cells (PBMC) from 7 human donors were incubated 
with mAb2 particle samples collected from the FACS separation and analyzed for cytokine 
release.  Sort I (containing enriched 1-2 µm particles) (A, C) and Sort III (containing enriched 5-
10 µm particles) (B, D) from FACS separation as well as the relevant controls were tested for the 
release of cytokines by multiplex cytokine analysis at the early phase (20 h) (A, B) and late 
phase (7 day) (C, D) at equal volume.  The average concentration across donors (N=7, colored 
bars) of the 11 cytokines tested at the early phase (A, B) and 12 cytokines tested at the late phase 
(C, D) is shown.  The percentage of responding donors (gray bars) represents the number of the 
8 donors tested that responded higher (by magnitude of secreted cytokine) to each sort.  The 
black dots represent the concentration of cytokines secreted by each individual donor. The LPS 
and PHA positive control responded much more intensely (SI>>2.0) than the aggregated protein 
samples (data not shown). 
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Figure 4.6.  Peripheral blood mononuclear cells (PBMC) from 8 human donors were incubated 
with FACS isolated mAb2 particle samples (containing very little soluble aggregates): Sort II 
(enriched in 2-5 µm particles) (A, D), Sort III (enriched for 5-10 µm particles) (B, E), and Sort 
IV (enriched for particles > 10 µm) (C, F) at similar particle numbers and analyzed for their 
cytokine release. These FACS samples as well as the relevant controls were tested for the release 
of signature cytokines by multiplex cytokine analysis at the early phase (20h) and late phase (7 
days).  The average concentration across donors (N=8, colored bars) of the 7 cytokines tested at 
the early phase and 9 cytokines tested at the late phase is shown.   The percentage of responding 
donors (gray bars) represents the number of the 8 donors tested that responded higher (by 
magnitude of secreted cytokines) to each sort.  The black dots represent the concentration of 
cytokines secreted by each individual donor.  
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Figure 4.7.  Biophysical analysis of mAb2 solutions containing stirring-induced particles that 
were used as starting material for FACS separation. Control samples (unstressed and heat 
denatured) and two stirred samples (Stir-20h, Bottom) of mAb2 were characterized for 
morphology by SEM and TEM, composition by EDS, overall secondary structure by solution 
FTIR and FTIR microscopy, and surface hydrophobicity by extrinsic fluorescence using 1,8-
ANS as indicated in this Figure.  Representative TEM and SEM are shown at two resolutions 
(the unstressed control had virtually no particles so no TEM and SEM images are shown).  For 
FTIR analysis, shifts in two peaks for intramolecular beta sheet content (occurring between 1620 
to 1640 cm-1 and 1690 to 1700 cm-1) were monitored in the second derivative FTIR spectra.  The 
peak minima are shown for each sample (N=3 with the error bars representing one standard 
deviation).  
1700 1680 1660 1640 1620 1600
0.0
0.5
1.0
1.5
2.0
dA
2 /d
2 ν
TEM$ SEM$ FTIR$EDS$ ANS$
Control$
Heat$
S5r620h$
Bo;om$
1700 1680 1660 1640 1620 1600
0.0
0.5
1.0
1.5
2.0
dA
2 /d
2 ν
1700 1680 1660 1640 1620 1600
0.0
0.5
1.0
1.5
2.0
dA
2 /d
2 ν
1700 1680 1660 1640 1620 1600
0.0
0.5
1.0
1.5
2.0
Wavenumber (cm-1) 
dA
2 /d
2 ν
400 420 440 460 480 500 520 540 560 580 600
0
100000
200000
300000
400000
500000
600000
700000
800000
In
te
ns
ity
 (c
ps
)
 
 
400 420 440 460 480 500 520 540 560 580 600
0
100000
200000
300000
400000
500000
600000
700000
800000
 
In
te
ns
ity
 (c
ps
)
400 420 440 460 480 500 520 540 560 580 600
0
100000
200000
300000
400000
500000
600000
700000
800000
 
In
te
ns
ity
 (c
ps
)
400 420 440 460 480 500 520 540 560 580 600
0
100000
200000
300000
400000
500000
600000
700000
800000
In
te
ns
ity
 (c
ps
)
 
Wavelength (nm)
1630.4'±'4.0'
1693.2'±'0'
1620.7'±'0.7'
1691.5'±'2.7'
1626.4'±'5.4'
1691.3'±'0.5'
1636.6'±'0.9'
1691.1'±'0.9'
200'nm' 5'μm'
 
 165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8.  Representative TEM (200 nm and 1 µm resolution) and SEM (5 µm resolution) 
images of mAb2 particles of four different FACS sorted samples (Sort I, II, III, IV).  The SEM 
particle images (representative graphs shown here), selected by the blue boxes, were also 
analyzed for their elemental composition by EDS as shown in far right column of figure.   
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Figure 4.9.  Radar plots of MFI morphology data (aspect ratio and intensity; refer to the key in 
Panel B) for subvisible particles of mAb2 present in the starting material for FACS (bottom 
sample) and FACS sorted samples (Sorts II-IV, see text) are shown in A.  Radar plots show MFI 
morphology data distributions of the micron sized particles that fall within each of the three size 
bins shown in the key of Panel B). The data shown are the average of three separate experiments 
(N = 3) and the error represents one standard deviation. 
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Figure 4.10.   (A) Nonreduced and (B) reduced SDS-PAGE gels of control mAb2 (unstressed), 
heat denatured mAb2, and two stirred mAb2 samples (stir-20h, bottom) in A5 buffer.  The 
bottom sample is the starting material for the FACS separation (see text). MW standards are 
shown with indicated values in kDa.  Please note the additional samples in the gel correspond to 
the supernatant and pellet samples of stirred mAb2 solutions from the slow speed centrifugation 
approach described in the Methods.    
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Figure 4.11. Representative TEM images at three size scales of buffer (sodium acetate buffer, 
pH 5), control mAb2 (unstressed), heat denatured mAb2, and two mAb2 stirred samples (stir-
20h, bottom) in A5 buffer.  The bottom sample is the starting material for the FACS separation 
(see text). 
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Figure 4.12. Representative EDS spectra and SEM images of buffer (sodium acetate buffer, pH 
5), unstressed, heat denatured, and two stirred samples (stir-20h, bottom) of mAb2 in A5 buffer.  
The bottom sample is the starting material for the FACS separation (see text). Regions in the 
SEM images (indicated by the white boxes or shapes) were selected for elemental composition 
determination.   Elements in greatest abundance are shown on the right hand side of the figure in 
ratio form.  The numerator depicts the number of times an element is detected in a region while 
the denominator depicts the total number of regions analyzed.  All samples show background 
levels of carbon and oxygen, uranium, copper, aluminum, silicon, and gold coming from the 
sample grids, sample studs, and coating required for acquiring proper images.  
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Figure 4.13. Representative EDS spectra and SEM images of bottom and FACS sorted samples 
(I, II, III, IV) are shown.  Regions in the SEM images (indicated by the white shapes) were 
selected for elemental composition determination.    Elements in greatest abundance are shown 
on the right hand side of the figure in ratio form.  The numerator depicts the number of times an 
element is detected in a region while the denominator depicts the total number of regions 
analyzed.  All samples show background levels of carbon and oxygen, uranium, copper, 
aluminum, silicon, and gold coming from the sample grids, sample studs, and coating required 
for acquiring proper images.  
Most%Abundant%Elements%
Sort%I%
Sort%II%
Sort%III%
Sort%IV%
C%,0,%N,%P%(17/17)%
F%(11/17),%S%(12/17),%%
Na,%Cl%%(10/17),%
C,%0,%N,%Na,%F,%P,%Cl%%(11/11)%
S%(3/11),%%
C%,0,%N,%Na,%F,%P,%Cl%(13/13)%
S%(4/13)%%
C%,0,%N,%P%(19/19)%
S%(9/19),%Na%(13/19),%
Cl%(18/19),%F%(17/19)%
BoEom%
C%,0,%N,%F%(17/17)%
S%(11/17),%%
Trace%amounts%of%Na,%
Cl,%P%
5%μm%
 
 171 
4.6 REFERENCES 
1. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ 2010. Immunogenicity of protein 
therapeutics: The key causes, consequences and challenges. Self/nonself  1(4):314-322. 
2. Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N 2005. Epoetin-
associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association  20 Suppl 3:iii33-40. 
3. Casadevall N 2005. What is antibody-mediated pure red cell aplasia (PRCA)? 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association  20 Suppl 4:iv3-8. 
4. Chirino AJ, Ary ML, Marshall SA 2004. Minimizing the immunogenicity of protein 
therapeutics. Drug discovery today  9(2):82-90. 
5. Claman HN 1963. Tolerance to a Protein Antigen in Adult Mice and the Effect of 
Nonspecific Factors. Journal of immunology  91:833-839. 
6. Gamble CN 1966. The role of soluble aggregates in the primary immune response of 
mice to human gamma globulin. International archives of allergy and applied immunology  
30(5):446-455. 
7. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, 
Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T, FVIII-LFB, Recombinant FVIII study 
groups 2006. Influence of the type of factor VIII concentrate on the incidence of factor VIII 
inhibitors in previously untreated patients with severe hemophilia A. Blood  107(1):46-51. 
8. Moore WV, Leppert P 1980. Role of aggregated human growth hormone (hGH) in 
development of antibodies to hGH. The Journal of clinical endocrinology and metabolism  
51(4):691-697. 
9. Wang W, Roberts CJ editors. 2010. Aggregation of Therapeutic Proteins. ed., Hoboken, 
NJ: John Wiley & Sons. p 486. 
10. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S 2012. Immunogenicity of 
protein aggregates--concerns and realities. International journal of pharmaceutics  431(1-2):1-11. 
11. Mahler HC, Friess W, Grauschopf U, Kiese S 2009. Protein aggregation: pathways, 
induction factors and analysis. Journal of pharmaceutical sciences  98(9):2909-2934. 
12. Cromwell ME, Hilario E, Jacobson F 2006. Protein aggregation and bioprocessing. The 
AAPS journal  8(3):E572-579. 
13. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO 2011. Classification and 
characterization of therapeutic antibody aggregates. The Journal of biological chemistry  
286(28):25118-25133. 
14. Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, Wypych J 2011. Chemical 
modifications in therapeutic protein aggregates generated under different stress conditions. The 
Journal of biological chemistry  286(28):25134-25144. 
15. Telikepalli SN, Kumru OS, Kalonia C, Esfandiary R, Joshi SB, Middaugh CR, Volkin 
DB 2014. Structural characterization of IgG1 mAb aggregates and particles generated under 
various stress conditions. Journal of pharmaceutical sciences  103(3):796-809. 
16. Iwura T, Fukuda J, Yamazaki K, Arisaka F 2014. Conformational stability, reversibility 
and heat-induced aggregation of alpha-1-acid glycoprotein. Journal of biochemistry. 
 
 172 
17. Liu L, Braun LJ, Wang W, Randolph TW, Carpenter JF 2014. Freezing-induced 
perturbation of tertiary structure of a monoclonal antibody. Journal of pharmaceutical sciences  
103(7):1979-1986. 
18. Sahin E, Grillo AO, Perkins MD, Roberts CJ 2010. Comparative effects of pH and ionic 
strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. Journal 
of pharmaceutical sciences  99(12):4830-4848. 
19. Sharma B 2007. Immunogenicity of therapeutic proteins. Part 2: impact of container 
closures. Biotechnology advances  25(3):318-324. 
20. Shire SJ, Shahrokh Z, Liu J 2004. Challenges in the development of high protein 
concentration formulations. Journal of pharmaceutical sciences  93(6):1390-1402. 
21. Wang W 2005. Protein aggregation and its inhibition in biopharmaceutics. International 
journal of pharmaceutics  289(1-2):1-30. 
22. Wiesbauer J, Prassl R, Nidetzky B 2013. Renewal of the air-water interface as a critical 
system parameter of protein stability: aggregation of the human growth hormone and its 
prevention by surface-active compounds. Langmuir : the ACS journal of surfaces and colloids  
29(49):15240-15250. 
23. Schellekens H 2005. Factors influencing the immunogenicity of therapeutic proteins. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association  20 Suppl 6:vi3-9. 
24. Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, 
Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, 
Wierda D 2009. Immunogenicity of biologically-derived therapeutics: assessment and 
interpretation of nonclinical safety studies. Regulatory toxicology and pharmacology : RTP  
54(2):164-182. 
25. Schellekens H 2002. Immunogenicity of therapeutic proteins: clinical implications and 
future prospects. Clinical therapeutics  24(11):1720-1740; discussion 1719. 
26. Jahn EM, Schneider CK 2009. How to systematically evaluate immunogenicity of 
therapeutic proteins-regulatory considerations. N Biotechnol  25(5):280-286. 
27. Johnson R, Jiskoot W 2012. Models for evaluation of relative immunogenic potential of 
protein particles in biopharmaceutical protein formulations. Journal of pharmaceutical sciences  
101(10):3586-3592. 
28. Perry LC, Jones TD, Baker MP 2008. New approaches to prediction of immune 
responses to therapeutic proteins during preclinical development. Drugs in R&D  9(6):385-396. 
29. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, Li L, Mytych D, Koscec 
M, Weeraratne D, Swanson S, Martin W 2007. Clinical validation of the "in silico" prediction of 
immunogenicity of a human recombinant therapeutic protein. Clinical immunology  124(1):26-
32. 
30. Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS 2007. 
Development of a maturing T-cell-mediated immune response in patients with idiopathic 
Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. Journal of 
clinical immunology  27(6):620-627. 
31. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V 
2010. Considerations for optimization and validation of an in vitro PBMC derived T cell assay 
for immunogenicity prediction of biotherapeutics. Clinical immunology  137(1):5-14. 
 
 173 
32. Jaber A, Baker M 2007. Assessment of the immunogenicity of different interferon beta-
1a formulations using ex vivo T-cell assays. Journal of pharmaceutical and biomedical analysis  
43(4):1256-1261. 
33. Stickler M, Rochanayon N, Razo OJ, Mucha J, Gebel W, Faravashi N, Chin R, Holmes 
S, Harding FA 2004. An in vitro human cell-based assay to rank the relative immunogenicity of 
proteins. Toxicological sciences : an official journal of the Society of Toxicology  77(2):280-
289. 
34. Brinks V, Jiskoot W, Schellekens H 2011. Immunogenicity of therapeutic proteins: the 
use of animal models. Pharmaceutical research  28(10):2379-2385. 
35. Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, Jiskoot W 
2005. Structural characterization and immunogenicity in wild-type and immune tolerant mice of 
degraded recombinant human interferon alpha2b. Pharmaceutical research  22(12):1997-2006. 
36. Braun A, Kwee L, Labow MA, Alsenz J 1997. Protein aggregates seem to play a key role 
among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and 
transgenic mice. Pharmaceutical research  14(10):1472-1478. 
37. Stewart TA, Hollingshead PG, Pitts SL, Chang R, Martin LE, Oakley H 1989. Transgenic 
mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol 
Biol Med  6(4):275-281. 
38. Whiteley PJ, Lake JP, Selden RF, Kapp JA 1989. Tolerance induced by physiological 
levels of secreted proteins in transgenic mice expressing human insulin. The Journal of clinical 
investigation  84(5):1550-1554. 
39. Gaitonde P, Balu-Iyer SV 2011. In vitro immunogenicity risk assessment of therapeutic 
proteins in preclinical setting. Methods in molecular biology  716:267-280. 
40. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin 
BA, Chirmule N, Narhi LO, Jawa V 2012. Highly aggregated antibody therapeutics can enhance 
the in vitro innate and late-stage T-cell immune responses. The Journal of biological chemistry  
287(30):25266-25279. 
41. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D 2012. Classification of protein 
aggregates. Journal of pharmaceutical sciences  101(2):493-498. 
42. Rombach-Riegraf V, Allard C, Angevaare E, Matter A, Ossuli B, Strehl R, Raulf F, 
Bluemel M, Egodage K, Jeschke M, Koulov AV 2013. Size fractionation of microscopic protein 
aggregates using a preparative fluorescence-activated cell sorter. Journal of pharmaceutical 
sciences  102(7):2128-2135. 
43. Espargaro A, Sabate R, Ventura S 2012. Thioflavin-S staining coupled to flow cytometry. 
A screening tool to detect in vivo protein aggregation. Molecular bioSystems  8(11):2839-2844. 
44. Mach H, Bhambhani A, Meyer BK, Burek S, Davis H, Blue JT, Evans RK 2011. The use 
of flow cytometry for the detection of subvisible particles in therapeutic protein formulations. 
Journal of pharmaceutical sciences  100(5):1671-1678. 
45. Nishi H, Mathas R, Furst R, Winter G 2014. Label-free flow cytometry analysis of 
subvisible aggregates in liquid IgG1 antibody formulations. Journal of pharmaceutical sciences  
103(1):90-99. 
46. Ludwig DB, Trotter JT, Gabrielson JP, Carpenter JF, Randolph TW 2011. Flow 
cytometry: a promising technique for the study of silicone oil-induced particulate formation in 
protein formulations. Analytical biochemistry  410(2):191-199. 
47. Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, Richmond K, Pan O, Sun J, 
Hokom M, Goletz TJ, Wypych J, Zhou L, Kerwin BA, Narhi LO, Arora T 2013. Development of 
 
 174 
a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated 
biotherapeutics. Journal of pharmaceutical sciences  102(10):3545-3555. 
48. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D 2007. Downstream processing of 
monoclonal antibodies--application of platform approaches. Journal of chromatography B, 
Analytical technologies in the biomedical and life sciences  848(1):28-39. 
49. Kalonia C, Kumru OS, Kim JH, Middaugh CR, Volkin DB 2013. Radar chart array 
analysis to visualize effects of formulation variables on IgG1 particle formation as measured by 
multiple analytical techniques. Journal of pharmaceutical sciences  102(12):4256-4267. 
50. Kalonia C, Kumru OS, Prajapati I, Mathaes R, Engert J, Zhou S, Middaugh CR, Volkin 
DB 2014. Calculating the mass of subvisible protein particles with improved accuracy using 
micro-flow imaging data. J Pharm Sci  In press. 
51. Mach H, Middaugh CR 2010. Ultraviolet spectroscopy as a tool in therapeutic protein 
development. Journal of pharmaceutical sciences  100(4):1214-1227. 
52. Kumru OS, Liu J, Ji JA, Cheng W, Wang YJ, Wang T, Joshi SB, Middaugh CR, Volkin 
DB 2012. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody 
after dilution into different intravenous administration bags. Journal of pharmaceutical sciences  
101(10):3636-3650. 
53. Jiao N. 2014. Personal Communication. ed. 
54. Shapiro HM. 2003. Practical Flow Cytometry. ed., New Jersey: Wiley. p 681. 
55. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR 2012. Improved data visualization 
techniques for analyzing macromolecule structural changes. Protein science : a publication of the 
Protein Society  21(10):1540-1553. 
56. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W 2006. 
Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune 
tolerant mice depends on type and level of aggregation. Journal of pharmaceutical sciences  
95(5):1084-1096. 
57. Johansen P, Senti G, Martinez Gomez JM, Wuthrich B, Bot A, Kundig TM 2005. Heat 
denaturation, a simple method to improve the immunotherapeutic potential of allergens. 
European journal of immunology  35(12):3591-3598. 
58. Fradkin AH, Carpenter JF, Randolph TW 2009. Immunogenicity of aggregates of 
recombinant human growth hormone in mouse models. Journal of pharmaceutical sciences  
98(9):3247-3264. 
59. Filipe V, Jiskoot W, Basmeleh AH, Halim A, Schellekens H, Brinks V 2012. 
Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant 
transgenic mice. mAbs  4(6):740-752. 
60. Fradkin AH, Mozziconacci O, Schoneich C, Carpenter JF, Randolph TW 2014. UV 
photodegradation of murine growth hormone: chemical analysis and immunogenicity 
consequences. European journal of pharmaceutics and biopharmaceutics : official journal of 
Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV  87(2):395-402. 
61. Rombach-Riegraf V, Karle AC, Wolf B, Sorde L, Koepke S, Gottlieb S, Krieg J, Djidja 
MC, Baban A, Spindeldreher S, Koulov AV, Kiessling A 2014. Aggregation of human 
recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate 
adaptive T-cell responses in vitro. PloS one  9(1):e86322. 
62. Van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W 2012. Immunogenicity 
of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. 
Journal of pharmaceutical sciences  101(1):187-199. 
 
 175 
63. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W 2011. 
Oxidized and aggregated recombinant human interferon beta is immunogenic in human 
interferon beta transgenic mice. Pharmaceutical research  28(10):2393-2402. 
64. Fradkin AH, Carpenter JF, Randolph TW 2011. Glass particles as an adjuvant: a model 
for adverse immunogenicity of therapeutic proteins. Journal of pharmaceutical sciences  
100(11):4953-4964. 
65. Seong SY, Matzinger P 2004. Hydrophobicity: an ancient damage-associated molecular 
pattern that initiates innate immune responses. Nature reviews Immunology  4(6):469-478. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 176 
 
CHAPTER 5: Summary, Conclusions, and Future Directions 
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5.1 SUMMARY AND CONCLUSIONS 
 The impact of protein aggregate and particle formation in biotherapeutics has been 
discussed extensively in literature.  Their presence can potentially impact the safety, 
pharmacodynamics, and efficacy of protein biologics upon patient administration.  The United 
States Pharmacopeia (USP) and European Pharmacopeia (EP) have some guidelines for 
assessing protein subvisible particles1.  For example, <USP 788> has defined limits for 
subvisible particulates greater than 10 and 25 µm based on light obscuration measurements.1,2  
These guidelines, however, were not established to monitor inherent, product related particles, 
but rather the presence of process related extrinsic particles because of their possibility of 
obstructing capillaries. No general guidelines exist for protein, product related subvisible 
particles or smaller aggregates and specifications are usually set on a case-by-case basis, 
especially since different analytical technologies may be required.  For example, limits on the 
number of protein aggregates in the 0.2 to 10 µm size range have not been generally specified, 
even though they have been suspected of producing increased immunogenicity risk.3,4 
As detailed in many studies, 5-8 aggregate size may not be the only factor that may impact 
immunogenicity.    In addition to size, aggregates can be classified in terms of morphology, 
reversibility, and the nature of the protein within the aggregates including covalent linking and 
higher order structure.9  Therefore it is important that in addition to sizing and counting, 
physicochemical characterization of aggregates is performed as well.  This rationale is the 
general theme of studies performed in Chapter 2.   
Characterization of aggregates is the first step to better understanding their clinical 
impacts. Regulatory agencies strongly suggest that protein therapeutics be subjected to various 
accelerated stress conditions and the resulting aggregates be monitored and assessed, often 
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requiring the use of a variety of methods.  Stress conditions typically encountered by a protein 
drug throughout various stages of manufacturing and shipping include thermal stresses, 
mechanical stresses, and freeze-thaw, among others.  In Chapter 2, we investigated the 
aggregation behavior of an IgG1 mAb as it is subjected to four different environmental stresses, 
with and without NaCl.  The resulting aggregates and particles were analyzed by a variety of 
sizing and counting techniques.  The stresses used were shaking, stirring, freeze-thaw, and 
thermal stresses.   The aggregates generated in the presence of NaCl were extensively 
characterized in terms of morphology, covalent-crosslinking, and the structure of the protein 
within protein particles.  Depending on the stress, very different types of aggregates formed, 
resulting from structural changes, colloidal interactions or a combination of the two.  
Comparisons with other, similar studies in the literature suggested that both the solution 
conditions and the nature of the protein itself also determine the type of aggregates generated.  In 
some instances, it was shown that the type of stress greatly impacts the types of aggregates 
formed.  This chapter was a case study that underscores the importance of characterizing the 
types of protein aggregates that result from different types of environmental stresses.  The 
importance of analytical methodology development cannot be emphasized enough as it can lead 
to more accurate characterization of protein aggregates across a large size range and can serve as 
the foundation for a better understanding of potential clinical consequences as a result of these 
aggregates.   
 Shaking experiments have often been used to mimic shipping and transportation stresses.  
There are an abundance of studies looking at the impact of this stress on solution-based protein 
formulations, but very few publications, if any, looking at the impact of this stress on lyophilized 
protein therapeutic dosage forms.  Previous studies have often focused primarily on stresses 
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encountered during the lyophilization process (e.g., freezing and dehydration) or during 
subsequent storage stresses on the physical stability of a lyophilized antibody formulation.  In 
Chapter 3, we investigated the effect of shaking stresses on the stability of a lyophilized IgG1 
protein formulation. Conditions were setup such that they mimic the environment that a 
therapeutic protein may encounter during worst-case shipping excursions. It was determined that, 
compared to the unstressed sample, the shake stressed lyophilized sample, upon reconstitution, 
showed a greater number of subvisible particles and increased turbidity.  These subvisible 
particles contained protein that showed only minor changes in overall secondary structure 
content.  In conjunction with this stress, we also investigated the effect of moisture content, 
reconstitution type, diluent addition rate, and subsequent storage stability at elevated 
temperatures.  The effect of moisture content did not show notable differences in aggregation.  
The effect of subsequent storage duration, temperature, and cake breakage was assessed and it 
was shown that increasing storage duration, cake breakage, and temperature all led to higher 
particle counts and higher turbidity upon reconstitution.  The effect of reconstitution medium 
was assessed and some differences in particle formation were seen, especially when solutions 
containing NaCl or a combination of NaCl and Tween 80 were added, thus emphasizing the 
importance of choosing the proper reconstitution medium to obtain lower subvisible particle 
counts. This study stresses that in addition to considering lyophilization cycle and other 
formulation development practices to ensure the stability of a lyophilized therapeutic, other 
precautions, especially those that can prevent excessive shaking stress on the protein (i.e., better 
packaging), should also be considered, and employed, if needed.  
 Chapter 4 was focused not only on characterization of protein aggregates and particles as 
described in Chapter 2, but further examined the biological impact of a certain subpopulations of 
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aggregates.  An IgG2 mAb in solution was stressed by stirring, as shown in previous reports, to 
study the impact of particle size in an in vitro immune response using human peripheral blood 
mononuclear cells (PBMC). 6,10 Prior to this in-vitro assay, however, it was necessary to first 
separate the highly aggregated stirred mAb sample into size-enriched fractions.  This was done 
most successfully using a combination of gravitational sedimentation and fluorescence activated 
cell sorting (FACS) to obtain four size-enriched samples.  The size-enriched samples were 
placed in the in-vitro assay and the cytokine response they induced in the PBMC was monitored.  
Concurrently, the stir stressed mAb samples were characterized for morphology, structural 
integrity, composition, and covalent crosslinking of the particles both before and after FACS 
separation.  Samples size-enriched in the 5-10 µm population showed a higher response than the 
other size-enriched samples in the in vitro cell assay, in terms of responding donors, but only 
marginally in terms of levels of cytokines released.  This was probably due to the dilute nature of 
the samples resulting from the FACS separation step itself.  Additionally, these stir induced 
particles contained protein with some structural alterations compared to the unstressed and heat 
stressed mAb control samples.  The aggregates appeared non-covalently linked with elevated 
levels of surface hydrophobicity compared to the same controls.  Interestingly, elemental fluorine 
was present in the stir-induced samples, probably arising from the Teflon stir-bars used for 
stirring.  The element was not present in the controls or buffers.  The potential advantages and 
disadvantages associated with this FACS separation technique and with the PBMC in vitro assay 
were discussed as well as methods for further improvement.  Overall, obtaining size-enriched 
protein particle samples was a challenge due to the narrow size range of particles that formed for 
this particular stress.  In addition, the intrinsic properties of the particles (i.e., their stickiness and 
fragility) and limitations imposed by the FACS instrument and by the in vitro assay were other 
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challenges that were encountered during these studies.  The key focus of this study is that the 
size of protein particles may indeed play a large role in the observed immune responses, but how 
large of a factor and whether size plays a synergistic role with other aspects such as type of 
aggregates (ex: oxidized, structurally perturbed, reversible, etc.) is not yet fully understood.     
 The abundance of literature present concerning protein aggregation is partly due to the 
fact that many properties of this phenomenon are not fully understood and factors that can 
instigate it sometimes cannot easily be predicted.  Nevertheless, the source of aggregation is not 
the same for all proteins and their clinical implications in humans is not thoroughly understood.  
The studies, presented in this thesis, use 3 different IgG monoclonal antibodies, one of the largest 
class of protein drugs, to understand various aspects of protein aggregation and their potential 
biological implications.  While we have gained a better understanding of the physical stability of 
these three IgG mAbs under the conditions tested, how well the results correlate with other 
similar proteins (containing different sequences, structure, and interactions with the 
environment) is not clear.  These studies further provide evidence of the complexities associated 
with protein aggregation.  A greater understanding of this process can be achieved by analyzing 
numerous similar case studies, making comparisons, and formulating predictions based on 
previous work.  Currently, there is no panacea available to prevent aggregation of all 
biotherapeutics.  This work underscores the importance of comprehensive aggregation 
characterization using a broad range of analytical instrumentation after subjecting the protein 
therapeutic to appropriate and relevant accelerated stability conditions to develop formulations 
that can minimize aggregate formation.   
 
5.2 FUTURE WORK 
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As mentioned earlier, an improved understanding of protein aggregation behavior of 
three different IgG mAbs has been gained by the studies presented in this Ph.D. thesis. Further 
work, however, related to better characterization of protein particles and analysis with the in 
vitro PBMC assay can enhance our current understanding of the stability and the in vitro 
biological responses of the relevant IgG mAbs.   
From an analytical point of view, one major challenge faced, not only in this work, but in 
nearly all work that requires characterization of protein aggregates is that largely spherical, non-
protein standards, such as polystyrene beads, are often used for calibration of many analytical 
instruments.  These standards have neither the shape, density, nor refractive index (especially 
important for light scattering experiments) sufficiently similar to that of proteinaceous particles 
for accurate characterization work.  Furthermore, what complicates this matter further is that 
protein aggregates themselves are not uniform so the challenges in making more protein-like 
standards that are representative of all aggregates are very difficult to resolve.  Developing and 
using more appropriate protein-like standards would provide more accurate sizing and counting 
of protein aggregates and particles by allowing for improved calibration of the analytical 
instruments.    
 FACS, as shown in Chapter 4, was a useful technique for obtaining size-enriched samples 
of micron-sized particles.  However, FACS greatly diluted the aggregates in the sample leading 
to low subvisible particle counts, which may have led to the low PBMC responses.  To get a 
higher PBMC response, it is necessary to scale-up the FACS purification procedure (i.e., 
preparative FACS) and/or increase the particle concentration while retaining the size enrichment.  
It will be important to implement a method to increase the concentration of particles using this 
technique or another to get a more robust response from PBMC from the in-vitro assay.  In 
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addition to separating particles based on size, FACS can be a valuable tool for separating and 
characterizing other aspects of protein aggregates.  The size range of FACS can be extended 
from roughly 0.5 µm to about 40 µm, depending on the nozzle used for the FACS instrument.  
FACS can be used to separate protein particles by their surface hydrophobicity with the use of a 
dye, assuming the dye doesn’t alter the conformation of the protein.  Overall, FACS is an 
underutilized tool, which has only recently been gaining in importance, to study protein 
aggregation.  Its ability to monitor individual fluorescent signals of subvisible particles makes it 
a unique and potentially powerful technique.  It is a method that should be included among 
others in the tool kit for characterizing protein subvisible particles and its capabilities should be 
further explored.   
From a clinical point of view, it is known that the best way to determine the 
immunogenicity potential of a human mAb based biotherapeutic is by conducting clinical studies 
incorporating sufficient numbers of diverse human patients.  However, for practical and ethical 
reasons, this type of clinical study is not always possible.  A more feasible thing to do is to use a 
combination of in-silico, in-vitro studies.  For example, by using human peripheral blood 
mononuclear cells, and in-vivo studies using transgenic mice or non-human primates, one could 
better understand the potential of different types of protein aggregates to elicit formation of anti-
drug antibodies (ADA).  In our study, performing the PBMC in-vitro assay using a larger, more 
genetically diverse MHC population, which is more representative of the world population, 
would be of interest.  This could provide a better representation of the cytokine response of the 
aggregates in the general human population.  For the biological assay results described in 
Chapter 4, the PBMCs were isolated from randomly chosen 7-8 human donors at Amgen, whose 
MHC types were not characterized.   
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Finally, performing shipping experiments as described in Chapter 3 using other 
lyophilized mAbs in different formulations might allow us to more fully elucidate the 
mechanism of subvisible particle formation. It was seen in Chapter 3 that increases in turbidity 
and subvisible particles were observed upon subjecting a lyophilized IgG1 mAb to shipping like 
stress and reconstitution.   Expanding these studies to a wider range of other lyophilized mAbs 
should permit us to better establish a more general trend, which will allow the mechanism of 
mAb particle formation upon shaking stress to be more fully elucidated.  
Performing all of these future study plans should help scientists obtain more accurate and 
precise sizing and counting data for protein aggregates and particles, free from many 
experimental assumptions. In addition, new analytical approaches such as incorporating the 
revised FACS method to characterize and isolate protein particles and modifying the PBMC in-
vitro assay to incorporate the genetic heterogeneity of donors, will aid us to better characterize 
the physical and biological properties of protein aggregates and improve our understanding of 
their immune potential.   
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